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Abstract 
Real-time reverse transcription loop-mediated isothermal amplification (RT-LAMP) is 
becoming a widely accepted method for use in the field of molecular diagnostics. This method 
makes use of a highly robust core enzymology’s that are tolerant to sample derived inhibitors, 
along with a priming mechanisms that permit impeccable amplification sensitivities and 
specificities. These are well documented attributes associated with LAMP, but little is known 
about factors that drive and interfere with the reverse transcription of RT-LAMP assays. 
This study aims to address a number of factors that affect RNA amplification, including 
impedance of priming related to template structure, inhibition of polymerase activities by 
sample derived inhibitors and the general effect of assay chemistry and primer function with 
respect to reverse transcription. In addition to the chemistry optimisation and choice of 
polymerase (DNA / RT), the secondary structure innate within RNA, could significantly affect 
the efficiency of RT.  Priming position and design would also need to be seriously considered 
with respect to the folding nature of these targets. Overtly, RT-LAMP showed an increased 
sensitivity to inhibition compared to its DNA counterpart.  
Similar observations of impeded RNA transcription were made during the development 
of an internal amplification control (IAC), which was designed to determine the exact 
inhibitory nature of any tested samples, in tandem with the RT-LAMP. This report clearly 
discloses that RT amplification controls must be synthesised ‘free of contaminating DNA’, to 
avoid poor characterisation of first strand DNA synthesis. 
Alternative ‘non-enzymatic methods’ of reporting amplification in real-time were 
compared to the bioluminescent assay real-time (BART) reporter; a well-established method 
of nucleic acid detection and quantification developed and patented by Lumora Ltd, 
Cambridgeshire (Fortes et al., 2013). Despite BARTs track record for detection of LAMP, its 
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indiscriminate reporting of amplification is of little use for duplexed assay characterisation, 
such as the IAC / RT-LAMP combined assay. Thus, methods of specific sequence detection 
were designed that could target single stranded elements of amplified products (STEMs and 
LOOP structures). It was demonstrated that the mechanism for RT-LAMP fluorescent probing 
‘presented here’ was unique to this Thesis and does not fall under the guise of Taqman or other 
molecular beacon detection mechanisms. Together with BART, this new form of probing was 
successfully deployed to distinguish between true RT-LAMP and IAC afflicted amplifications. 
The possibility of utilising the LAMP / BART technologies for microRNA (miRNA) 
detection was also explored. Even though it is well known that miRNAs have crucial roles in 
responding to and regulating a wide range of biological and cellular processes, no real headway 
has been made in developing highly sensitive, low resource methods for their detection. Here 
we develop novel methods of miRNA detection capable of sensing picomolar levels that also 
make use of the LAMP and BART chemistry.   
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Abbreviations 
APS – Adenosine 5’ phosphosulfate 
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Chapter 1 
1 Introduction 
1.1 Molecular diagnostics 
The field of molecular diagnostics has undergone major developments in recent years, as the 
increasing need for highly accurate detection methods capable of screening a wide range of 
clinical and environmental samples has driven the development of these diagnostic tools (Opel 
et al., 2010, Craw and Balachandran, 2012). Most molecular diagnostics (MDx) platforms 
amplify and detect nucleic acid (NA) sequences, which are specific to a particular disease or 
phenotype. Increasingly, MDx has been adopted for a wide range of research and biomedical 
screening solutions that include pathogen testing, cancer diagnostics, GM / contaminant 
screening, DNA profiling, conservational biology and environmental monitoring (Young and 
Cotter, 1992, Fenton and Lowndes, 2004, Kiddle et al., 2012).  
Molecular diagnostics have proven particularly useful for detection of infectious diseases, and 
as a consequence, have seen an explosion in advances over the last decade, as the need for 
quick and highly accurate detection methods have become more critical to our well-being 
(Euler et al., 2012, Scott and Gretch, 2007). The evolution and advances in MDx has been 
particularly useful, as the human population faces more acute challenges, caused by emerging 
and re-emerging infectious diseases. Research into molecular diagnosis of various diseases has 
provided scientists with a better understanding of all the molecular factors affecting human 
health, but has also offered solutions for treatment that can greatly improve a patient’s 
prognosis and reduce the risk of new infections (Muldrew, 2009).    
Serological-based diagnostics have been the methods of choice for decades, but many of these 
tests are stricken with problems that lead to poor performance, and significant variations in 
accuracy and reliability (Fierz, 2004). Serological diagnosis are surrogate tests that do not 
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qualify the presence of the disease causing agent or its cause directly, but rather the immune 
response of the host; which can lead to a misdiagnosis of positivity and negativity. Each 
patient’s immunity is unique and large variabilities with respect to the amplitude and time to a 
response have been recorded (Kunisaki and Janoff, 2009, Simon et al., 2015). Accordingly, 
differences in immune response can not only result in a misdiagnosis, but also this variability 
greatly increases the risks of the disease spreading within a population. In addition, indirect 
measurements of one’s antibodies gives a much less accurate prediction of disease outcome 
with respect to medical treatments (Zhang et al., 2011). Furthermore, during the acute phase of 
any infection (termed the eclipse), the immune response is undetectable, as these technologies 
have poor sensitivity and often the infected have not seroconverted (Kharsany et al., 2010).  
Nucleic acid amplification technologies (NAAT) that directly measure the presence of a 
microorganism offer clinicians highly reliable alternative to serological tests and this type of 
diagnosis often leads to a much faster and more accurate diagnosis. These technologies are also 
far more sensitive than immunoassays, but are often expensive and require sophisticated 
machinery.  
1.1.1 PCR-based platforms  
Currently, quantitative, real-time polymerase chain reaction (PCR), is the method of choice 
used for MDx of infectious disease (Kurkela and Brown, 2009). Although, the PCR approaches 
have greatly improved the sensitivity and sample throughput of MDx assays, the technology 
still carries major limitations (Patel et al., 2006, Curtis et al., 2008, Yang and Rothman, 2004, 
Ding et al., 2011, Kiddle et al., 2012, Liolios et al., 2001). Firstly, the real time PCR-based NA 
detection techniques often employ expensive fluorescent probes, which require complex 
equipment that is capable of detecting the fluorescent signal but also complicated hardware 
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capable of driving thermal cycles (Figure 1). 
Secondly, depending on the source of the 
biological material tested (e.g. clinical samples 
such as blood, urea or faeces; processed foods or 
even environmental samples including soils and 
plan material), PCR amplification can suffer 
from severe inhibition resulting which may result 
in false negatives (Tebbe and Vahjen, 1993). 
Finally, due to the increased sensitivity of this 
technology, PCR assays have to be carried out in 
a nucleic acid-free laboratory, by experienced scientists in order to reduce potential for reagent 
contamination, which can often produce false positive results. 
1.1.2 Isothermal amplification of nucleic acids 
To prime any polymerised chain reaction requires the opening of the DNA or RNA structure 
to allow for a primed polymerisation. This is often performed using a thermal stable polymerase 
and denaturing conditions which melt the target polynucleotide prior to primer annealing and 
extension; this type of reaction requires sophisticated machinery capable of managing a thermal 
cycle. Alternative isothermal amplifications exist that make use of a unique property of certain 
DNA polymerases (e.g. Bst DNA polymerase from Bacillus stearothermophilus) that have 
helicase or strand displacement activity and unique primer design strategies enable nucleic acid 
synthesis to be carried out at a constant temperature eliminating the requirements for expensive 
thermocycling equipment.  
Currently, there are over a dozen isothermal technologies that make use of displacement 
polymerases and priming mechanisms: Loop-mediated isothermal amplification (LAMP), 
rolling circle amplification (RCA), nucleic acid sequence based amplification (NASBA), 
Figure 1.  Typical real-time PCR equipment used in a wide 
range of biomedical research for detection and 
quantification of nucleic acids. 
Source: http://www.gene-
quantification.de/platform1.html 
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recombinase polymerase amplification (RPA), helicase-dependent amplification (HDA), 
transcription-mediated amplification (TMA), single primer isothermal amplification (SPIA) 
and strand displacement amplification (SDA(Gill and Ghaemi, 2008). However, among the 
techniques mentioned above, LAMP has been shown to be one of the most rapid and sensitive 
methods of nucleic acid amplification with an average assay time of 60 min or less (Gandelman 
et al., 2011, Walker et al., 1992, Compton, 1991).  
1.1.2.1 Rolling circle amplification (RCA) 
The rolling circle nucleic acid amplification employs a unique property of ɸ29 DNA 
polymerase with a strand displacement activity and circle-hybridized primers to generate 
multiple copies of a circular DNA/RNA probe via numerous rounds of isothermal amplification 
(Fire and Xu, 1995). More recent developments in the RCA technology has given rise to a 
much faster way of amplifying circular DNA directly from cells and plaques. Multiple-primed 
RCA involves addition of random primers, 
complementary to the sequences of interest, that target 
both the circular DNA template as well and the single-
stranded (ss) DNA concatemers generated from 
replication of these targets (Figure 2)(Dean et al., 2001).  
 
 
 
 
 
Figure 2. Graphic representation of multiply-primed RCA. Random 
oligonucleotides complementary to the target sequences hybridize to the circular 
template. Biding of the ɸ29 DNA polymerase initiate amplification. Multiple 
rounds of DNA synthesis results in generation of long single-stranded DNA 
concatemers with tandemly repeated target sequences. 
Source:https://www.researchgate.net/publication/6416450_Error-
prone_rolling_circle_amplification_The_simplest_random_mutagenesis_protoco
l 
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1.1.2.2 Nucleic acid sequence based amplification (NASBA) 
Nucleic acid sequence-based amplification or self-
sustained sequence replication (3SR) is another isothermal 
amplification method used in synthesis of nucleic acids 
(Compton, 1991). Unlike the previously mentioned RCA, 
NASBA uses RNA as the target for amplification. NASBA 
technology makes use of avian myeloblastosis virus 
reverse transcriptase (AMV-RT), RNase H and a T7 RNA 
polymerase to generate multiple copies of anti-sense RNA 
and single-stranded cDNA (sscDNA) molecules (Figure 
3). The amplification reaction begins with hybridisation of 
specific primers containing T7 RNA polymerase-binding 
sites to the target RNA molecules. Once bound, reverse 
transcriptase begins the synthesis of a cDNA copy of the 
target RNA forming a RNA/DNA double-stranded hybrid molecule.  Unique property of the 
RNase H enzyme to recognise such hybrids and degrade the RNA portion of the RNA/DNA 
complex results in generation of sscDNAs. A second set of primers binds to the sscDNA 
molecules initiating replication of the complementary strands. Once a double-stranded cDNA 
is formed the T7 RNA polymerase binding site becomes activated. 
T7 RNA polymerase produces multiple copies of the anti-sense RNA template, which can be 
used in a self-sustained phase of the amplification procedure. Each anti-sense RNA, can be 
reverse transcribed into a double-stranded cDNA version of itself therefore carrying an active 
binding site for the RNA polymerase enzyme.  
 
 
Figure 3. Schematic representation of the NASBA 
amplification technology. The straight arrow 
represents the initiation step of the amplification 
procedure required to start off the self-sustained 
phase (circular arrow) of the synthesis procedure by 
generating anti-sense RNA templates. 
Source: 
https://www.researchgate.net/figure/259155941_fi
g2_Principles-of-nucleic-acid-sequence-based-
amplification 
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1.1.2.3 Recombinase polymerase amplification (RPA) 
Recombinase polymerase amplification (RPA) utilizes three core enzymes including: a 
recombinase, a single-stranded DNA binding protein (SSB) and DNA polymerases with strand 
displacement activity (Euler et al., 2012).    
In principle, the system relies on the ability of the 
recombinase to facilitate primer invasion which in 
turn allows the binding of DNA polymerases and 
initiation of the replication reaction (Figure 4). 
Once the DNA polymerase begins the 
amplification of new DNA strands, the parental 
strand (complementary to the strand used as the 
template for the DNA polymerase enzyme) is 
displaced and coated with the single-stranded DNA 
binding proteins to prevent re-hybridisation to its 
complement.   
Recent developments in RPA have attracted the 
attention of diagnostic companies such as TwistDxTM due to the efficiency and the simplicity 
of the assays with potential applications in rapid, near care diagnostics (Aebischer et al., 2014, 
Kersting et al., 2014).   
 
 
 
 
 
 
Figure 4. Schematics representation of the principle 
behind the RPA-based DNA amplification technology. 
Source: 
https://www.researchgate.net/figure/264796231_fig1
_The-three-core-proteins-recombinase-single-strand-
DNA-binding-protein-SSB-and  
15 
 
1.1.2.4 Helicase-dependent amplification (HDA)  
Helicase-dependent amplification is very similar mechanism to PCR amplification. Instead of 
the heat denaturation of the DNA double helix required in PCR, HDA uses helicase enzymes 
to unwind DNA molecules, thereby generating single-stranded DNA templates (Vincent et al., 
2004). 
 In general, the HDA-based DNA amplification is 
carried out in two main steps (Figure 5). Firstly, 
helicases unwind and separate both strands of the 
target DNA molecules allowing primers to anneal to 
their complementary sequences. Secondly, DNA 
polymerase binds and extends annealed primers 
until the entire complementary strand is fully 
synthesised. In addition, it has also been reported 
that the use of SSB proteins is crucial for the DNA 
replication step. SSB proteins prevent re-
hybridization of the separated complementary strands which in turns indirectly facilitates the 
primer binding step of the amplification process (Cao et al., 2013, Chase and Williams, 1986). 
Recent studies have shown that the HDA-based assays have the potential of being developed 
into hand-held diagnostic devices suitable for the point-of-care or in-field diagnostics due to 
its simplicity and low energy requirements (Li et al., 2013).  
 
 
 
 
 
Figure 5. The figure shows HDA-based isothermal 
DNA amplification process. 
Source: https://www.neb.com/products/h0110-isoamp-
ii-universal-thda-kit 
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1.1.2.5 Strand displacement amplification (SDA) 
Strand displacement amplification relies on 
restriction enzymes that introduce nicks to double-
stranded DNA molecules and the action of DNA 
polymerases, lacking the exonuclease activity (e.g. 
klenow exo-), to displace the complementary strand 
downstream from the nick. As a result, both the 
displaced and the complementary strands serve as 
templates for DNA replication generating multiple 
copies of the target sequence (Figure 6)(Walker et 
al., 1992).  
In essence, the SDA amplification begins with a 
denaturation step, which is crucial for this 
technology. Four different primers (B1, B2, S1, S2) 
bind to the ssDNA templates, which initiate primer 
elongation and strand displacement events. The S1 
and S2 primers are designed to target the sequence of 
interest as well as to introduce the HincII restriction 
sites to the target DNA which, the later stages of the 
SDA amplification, are required to sustain the isothermal amplified (Figure 6). Nick sites are 
then recognized by the klenow DNA polymerase, which initiates DNA replication and the 
displacement of the complementary, parental strand, which in turns acts as the template for 
further DNA replication reactions (Figure 6). The SDA technology has mainly been used in 
clinical diagnostics for infectious diseases such as chlamydia or gonorrhea. However, since the 
initial step of the SDA-based nucleic acid amplification involves a denaturation step, it is 
Figure 6. Graphic representation of the SDA-based 
DNA amplification technology. (A) This figure reflects 
the initial step of the SDA reaction which generates 
multiple copies of the target sequence flanked with 
HincII restriction sites. Primers S1 and S2 carries the 
HincII restriction sites targeting the sequence of 
interest. Primers B1 and B2 are displacement primers 
that anneal downstream of the S1/S2 primer binding 
sites. (B) The SDA reaction cycle.  
Source: 
https://www.researchgate.net/figure/259155941_fig
3_Target-generation-scheme-for-strand-
displacement-amplification 
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unlikely that this technology will be used for rapid in-field diagnostics (Walker et al., 1992, 
Gill and Ghaemi, 2008, Chan et al., 2000). 
1.1.2.6 Transcription-mediated amplification (TMA) 
Transcription mediated amplification is a rapid method of nucleic acid amplification based on 
RNA transcription technology (Figure 7). In general, unlike most currently used isothermal 
methods, TMA produces RNA amplicons via T7 transcription using two core enzymes, T7 
RNA polymerase and a reverse transcriptase 
(RT). Firstly, a specific primer containing a T7 
promoter sequence at its 5’ end binds to the 
target RNA molecule followed by a reverse 
transcription process carried out by the RT 
enzyme. During this step, a complementary 
cDNA strand is synthesized while the RNA 
template is being degraded by an RNase H 
activity of the chosen RT. Once a single-
stranded cDNA is formed, a second primer 
anneals and triggers synthesis of the missing 
second strand of the cDNA, resulting in 
generation of a double stranded T7 promoter 
site.  
T7 RNA polymerase binds to the promoter site 
and begins transcription of the target RNA molecules, which in turns are again targeted by the 
T7 promoter site containing primer, repeating the described amplification cycle. TMA has been 
reported to be able to generate billions of amplicons in 60 min or less and has been successfully 
used in HIV or TB diagnostics.  
Figure 7. Graphic representation of the TMA NA amplification 
technology. 
Source: 
https://www.researchgate.net/figure/11169695_fig3_Figure-
2-Transcription-mediated-amplification-TMA 
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1.1.2.7 Loop-mediated isothermal amplification (LAMP) 
Loop-mediated isothermal amplification (LAMP) is a rapid and highly specific method of 
nucleic acid amplification, developed by the EIKEN Chemical Company, in-which the 
polymerization reactions proliferate at a constant temperature (Notomi et al., 2000, Nagamine 
et al., 2002). A typical LAMP mechanism can be sub divided into three main phases: I – the 
initiation; II – cycling amplification and III – recycling and elongation, which together amplify 
each original template molecule 109 times within 60 min (Figure 8).  
Classical LAMP relies on at least two classes of primers that initiate and maintain 
amplification; known as inchworm and displacement primers. Two reciprocal inchworm 
primers (FIP and BIP) are utilized throughout all the phases of LAMP amplification, targeting 
the sense and antisense strands of each invaded DNA template. In contrast, the use of the 
displacement primers is only limited to the phase I.  
Once amplification is initiated via the inchworm primers, the first order amplicon is chased 
from the original DNA template by dedicated displacement primers, releasing strands of DNA 
that contain self-replicating loops derived from the inchworm primer at the 5’ terminus (Figure 
8 I4). This molecule is then subjected to an amplification from the alternate inchworm 
generating a second order displaced molecule with two terminal self-hybridizing loop 
structures known as the dumbbell that has great potential for further rounds of amplification 
(Figure 8 I6). The terminal loop structures of the dumbbell are single-stranded and contain 
engineered sites originating from the inchworm primer that readily hybridize additional 
inchworm primers (Figure 8 II7).  
Further to the described, other LAMP derivatives are engineered to include additional unique 
template-derived priming sites, within the single stranded portions of the replication loops or 
dumbbell stems; these are aptly named Loop or Stem primers. Both primers serve to increase 
the overall concentration of DNA that can be specifically polymerized from the initiated 
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reaction, and therefore increase the kinetics of amplification detected in real time or shorten 
the time to result for endpoint reactions (Gandelman et al., 2011, Nagamine et al., 2002).  
The final phase III of the amplification relies on the activity of both the LAMP and loop primers 
where the overall amplification kinetics are significantly accelerated resulting in the formation 
of a mixture of a wealth of secondary cauliflower-like, stem-loop structures of various lengths,  
as well as branch chain concatemers (Figure 8III) (Notomi et al., 2000).   
From the point at which the dumbbell is synthesized, all down-stream amplification processes 
are cyclical and propagating through phase III, until either the primer and amplification 
precursors are exhausted or until the products of the reaction become intoxicating.  
Like all isothermal amplification methods, LAMP is a displacement technology that does not 
just rely on sophisticated priming mechanisms, but also on highly displacing polymerases that 
have the capacity to unwind the double helix. The helicase activity associated with these 
enzymes defines their function. Of the commercialized enzymes such as Bst large fragment, 
Bst 2.0, Bst 2.0 WarmStart, Bst 3.0 (NEB), GSP-SSD (OptiGene) or phi29 (NEB), many have 
big variations in their temperature optimum, which can range from 30 to 75oC. Some enzymes 
also possess additional associated activities that are helpful to biotechnologists such as reverse 
transcription, which is particularly useful in diagnostic tests, which check RNA expression or 
retro-viral loads (GSP-SSD, Bst 3.0). In addition, some of these enzymes are also marketed for 
their tolerance to sample derived inhibitors that are known to affect PCR-based platforms, such 
as humic acid or various salts (Bst 2.0, NEB; GSP-SSD, OptiGene) (Kiddle et al., 2012, Opel 
et al., 2010).  
Furthermore, in comparison to other nucleic acid amplification technologies, such as PCR or 
TMA, LAMP offers a higher specificity, since any successful propagation of polymerization 
is reliant on coordinated priming from at least six annealing positions, which reduces the 
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number of false positive results caused by non-specific priming (Gandelman et al., 2011, 
Buhlmann et al., 2013).    
As a consequence of the above the LAMP technology is attractive to companies and it has been 
licensed for food and clinical testing, and continues to grow as the preferred method for 
molecular diagnosis (Mori and Notomi, 2009).   
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Figure 8. Schematic representation of the principle behind the LAMP-based DNA amplification technology. (I) The initiation of the LAMP amplification 
begins with a series of primer invasion, DNA replication and strand displacement events that result in generation of the starting LAMP material; 
dumbbell-like DNA structure (I6). This self-priming structure is a crucial element of the LAMP reaction enabling nucleic acid amplification without the 
need for heat-denaturation steps. (II) In the cycling amplification steps, DNA fragments of various length and stem structure are formed. (III) The 
elongation and recycling steps involve both, the LAMP and Loop primers targeting the previously formed dumbbell-like DNA fragments resulting in 
formation of cauliflower-like, multi-loop structures.   
Source: https://www.researchgate.net/figure/260915985_fig5_Fig-10-Mechanism-of-Loop-mediated-amplification-LAMP-Four-probes-F1c-F2-F3-
R1c-R2  
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Table 1. Characteristics of various isothermal nucleic acid amplification technologies and PCR. 
 
 
 
 
 
 
 
 
 
 
 
*- denaturation step required when DNA template is used 
 
 
 
 
Property PCR NASBA SDA RCA LAMP HDA RPA 
DNA amplification + + + + + + + 
RNA amplification + + + + + + + 
Temperature [°C] 95, 55-60,72 37-42 37 37 55-65 22-24, 37, 60-65 37-42 
Primer design simple simple complex simple complex simple simple 
Multiplexing + + - + - + + 
Tolerance to inhibition - - - - + + - 
Need for template 
denaturation 
+ +* + - - - - 
Denaturing agent 
heat RNase H 
restriction 
enzymes 
strand 
displacement 
primer invasion helicase recombinase 
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1.1.3 Summary of isothermal amplification technologies 
Isothermal amplification technologies are slowly becoming the method of choice and are used in 
a wide range of molecular applications, offering several advantages over the traditional PCR-based 
techniques. However, all of the currently available isothermal nucleic acid amplification methods, 
convey several advantages and disadvantages, which potentially limit their use (Table 1). 
Although, all of the isothermal amplification techniques mentioned previously can use both DNA 
and RNA, as the templates for replication reaction, some of them require additional steps to initiate 
self-sustained polymerisation. For example, SDA technology requires the use of four primers, an 
initial heat-denaturation step, as well as modified dNTPs in order to generate initial amplicons 
with strand-specific nicking (Walker et al., 1992).  Furthermore, this technology is rather 
inefficient for amplifying of long sequences (Gill and Ghaemi, 2008).  
LAMP requires four to six different primers to sustain nucleic acid amplification, which could be 
problematic if their design was poor. Despite the complexity of the LAMP primer design, the use 
of multiple primers to target the sequence greatly increase the specificity of detection. 
Furthermore, the final LAMP amplicons are a complex, they have cauliflower-like structures of 
different sizes that can limit their use in several downstream applications, such as sequencing and 
hybridization techniques (Gill and Ghaemi, 2008).   
One of the most important advantages of the isothermal amplification technologies are their 
tolerance to inhibitory substances that are known to greatly affect PCR (e.g. haem, urea, humic 
acids). LAMP and HDA have been demonstrated to be least sensitive to inhibitory substances 
commonly encountered in molecular diagnostics (Niemz et al., 2011, Gill and Ghaemi, 2008, 
Vincent et al., 2004, Kiddle et al., 2012). According to those studies, LAMP was highly resistant 
to several components of various clinical samples where PCR was shown to fail.  
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Higher resistance to biological samples carries a huge advantage in terms of sample preparation 
where for some steps of  the nucleic acid purification steps could potentially be omitted (e.g. HDA 
has been shown to be able to successfully amplify target DNA directly from human blood)(Vincent 
et al., 2004).  
Isothermal amplification technologies eliminate the need for heat denaturation which reduce the 
costs of the equipment required to carry out such reactions. Since LAMP does not require initial 
DNA melting steps to facilitate primer binding and subsequent DNA replication events, this 
technology is much better suited for rapid and highly specific molecular diagnostic tests (Gill and 
Ghaemi, 2008, Gandelman et al., 2010).  
In conclusion, current isothermal amplification technologies differ in their method of 
amplification, reaction volumes and sample preparation. There is no doubt that the simplicity and 
the isothermal nature of these technologies has huge implications for the development of hand-
held molecular diagnostic devices suitable for near-care or in-field detection.    
1.1.4 Bioluminescent Assay in Real Time 
Currently, the most commonly used method of reporting nucleic acid amplification in real-time, 
for both the PCR- and isothermal- based technologies, is the use of fluorescent probing and inter 
chelating dyes (e.g. SYBR-green, molecular beacons or TaqMan probes)(Figure 9)(Freeman et 
al., 1999). Although, these methods of detection offer many advantages, such as the specificity of 
detection (TaqMan), or simplicity (SYBR-green) and the possibility of multiplexing (TaqMan / 
beacons) by combining probes derivatised with different colour dyes, fluorescence-based detection 
does have its limitations.  These mainly include: complexed primer design, the expense of 
detectors capable of differentiating between fluorophores, and the inhibition of amplification by 
chelating dyes. 
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As well as fluorescence technologies, bioluminescence approaches for detecting polymerisation 
were realised commercially at the turn of this century, but it was a while before these evolved to 
be mainstream detection of DNA amplification (Nyrén et al., 1993, Gandelman et al., 2010).  
A method called enzymatic luminometric detection of inorganic pyrophosphate (ELIDA) was the 
first bioluminescent chemistry to detect the instantaneous production of pyrophosphate (PPi) 
generated as a biproduct of pyrosequencing (Figure 10)(Nyrén et al., 1993). 
In this technology, the addition of one of the four deoxynucleotide triphosphates (dNTPs) during 
the sequencing reaction releases PPi that is converted into ATP via ATP sulphurylase in the 
presence of adenosine 5´ phosphosulfate. This ATP then acts as a substrate for the luciferase-
Figure 9. Current, commonly used, fluorescence-based DNA detection probes. (A) SYBR-green dye used for detection of double-
stranded DNA molecules. In principle, the dye binds to any double-stranded DNA which results in emission of a fluorescent signal under 
blue light. The fundamental property of this dye is the fact that no signal emission occurs unless the dye molecules are bound to dsDNA. 
(B) TaqMan probes, unlike the SYBR-green, are designed to increase the specificity of DNA quantification (e.g. Quantifiler®DNA 
quantification kit uses probes specific only to human DNA). In general, the TaqMan probes are hydrolysis-based probes with covalently 
attached fluorophore (e.g. FAM) at the 5’ end and a quencher (e.g. TAMRA) at the 3’ end. The role of the quencher is to absorb any 
signal emitted by the fluorophore whilst both bound to the detection probe to prevent any false results. Once the probe binds to its 
target sequence and the DNA replication takes place, the exonuclease activity of Taq polymerase hydrolyse the probe releasing the 
fluorophore. Since the released fluorophore is no longer in close proximity to the quencher, emitted fluorescent signal can be detected.    
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mediated conversion of luciferin to oxyluciferin resulting in generation of visible light, which can 
then simply be detected by a camera or photodiode.  
However, DNA amplification reactions were never monitored in real-time using continuous 
ELIDA, because of the high temperatures essential for most nucleic acid polymerisation typically 
ranging from 60-74oC. The temperatures of these reactions inhibit wild type luciferase enzymes 
but in 2002 a thermostable recombinant version of the firefly luciferase was developed by 
Cambridge University (Tisi et al., 2002). This engineered luciferase was demonstrated to be 
functional at temperatures exceeding 60oC and this changed the prospects for measuring DNA 
polymerisation by bioluminescence in real-time and realised the potential for simple diagnostic 
platforms (Tisi et al., 2001, Kiddle et al., 2012). 
Following on, BART (Bioluminescent assay real-time) emerged; a detection technology that 
capitalised on the ELIDA chemistry in conjunction with the thermostable firefly luciferase to 
monitor NAATs (patented by Lumora Ltd, Cambridgeshire) (Fortes et al., 2013).  
BART is well suited to most isothermal methods as these produce copious amounts of PPi, and 
amplification technologies such as LAMP operate within a thermal window suited to the 
recombinant enzyme used for generating light.  
BART, like ELIDA, relies on the detection of pyrophosphate ions (PPi) released during DNA 
polymerisations. As the rate of amplification progresses and becomes exponential, the amount of 
released PPi ions and subsequently ATP molecules increases substantially, resulting in an increase 
in the intensity of the light signal emitted by the sample. Once the amount of PPi ions reaches a 
critical concentration, both the ATP sulphurylase and the luciferase enzymes become significantly 
inhibited leading to a complete switch off of BART. This results in a sharp-peak of light emission 
when monitored in real time, where the time to the highest emission is inversely proportional to 
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starting amount of target.  In addition, this unique signature of the BART light signal greatly 
simplifies the detection of positive samples (Figure 11).  
The BART-based assay offers a very sensitive and simple method of nucleic acid quantification 
that can be performed in a closed-tube, real-time format greatly reducing the contamination risks 
posed by this type of analysis due to the large amount of amplicon generated. In addition, similarly 
to the ELIDA technology, BART can be observed and detected by a CCD camera or photodiodes 
(Gandelman et al., 2010). Thus, offers the simplest and most cost effective, but yet sophisticated 
and highly sensitive, closed-tube format detection system available on the market. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Enzymatic luminometric detection of 
inorganic pyrophosphate(ELIDA). PPi realised during 
DNA synthesis react with APS in reaction catalysed 
by ATP sulphurylase, resulting in generation of ATP 
molecules. Formed ATPs together with luciferin 
under aerobic conditions undergo reduction reaction 
catalysed by a firefly luciferase enzyme resulting in 
emission of a light signal.   
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1.1.5 Fluorescence-based detection systems 
Real-time PCR has been the method of choice for detection and quantification of both DNA and 
RNA targets. This technology combines the specificity and sensitivity of standard PCR with a 
fluorescence-based reporting system that enable monitoring of amplicon generation during each 
cycle of the PCR reaction. Thus, similarly to the BART technology, this eliminates the need for 
post-PCR amplicon analysis, which in turn can greatly reduce the contamination risks, as well as 
the hands-on time required to complete the analysis. Furthermore, real-time monitoring of 
amplification not only simplifies the detection but also can give some valuable insights to the 
quantities of the nucleic acid in the tested samples (Bashiardes et al., 2008, Chevaliez et al., 2007).       
Yet, fluorescent detection of amplification has not been exclusively confined to PCR 
amplification. Many isothermal methods, currently use fluorescent detection methods, such as 
TMA and LAMP that are reported using the standard assay chemistries. Three distinct 
fluorescence detection approaches for amplification detection are introduced below. 
Figure 11. Graphic representation of a typical LAMP-
BART amplification profile.  Time-to-max (TTM) is a 
measure of time required for a LAMP-BART assay to 
reach its maximum light emission stage, which is 
inversely proportional to the initial amount of target 
DNA (red and blue curves represent reactions 
containing 1000 and 100 copies of DNA, respectively, 
whereas no template control (NTC) results in a flat 
baseline trace (black)). A typical LAMP-BART positive 
amplification signature is divided into three phases: 
initiation phase (A), exponential phase (B) and 
switch-off phase(C). Phase A represent the initiation 
stage of the LAMP amplification where the dumbbell 
structures are generated, whereas phases B and C 
corresponds to the elongation and recycling stages 
of DNA synthesis. Phase B represents the early 
exponential stage of DNA synthesis where the 
majority of PPi ions are converted into ATP. In 
contrast, the C phase corresponds to the later stage 
of the exponential amplification where the amounts 
of produced PPi ions becomes inhibitory to BART 
causing a complete switch off of light emission.   
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1.1.5.1 Intercalating dyes 
SYBR green has been the most widely used intercalating dye for the detection of DNA 
amplification. In principle, these dye molecules bind to the minor grove of a double stranded (ds) 
DNA template, which in turns causes up to a 1000-fold increase in the fluorescent properties of 
the dye (Dragan et al., 2012) (Figure 9A). Upon excitation at wavelength of 480 nm, the dye emits 
a green fluorescent signal at 520 nm which is then detected by specrofluorometer detectors. The 
relative change in the emission of the fluorescent signal after each amplification cycle can therefore 
be associated with the amount of amplicon generated, and the initial target input. 
The ability of the dye to bind to any dsDNA is a major advantage and disadvantage for monitoring 
polymerisation. SYBR green and other fluorescent inter-chelators offer quick and relatively cheap 
methods for monitoring DNA amplification where minor optimisations of the chemistry are 
required. However, the intercalating dyes do not allow discrimination between the amplification 
of the main target DNA template and any secondary targets including primer dimers in real-time. 
Nonetheless, the differentiation can be performed by including a dissociation analysis where 
different size amplicons are discriminated from one another based on their differences in melting 
temperatures (Tm) (Kochan et al., 2008). However, this step can significantly increase the overall 
time of an analysis which can be a significant limitation in a diagnostics setting. In addition, it has 
been reported that such dyes can reduce sensitivity of PCR assays (Gudnason et al., 2007).  
1.1.5.2 Taqman probes 
Unlike previously described intercalating dyes, TaqMan probes have been designed to increase the 
specificity of amplicon detection by employing dually labelled probes (Roche diagnostics). In 
principle, TaqMan probes consist of a single-stranded oligonucleotides labelled with a fluorophore 
at the 5’ and a quencher molecule at the 3’ end (Vermehren et al., 2008, Holland et al., 1991). The 
30 
 
probe is designed to anneal to a specific region of the template / amplified DNA target molecule 
that is flanked by typical PCR forward and reverse primers. The TaqMan probes rely on fluorescent 
resonance energy transfer (FRET) between the quencher and the fluorophore. In a free, un-bound 
state, the close proximity of the fluorophore to the quencher molecule, prevents any fluorescent 
signal emission. However, upon binding of the probe to its target, extension of the sense primer 
by the Taq DNA polymerase (Figure 9B) causes hydrolysis of the probe by the 5’ -> 3’ 
endonuclease activity of the DNA pol., releasing the fluorophore which in turns enables 
fluorescent signal emission upon excitation.      
 
1.1.5.3 Molecular beacons 
Similar, to TaqMan probes, the molecular beacons (MB) rely on the interactions between a 
oligonucleotide quencher and a fluorophore (Tyagi and Kramer, 2012). MBs do not require 
degradation of the probe in order to release fluorescence, this occurs when the probe sequence 
hybridises to is complementary amplified sequence. The MBs are hairpin shaped structures 
consisting of a fluorophore and a quencher covalently bound to the 5’ and 3’ ends respectively, a 
double-stranded stem region and a bigger single-stranded, open loop with at least 15 nt 
complementary to the target of interest (Figure 12). The double-stranded part of the probe is 
designed to maintain a sufficient proximity between the quencher and the chosen fluorophore, 
preventing any fluorescence release, in an un-bound state. Once, the target molecule is amplified, 
the MBs hybridise to the complementary region of its amplicon via the single-stranded loop, 
forcing stem region to disassociate and resulting in the separation of the fluorophore from the 
quencher that in turn enables fluorescence signal detection upon excitation.   
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MB have been widely used in a wide range of commercial diagnostic tests with an increased 
popularity amongst isothermal technologies. Since most of the DNA polymerases used in 
isothermal tests do not possess 5’ 3’ endonuclease activity, the TaqMan technology was found 
to be unsuitable for this type of analysis, making the MB probing the method of choice for specific 
amplicon detection.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Graphic representation of molecular beacons technology. 1 – showing a secondary structure of 
a unbound probe consisting of a double-stranded stem with fluorophore and quencher at 5’ and 3’ ends, 
respectively, and a single-stranded loop region complementary to the target of interest; 2 – Bound 
beacon with an open structure caused by loop hybridisation to its target. 
Source: http://www.sigmaaldrich.com/technical-documents/articles/biology/molecular-beacons.html  
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1.1.6 Summary 
Probe-based detections systems offer real-time monitoring and quantification of amplification but 
also offer a significantly increase the sensitivity of molecular assays. TaqMan probes have been 
the most widely used in PCR-based detection systems. However due to their requirements for 
probe hydrolysis, are incompatible with most isothermal amplification technologies. Molecular 
beacons, on the other hand, offer the specificity of TaqMan probes without the need for probe 
digestion thus their use in isothermal platforms has significantly grown over the past 20 years (Yan 
et al., 2014). Although, fluorescent based detection systems have been widely used by PCR and 
isothermal technologies and offer some advantages over BART, such as the ability to 
simultaneously detect multiple targets (multiplexing), they require expensive optical components 
capable of detecting such signals, resulting in a significantly increased cost of both, assays and 
equipment. 
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Chapter 2 
2 Material and methods 
2.1 Materials 
2.1.1 Samples 
a) Freeze-dried Hepatitis C 5’UTR RNA and DNA fragments (RNA: LGC (ATCC), USA; 
DNA: ERBAM, UK) 
b) Freeze-dried Mycobacterium bovis genomic DNA and rRNA (ERBAM, UK) 
c) Freeze-dried Hepatitis B genomic DNA (ERBAM,UK) 
2.1.2 Consumables 
a) 2.0 mL ultra-non-stick screw-cap tubes (BioLabs, UK) 
b) 96-well plates, White (ThermoFisher Scientific, UK) 
c) 96-well plate adhesive seals (Sigma, Aldrich, UK) 
d) Ultra-non-stick tips (10,100 and 1000) uL and Nishi/Gilson pipettes 
e) Gloves  
2.1.3 Reagents 
a) 10x Isothermal buffer (NEB, UK) 
b) 10x Thermopol buffer (NEB, UK) 
c) 1M DTT (Sigma, Aldrich, UK) 
d) 1x TAE buffer 
e) 4x 50 mM Bicene Buffer (ERBAM, UK) 
f) 4x 500 mM Bicene Buffer (ERBAM,UK)  
g) Acrylamide (30%) (Sigma, Aldrich, UK) 
h) APS (Biolog Institue, UK) 
i) ATP sulphurylase (NEB, UK) 
j) Bst 1.0 Large fragment (NEB, UK) 
k) Bst 2.0  (NEB, UK) 
l) Bst 2.0 Warm Start Large fragment (NEB, UK) 
m) carrier tRNA (ThermoFisher Scientific, UK) 
n) Collagen from calf skin (Sigma, Aldrich, UK) 
o) dNTPs (Sigma, Aldrich, UK) 
p) GSP-SSD (Optigene, UK) 
q) Humic Acid (Sigma, Aldrich, UK) 
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r) Luciferase (NEB, UK) 
s) Luciferin (Sigma, Aldrich, UK) 
t) Maxima RNaseH- (ThermoFisher Scientific, UK) 
u) Maxima RNaseH+ (ThermoFisher Scientific, UK) 
v) Mineral oil (ThermoFisher Scientific, UK) 
w) Molecular biology grade water (Sigma, Aldrich, UK) 
x) Polyvinylpyrrolidone (PVP) (Sigma, Aldrich, UK) 
y) Potassium Acetate (KAc) (Sigma, Aldrich, UK) 
z) Potassium Chloride (KCl) (Sigma, Aldrich, UK) 
aa) Salmon sperm DNA (NEB, UK) 
bb) Sodium Chloride (NaCl)(Sigma, Aldrich, UK) 
cc) SuperScript IV (ThermoFisher Scientific, UK) 
dd) TEMED 10x (Sigma, Aldrich, UK) 
ee) Trehalose (Sigma, Aldrich, UK) 
2.1.4 Equipment  
a) “BISON” LAMP-BART instrument (Lumora Ltd., UK) 
b) “Lucy” LAMP-BART instrument (Lumora Ltd, UK) 
c) Centrifuge (Technico mini, Thermo Scientific, UK) 
d) CX-2000 UV crosslinker (Fisher Scientific UK Ltd., UK) 
e) Freezer 
f) Fridge  
g) Gel electrophoresis tanks (BioRad, UK) 
h) Laminar flow hood (BioQuell, UK) 
i) UV-transilluminator (Syngene, Cambridge, UK) 
j) Vortex 
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2.2 Methods 
All samples used in this study, including HCV 5’ UTR DNA and RNA, TB M. bovis gDNA and 
23s rRNA as well as the IAC RNA, were prepared by ERBAM, UK. Samples were stored as a 
single-use aliquots at -80 °C.   
2.2.1 Contamination control 
Every precaution was taken throughout the study to minimize the risks of sample contamination. 
Preparation of the DNA and RNA templates and reaction mixes were carried out in a laminar flow 
hood crosslinked for 10 mins prior to each experiment. In addition, no-template controls (NTCs) 
were run each time new aliquots of the LAMP-BART reaction were prepared. Each aliquot was 
used only once per assay to minimize contamination events caused by sample handling. 
2.2.2 DNA quantity and purity  
All DNA and RNA templates were quantified by measuring its absorbance between 230 and 300 
nm on a NanoDrop 2000 spectrophotometer. 1 ul of each aliquot of the linearized plasmid was 
analysed to check its purity and quantity. In addition, the samples were also quantified using the 
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., UK). 
Note that the HCV RNA template was quantified by a certified reference materials supplier that 
guaranties the highest accuracy quantifications. Thus, the concentration determined by the supplier 
was used to generate the working stock aliquots.   
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2.2.3 Reagents preparation for LAMP-BART assays 
Reagents used for the development of isothermal miRNA detection systems were prepared 
according to the Protocol 26: Reagents preparation for miRNA assays (see Appendix 26). 
All other reagents were supplied by ERBAM, UK and stored at -20 °C. 
2.2.4 Reconstitution of primers    
Oligonucleotides used for HCV, TB and HBV LAMP assays were purchased from Eurofins 
MWG-BioTech, Germany. Oligonucleotides, including primers and probes, used for the 
development of isothermal miRNA detection systems were purchased from Sigma, UK.  
All primers and probes used in this study were reconstituted with the required volume of 1x TE 
buffer (pH=8.0), as indicated on the company’s technical datasheet, to 100 µM. The primers were 
then labelled and stored at -20 °C. 
2.2.5 Amplicon visualisation  
Analysis of ligation and endonuclease digestion of the target oligonucleotides was performed using 
polyacrylamide gel electrophoresis (SDS-PAGE) according to the Protocol 34: SDS-PAGE 
protocol (see Appendix 34).  
Gels were stained using 5 uL of 10000x GelRed per every 50 mL of the gel solution. 
Electrophoresis was performed at 45 V for 60-85 min. Nucleic acid bands were visualised with a 
UV transilluminator. 
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2.2.6 Preparation of the internal amplification control RNA 
IAC RNA template was in vitro transcribed using MEGAscript T7 transcription kit (ThermoFisher 
Scientific, UK) according to the protocol provided by the manufacturer [see MEGAscript T7 
transcription kit manual: URL: https://www.thermofisher.com/order/catalog/product/AM1334].  
pEX DNA plasmid containing the IAC insert and the T7 promoter sequence was purchased from 
Eurofins Genomics.  
Full preparation of the final IAC RNA product was performed by ERBAM, UK.  
2.2.7 Secondary structure analysis 
Vienna RNAfold online software was used to determine the secondary structures of the 5’UTR 
HCV RNA [URL: http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi]. The analysis 
was performed using the minimum free energy and partition function at 60 °C.   
2.2.8 Data analysis and statistics 
Microsoft EXCEL 2013 was used for analysis of the experimental data including ANOVA and t-
test statistical analysis. Note that standard deviation was calculated from technical replicates, and 
was used as a measure of the reproducibility of an assay preformed on a given day.   
Sequence alignments were visualised using GeneDoc free software [URL: 
http://genedoc.software.informer.com/]  
2.2.9 LAMP primer design 
2.2.9.1 HCV LAMP primers 
HCV LAMP primers were designed to target the 5’UTR region of the Hepatitis C virus RNA 
genome. The sequence alignments were retrieved from HCV database [URL: 
https://hcv.lanl.gov/content/sequence/HCV/ToolsOutline.html]. Melting temperatures of all of the 
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HCV LAMP primers were assessed using IDT oligo analyser [URL: 
https://www.idtdna.com/calc/analyzer] under 50 mM sodium, 2 mM magnesium ions and 0.3 mM 
dNTPs. Self- and cross-priming interactions were assessed using multiple primer analyser 
provided by ThermoFisher [URL: https://www.thermofisher.com/uk/en/home/brands/thermo-
scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-resource-
library/thermo-scientific-web-tools/multiple-primer-analyzer.html] under sensitivity setting 1.  
Primer sequences were adjusted accordingly in order to minimise 3’ interactions and thus reduce 
the NTC formation.  
2.2.9.2 HBV LAMP primers 
HBV LAMP primers were designed by ERBAM, UK (see Appendix 39). 
2.2.9.3 TB LAMP primers  
TB LAMP primers were designed by ERBAM, UK (see Appendix 39). 
2.2.9.4 miRNA primers and probes 
LAMP primers were designed to target the cauliflower mosaic virus 35S promoter sequence 
(GeneBank accession number X79465) by Dr Patrick Hardinge.  
Ligation probes were designed based on the dumbbell sequence generated by the 35S LAMP 
primers where 22 nt of its stem sequence was substituted with the target miRNA complementary 
binding site. Each probe (P1 and P2) contained 11 nt of the miRNA binding site (refer to the 
ligation-based miRNA detection design, Appendix 37). 
Note that a phosphate group at the 5’ end of the P2 probe was introduced in order to enable ligation. 
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Endonuclease probes were designed based on the dumbbell sequence generated by the 35S LAMP 
primers where the loop F and FIP primer binding sites were substituted with an artificial stem loop 
sequence. miRNA binding site was introduced at the 3’ end of the probe (see Appendix 38).  
The sequence of the target miRNA lin-4 was retrieved from: Lee RC, Feinbaum RL, Ambros V 
(1993). "The C. elegans heterochronic gene lin-4encodes small RNAs with antisense 
complementarity to lin-14.". Cell. 75 (5): 843–854.  
2.2.10 LAMP BART assays 
All LAMP BART amplification reactions were performed on dedicated instruments that 
simultaneously control temperature and record bioluminescence (“BISON” and “Lucy”, ERBAM., 
UK). Each LAMP-BART assay was performed in nuclease free 96-well plates (white) under 
molecular grade mineral oil, at 60 °C for 90-120 min. In addition, all LAMP-BART reactions were 
performed in a total volume of 20 uL, unless otherwise stated. 
2.2.10.1 HCV LAMP BART assays 
2.2.10.1.1 Primer screening assay 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 2. 1388 
uL of the initial reaction mix was then split into four aliquots of 347 uL each. Final master mix 
was prepared by adding 2 uL of F3 and B3, 4 uL of Loop B and F and 8 uL of FIP and BIP of the 
appropriate LAMP primer sets to the aliquots containing 347 uL of the initial master mix. 15 uL 
of the final master mix was then mixed with 5 uL of the HCV 5’ UTR RNA template [10^4 cp/5uL] 
in a 96-well plate (white) followed by an addition of two drops of mineral oil. Samples were sealed 
using a clear adhesive film and loaded onto BISON set at 60 °C and ran for 90 min.  
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2.2.10.1.2 DNA polymerase screening assay 
Initial master mixes (2x) were prepared according to the reaction mix set up shown Appendix 3. 
1498 uL of each of the prepared initial reaction mixes were then split into two aliquots of 749 uL. 
Final master mixes were prepared by adding 1 uL of either GSP-SSD [100 U/uL], Bst 2.0 [200 
U/uL] or Bst 2.0WS [200 U/uL], or 1.3 uL of Bst large fragment [160 U/uL] to separate aliquots 
containing 749 uL of the initial master mix. 15 uL of the final master mix was then mixed with 5 
uL of the appropriate HCV template in a 96-well plate (white) followed by an addition of two 
drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto BISON set 
at 60 °C and ran for 90 min.  
HCV RNA at concentrations 10^4, 10^3, 100, 50 and 10 cps/5uL were used in this study. 
2.2.10.1.3 Reverse transcriptase screening assay 
Initial master mixes (2x) were prepared according to the reaction mix set up shown in Appendix 
4. 1498 uL of each of the prepared initial reaction mixes were then split into two aliquots of 749 
uL. Final master mixes were prepared by adding 1 uL of either Maxima RNaseH+ [200 U/uL], 
Maxima RNaseH+ [200 U/uL] or SuperScriptIV [200 U/uL] to separate aliquots containing 749 
uL of the initial master mix. 15 uL of the final master mix was then mixed with 5 uL of the 
appropriate HCV template in a 96-well plate (white) followed by an addition of two drops of 
mineral oil. Samples were sealed using a clear adhesive film and loaded onto BISON set at 60 °C 
and ran for 90 min.  
HCV RNA at concentrations 10^4, 10^3, 100, 50, 10 and 1 cps/5uL were used in this study. 
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2.2.10.1.4 Reaction buffers screening assay 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 5. 1300 
uL of the prepared initial reaction mixes was then split into two aliquots of 650 uL each. Final 
master mix was prepared by adding 100 uL of either Isothermal [10x] or Thermopol [10x] buffers 
to separate aliquots containing 650 uL of the initial master mix. 15 uL of the final master mix was 
then mixed with 5 uL of the appropriate HCV template in a 96-well plate (white) followed by an 
addition of two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded 
onto BISON set at 60 °C and ran for 90 min. 
HCV RNA at concentrations 10^4, 10^3, 100, 50, 10 and 1 cps/5uL were used in this study. 
2.2.10.1.5 Inhibitory substances screening assay: KCl, KAc and NaCl  
Initial master mix was prepared according to the reaction mix set up shown in Appendix 6. 1498 
uL of the initial reaction mixes was then split into two aliquots of 749 uL each. Final master mix 
was prepared by adding 1 uL of either GSP-SSD [100 U/uL] or Bst 2.0 [200 U/uL] to separate 
aliquots containing 749 uL of the initial master mix. 15 uL of the final master mix was then mixed 
with 5 uL of the appropriate inhibitory substance in a 96-well plate (white) followed by an addition 
of two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto 
BISON set at 60 °C and ran for 90 min.  
Potassium and sodium chloride and Potassium acetate at concentrations 0 to 50 mM, were tested 
in this study.  
2.2.10.2 TB LAMP BART assays 
All TB LAMP BART assays used GSP-SSD DNA polymerase and 500 mM Bicine buffer [4x], 
unless otherwise stated. 
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2.2.10.2.1 DNA polymerase screening assay 
Initial master mixes (2x) were prepared according to the reaction mix set up shown in Appendix 
8. 1498 uL of each of the prepared initial reaction mixes were then split into two aliquots of 749 
uL. Final master mixes were prepared by adding 1 uL of either GSP-SSD [100 U/uL], Bst 2.0 [200 
U/uL] or Bst 2.0WS [200 U/uL], or 1.3 uL Bst large fragment [160 U/uL] to separate aliquots 
containing 749 uL of the initial master mix. 15 uL of the final master mix was then mixed with 5 
uL of the appropriate TB M. bovis template in a 96-well plate (white) followed by an addition of 
two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto BISON 
set at 60 °C and ran for 90 min.  
M. bovis nucleic acids concentrations of 1000 and 100 cps/5uL were used in this study. 
Both genomic DNA and 23s rRNA were used.  
2.2.10.2.2 Inhibitory substances screening assay: LDS (no IAC) 
Master mix was prepared according to the reaction mix set up shown in Appendix 9. 15 uL of the 
master mix was then mixed with 5 uL of the appropriate M. bovis template* in a 96-well plate 
(white) followed by an addition of two drops of mineral oil. Samples were sealed using a clear 
adhesive film and loaded onto BISON set at 60 °C and ran for 90 min.  
*- dilutions of the templates were performed using the appropriate concentrations of the tested 
inhibitors as diluents. 
M. bovis 23s rRNA at concentration 1000 and 100 cps/5uL was used in this study.  
Serial dilutions (20 uL sample + 180 uL diluent) of the 23s rRNA top stock [10^6 cps/5uL]   were 
carried out in order to obtain the appropriate template concentrations. 
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For the inhibitory samples, 0.01 and 0.05% LDS was used as diluents. 
2.2.10.2.3 Inhibitory substances screening assay: Bicine buffers 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 10. 1000 
uL of the initial reaction mix was then split into two aliquots of 500 uL each. Final master mix was 
prepared by adding 250 uL of either 500 mM [4x] or 50 mM [4x] Bicine buffers to separate aliquots 
containing 500 uL of the initial master mix. 15 uL of the final master mix was then mixed with 5 
uL of the appropriate M. bovis template* in a 96-well plate (white) followed by an addition of two 
drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto BISON set 
at 60 °C and ran for 90 min.  
*- dilutions of the templates were performed using the appropriate concentrations of the tested 
inhibitors as diluents. 
M. bovis 23s rRNA at concentration 10000 and 1000 cps/5uL was used in this study.  
Serial dilutions (20 uL sample + 180 uL diluent) of the 23s rRNA top stock [10^6 cps/5uL]   were 
carried out in order to obtain the appropriate template concentrations. 
For the inhibitory samples, 0.05% LDS was used as diluent. 
2.2.10.2.4 Inhibitory substances screening assay: carrier DNA (no IAC) 
Master mix was prepared according to the reaction mix set up shown in the Appendix 11. 15 uL 
of the master mix was then mixed with 5 uL of the appropriate M. bovis template* in a 96-well 
plate (white) followed by an addition of two drops of mineral oil. Samples were sealed using a 
clear adhesive film and loaded onto BISON set at 60 °C and ran for 90 min.  
44 
 
*- dilutions of the templates were performed using the appropriate concentrations of the tested 
inhibitors as diluents. 
M. bovis 23s rRNA at concentration 1000 and 100 cps/5uL was used in this study.  
Serial dilutions (20 uL sample + 180 uL diluent) of the 23s rRNA top stock [10^6 cps/5uL]   were 
carried out in order to obtain the appropriate template concentrations. 
For the inhibitory samples, 1000 ng/5uL of salmon sperm DNA was used as diluent. 
2.2.10.2.5 Inhibitory substances screening assay: carrier DNA (incl. IAC) (50 vs 10 uL reactions) 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 19. 1470 
uL of the initial reaction mixes was then split into two aliquots of 735 uL each followed by an 
addition of 7.5 uL either MGW or TB M. bovis RNA. The two prepared initial master mixes (after 
additions) were then split into two smaller aliquots of 371.25 uL each. Final master mix was 
prepared by adding 3.75 uL of either MGW or carrier DNA [1000 ng/uL] to separate aliquots 
containing 371.25 uL of the initial master mix with either added TB RNA or MGW. 50 uL and 10 
uL of the final reaction mix (including templates) were then dispensed across  a 96-well plate 
(white) covered with 2 drops of mineral oil and sealed using adhesive clear film. Samples were 
run at 60 °C for 90 min on BISON.   
2.2.10.2.6 Inhibitory substances screening assay (incl. IAC) 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 16. 1480 
uL of the initial reaction mix was then split into two aliquots of 740 uL each. Final master mix was 
prepared by adding 5 uL of both MGW and IAC RNA or 5 uL of IAC and TB RNA to the separate 
aliquots containing 740 uL of the initial master mix. 15 uL of the final master mix was then mixed 
with 5 uL of the appropriate inhibitory substance in a 96-well plate (white) followed by an addition 
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of two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto 
BISON set at 60 °C and ran for 90 min. 
Inhibitory substances used in this study: 
Sodium chloride at concentrations 20, 30 and 40 mM; 
Salmon sperm DNA at concentrations 50, 500 and 1000 ng/5uL; 
tRNA at concentrations 50, 500 and 1000 ng/5uL; 
Mucin solution at concentrations 400, 500 and 700 ng/rxn; 
NaOH at concentrations 1333, 1667 and 2326 µM; 
2.2.10.2.7 Inhibitory substances screening assay: Mucin 
Master mix was prepared according to the reaction mix set up shown in Appendix 9. 15 uL of the 
master mix was then mixed with 5 uL of the appropriate M. bovis [100 cps/5uL] or IAC RNA 
[10^6 cps/uL] template* in a 96-well plate (white) followed by an addition of two drops of mineral 
oil. Samples were sealed using a clear adhesive film and loaded onto BISON set at 60 °C and ran 
for 90 min.  
*- dilutions of the templates were performed using the appropriate concentrations of the tested 
inhibitors as diluents.  
Serial dilutions (20 uL sample + 180 uL diluent) of the 23s rRNA top stock [10^6 cps/5uL]   were 
carried out in order to obtain the appropriate template concentrations. 
For the inhibitory samples, 50, 200 and 400 ng/uL Mucin solution and 1333 mM NaOH were used 
as diluents. 
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2.2.10.2.8 Primer mutations screening assay 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 12. 1468 
uL of the initial reaction mix was then split into four aliquots of 367 uL each. Final master mix 
was prepared by adding 8 uL of the appropriate version of the LAMP F primer to separate aliquots 
containing 367 uL of the initial master mix. 15 uL of the final master mix was then mixed with 5 
uL of the appropriate M. bovis template [10^4 cps/5uL] in a 96-well plate (white) followed by an 
addition of two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded 
onto BISON set at 60 °C and ran for 90 min. 
Note that the loop primers were not added. 
2.2.10.2.9 Standard TB assay (50 µL reactions) 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 18. 1470 
uL of the initial reaction mixes was then split into two aliquots of 735 uL each. Final master mix 
was prepared by adding 7.5 uL of MGW and 7.5 uL of either M. bovis TB template [10^4 cps/5uL] 
or IAC RNA [10^7 cps/5uL] to separate aliquots containing 735 uL of the initial master mix. 50 
uL of the final reaction mix (including templates) was then dispensed across 30 wells of a 96-well 
plate (white) covered with 2 drops of mineral oil and sealed using adhesive clear film. Samples 
were run at 60 °C for 90 min on BISON.   
2.2.10.2.10 Assessment of DNA contamination in the IAC RNA samples 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 7. 
However, Maxima RNaseH+ was not added to the initial master mix. 1498 uL of the initial master 
mix was then split into two aliquots of 749 uL each followed by an addition of 1 uL of either 
Maxima RNaseH+ [200 U/uL] or MGW. 15 uL of the final master mix was then mixed with 5 uL 
of the appropriate IAC template in a 96-well plate (white) followed by an addition of two drops of 
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mineral oil. Samples were sealed using a clear adhesive film and loaded onto BISON set at 60 °C 
and ran for 90 min.  
IAC RNA and DNA concentrations of 10^8, 10^7, 10^6 and 10^5 cps/5uL, were used in this study. 
2.2.10.2.11 IAC interference study 
Master mix was prepared according to the reaction mix set up shown in Appendix 14. 15 uL of 
the master [10^6 cp/rxn IAC RNA] mix was then mixed with 5 uL of the appropriate M. bovis 
template in a 96-well plate (white) followed by an addition of two drops of mineral oil. Samples 
were sealed using a clear adhesive film and loaded onto BISON set at 60 °C and ran for 90 min.  
M. bovis 23s rRNA at concentrations 10^4, 10^3 and 100 cps/5uL were used in this study. 
2.2.10.2.12 Effects of HIV ROX-loop probes on IAC RNA amplification 
Initial master mix was prepared according to the reaction mix set up shown Appendix 15. 1482 
uL of the initial reaction mix was then split into two aliquots of 741 uL each, followed by an 
addition of either 1 uL GSP-SSD or 1.3 uL Bst large fragment. Each of the two prepared aliquots 
was then split into two smaller aliquots of 370.5 uL each. Final master mix was prepared by adding 
4 uL of either HIV probe or MGW to the separate aliquots containing 370.5 uL of the initial master 
mix with either GSP-SSD or Bst large fragment. 15 uL of the final master mix was then mixed 
with 5 uL of the IAC RNA template [10^6 cps/5uL] in a 96-well plate (white) followed by an 
addition of two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded 
onto BISON set at 60 °C and ran for 90 min. 
Note: 50 mM Bicine buffer was used in this study 
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2.2.10.2.13 Effects of DNA polymerases on the performance of HIV ROX loop probe-based 
detection 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 23. 1498 
uL of the initial reaction mixes was then split into two aliquots of 749 uL each. Final master mix 
was prepared by adding 1 uL of GSP-SSD [100 U/uL] or 1.3 uL Bst large fragment [160 U/uL] to 
separate aliquots containing 749 uL of the initial master mix. 15 uL of the final reaction mix was 
then mixed with 5 uL of the appropriate IAC template in a 96-well plate (white) covered with 2 
drops of mineral oil and sealed using adhesive clear film. Samples were run at 60 °C for 90 cycles 
on Strategene.  Note: each cycle was set to run for 1 min.  
2.2.10.3 HBV LAMP BART assays 
All HBV LAMP BART assays were performed using 10x Isothermal buffer and Bst 2.0 WS. 
2.2.10.3.1 Effects of BART on HBV ROX loop probe-based detection 
Initial master mix was prepared according to the reaction mix set up shown in Appendix 21-22. 
742 uL of the initial reaction mixes was then split into two aliquots of 371 uL each. Final master 
mix was prepared by adding 4 uL of either MGW or ROX-labelled loopF probe [100 uM] to 
separate aliquots containing 371 uL of the initial master mix. 15 uL of the final reaction mix was 
then mixed with 5 uL of the appropriate HBV template in a 96-well plate (white) covered with 2 
drops of mineral oil and sealed using adhesive clear film. Samples were run at 60 °C for 90 cycles 
on Strategene.  Note: each cycle was set to run for 1 min.  
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2.2.10.3.2 Effects of labelled loop probes on amplification of HBV DNA 
Master mix was prepared according to the reaction mix set up shown in Appendix 20. Note that 
Loop F primer was not added during reaction mix preparation. 1484 uL of the intial master mix 
was split into four aliquots of 470 uL each followed by an addition of 5 uL of the appropriate loop 
probe/primer. 
15 uL of the final master mix was then mixed with 5 uL of the appropriate HBV template in a 96-
well plate (white) followed by an addition of two drops of mineral oil. Samples were sealed using 
a clear adhesive film and loaded onto BISON set at 60 °C and ran for 90 min.  
2.2.10.4 miRNA LAMP BART assays 
2.2.10.4.1 Ligation-based miRNA detection assay  
Master mix was prepared according to the reaction mix set up shown in Appendix 24. 15 uL of 
the master mix was then mixed with 5 uL of the appropriate miRNA template in a 96-well plate 
(white) followed by an addition of two drops of mineral oil. Samples were sealed using a clear 
adhesive film and loaded onto “Lucy” set at 60 °C and ran for 90 min.  
2.2.10.4.2 Endonuclease-based miRNA detection assay 
Master mix was prepared according to the reaction mix set up shown in Appendix 35. 15 uL of 
the master mix was then mixed with 5 uL of the appropriate miRNA template in a 96-well plate 
(white) followed by an addition of two drops of mineral oil. Samples were sealed using a clear 
adhesive film and loaded onto “Lucy” set at 60 °C and ran for 90 min.  
 
 
 
 
50 
 
2.2.11 Ligation reactions 
Ligation reactions were performed at room temperature according to the protocols 27-30 (see 
Appendix 27-30), unless otherwise stated. All ligation reactions underwent an inactivation step 
performed at 95 °C for 20 min. 
2.2.11.1 Standard miRNA detection asay using SplintR ligase  
Initial SplintR reaction mix was prepared according to the protocol 27 (see Appendix 27). Note 
that P1, P2 and the target miRNA were not added to the initial reaction mix. 340 uL of the initial 
reactions mix (set up for 20 rxn) was split into four aliquots of 85 uL each. Final reaction mix was 
prepared by adding 1 – 5 uL P1 [1 uM] and 10 uL MGW; 2 – 5 uL P2 [1 uM] and 10 uL MGW; 3 
– 5 uL of both P1 and P2 [1 uM] and 5 uL MGW; 4 – 5 uL of both P1 and P2 [1 uM] and 5 uL 
miRNA lin-4 [100 uM].  
Reactions were incubated for 30 min followed by an inactivation step. 100x dilution of each 
ligation sample was then performed using MGW. 5 uL of the diluted ligation sample was then 
mixed with the standard LAMP BART reaction mix (see Appendix 24).  
2.2.11.2 Ligases screening assay  
Separate reaction mixes were prepared according to the appropriate ligation protocol (see 
Appendix 27-30). 
Note that 100x dilution [1 uM] of each probe was used in this study. 
Reactions were incubated for 30 min followed by an inactivation step. 100x dilution of each 
ligation sample was then performed using MGW. 5 uL of the diluted ligation sample was then 
mixed with the standard LAMP BART reaction mix (see Appendix 24).  
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2.2.11.3 Time course study 
SplintR reaction mix was prepared according to the protocol 27 (see Appendix 27). Note that 100x 
dilution [1 uM] of each probe was used in this study. 
Samples were initially incubated for 5 min followed by transferring 100 uL of the ligation mix to 
a separate tube and placed on ice. The remaining volume was left at room temperature for 
additional 25 min. Both aliquots were then transfer onto a heating block for inactivation. 100x 
dilution of each inactivated sample was performed using MGW. 5 uL of the diluted ligation sample 
was then mixed with the standard LAMP BART reaction mix (see Appendix 24).  
2.2.11.4 Probe optimisation study 
Initial SplintR reaction mix was prepared according to the protocol 27 (see Appendix 27). Note 
that probes P1 and P2 were not added to the initial reaction mix. 540 uL of the initial reaction mix 
(set up for 30 rxn) was then split into six aliquots of 90 uL each. Final reaction mix was prepared 
by adding of 5 uL of both P1 and P2 probes.  
Dilutions tested: 10, 1, 0.1, 0.05, 0.02 and 0.01 uM. Note that the final concentrations of the probes 
in the reaction mixture was 20x lower.   
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2.2.12 Restriction digest  
Restriction digest was performed according to the protocols 31-32 (see Appendix 31-32). 
Templates were prepared according to the PCR protocol 33 (see Appendix 33). 
10 uL of each restriction digest reaction was then loaded onto a SDS-PAGE and run for 85 min at 
45 V. 
2.2.13 Endonuclease heat inactivation  
Heat inactivation was performed at 95 °C for 30 min in the appropriate reaction buffer provided 
by the supplier. 
2.2.14 Pre-incubation procedure 
Nb.bsmI was pre-incubated in a modified LAMP BART reaction mix at 60 °C for 60 min followed 
by the standard endonuclease heat inactivation step.  
LAMP BART reaction mix was prepared according to the protocol 24 (see Appendix 24). Note 
that enzymes were not added.  
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Chapter 3  
3 Development of RT-LAMP assay for diagnosis of Hepatitis C 
infections 
 
3.1 Introduction  
Hepatitis C is a highly infectious disease caused by the Hepatitis C virus (HCV) that mainly infects 
the liver (Choo et al., 1989, Seeff and Hoofnagle, 2003). Initial infection usually results in very 
mild or no symptoms, which makes an early diagnosis very problematic (Zhang et al., 2016, Seeff 
and Hoofnagle, 2003). It has been estimated that an approximately 130–200 million people are 
infected with hepatitis C, worldwide (Modi and Liang, 2008, Zhang et al., 2016, Cloherty et al., 
2016). In 2013, the vast majority of the 11 million new reported cases of HCV infections, occurred 
in Africa and Central and East Asia.  In addition, that year alone, almost 800,000 deaths related to 
the chronic HCV infections, were reported (Petruzziello et al., 2016, Karoney and Siika, 2013).  
HCV can primarily be transmitted via blood-to-blood route, and is mainly associated with 
intravenous drug users, poorly sterilised medical equipment, transfusions or needle stick injuries 
amongst healthcare personnel.  However, HCV can also be transmitted from mother to child during 
birth (Tibbs, 1995, WHO, 2017, Maheshwari and Thuluvath, 2010, Pondé, 2011).  
The HCV virus persists in up to 80 % of the infected individuals and the vast majority do not 
develop any symptoms during the early stages of the disease. However, during prolonged 
infection, HCV infection leads to liver disease and in some cases cirrhosis.  In addition, patients 
with cirrhosis have an increased risk of developing liver failure, liver cancer or 
oesophageal and gastric varices (Kim, 2016, Alter, 2007, Xu et al., 2013).  
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Currently, there is no vaccine available against HCV infections. Prevention strategies involve harm 
reduction methods, amongst drugs abusing individuals, as well as extensive blood product 
screening prior to transfusions (Alter, 2007, Abdelwahab and Ahmed Said, 2016, Hagan et al., 
2011).  HCV treatment involving sofosbuvir and simeprevir, have been shown to be capable of 
curing up to 90 % of the chronic infections if diagnosed in the earlier stages of the disease (Panel, 
2015, WHO, 2017, Abergel et al., 2016).  
3.1.1 The Hepatitis C virus 
Hepatitis C is an enveloped RNA virus with a diameter of approximately 50 nm and it belongs to 
the flaviviridae family. The HCV viron consists of a single-stranded, positive sense RNA ((+) 
RNA) molecule encapsulated by an icosahedral capsid composed of the core protein and an outer 
lipid layer of host’s origin. Two key viral glycoproteins, E1 and E2, are embedded within the outer 
lipid layer and facilitate the viral attachment and entry to the host’s cell (Ashfaq et al., 2011) 
(Figure 13). 
It has been reported that the HCV virus can circulate in three main forms within the serum of 
infected individuals: a) as a free viron; b) virons bound to lipoproteins and c) non-enveloped 
nucleocapsid (Maillard et al., 2001, André et al., 2005). It has been suggested that the core protein 
functions not only as a structural protein, but it also has an effect on the host cells gene expression 
and in the regulation of apoptosis (one of the host’s defence mechanisms against viral infections) 
(Okuda et al., 2002, Su et al., 2002, Song et al., 2016, Kwak et al., 2016).    
55 
 
 
 
3.1.2 Hepatitis C genomics 
The genome of HCV is made of a positive-sense, single-stranded RNA of 9400 nt (Kato, 2000). It 
contains a single open reading frame (ORF) encoding a polyprotein of approximately 3000 amino 
acids. The ORF is flanked by 5’ and 3’ untranslated regions (UTR or NTR) of approximately 341 
and 230 nucleotides, respectively.  However, the length of the 3’UTR can vary significantly 
between different subtypes of the HCV virus, but it normally consists of a short poorly conserved 
region of approximately 28-42 nucleotides, poly-(U) / polypyrimidine (T/C) track and a highly 
conserved base element of 98 nucleotides (known as a 3’X region). The 3’X region together with 
the 52 upstream nt of the poly(U/C) domain have been reported to play a crucial role in the viral 
RNA replication (Jubin, 2001, Berry et al., 2011). 
Figure 13. Graphic representation of the Hepatitis C viral particle structure. 
Source: http://www.abcam.com/index.html?pageconfig=resource&rid=13135 
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Of the two UTRs, the 5’UTR exhibits the highest degree of conservation for all the known HCV 
genotypes. It consists of four heavily structured domains (I-IV) made of many stem-loops and 
pseudoknots. It has been reported that the domain II-IV together with the first 30 nucleotides of 
the coding region make up the internal ribosome entry sequence (IRES). IRES is responsible for 
binding to the host’s 40s ribosomal subunits and initiating the translation of the viral polyprotein 
in a cap-independent manner (Berry et al., 2011, Lukavsky, 2009). The translated polyprotein is 
subsequently co-translationally and post-translationally modified by the viral and host’s proteases 
to produce 10 mature proteins (Figure 14).  The N terminal part of the viral genome encodes for 
structural proteins: a) non-glycosylated nucleic acid-binding nucleocapsid protein, known as the 
core protein (approx. 190 aa/21kDa); b) two membrane-associated glycoproteins E1 and E2 of 190 
and 370 aa, respectively (Moradpour and Penin, 2013).  
The non-structural viral proteins include: a) NS1 (p7) thought to be involved in generation of the 
viroporin in the host’s ER membrane; b) NS2 to NS5B are involved in the modification and 
processing of the viral polyprotein as well as viral genome replication.  The post-translational 
processing of the viral polyprotein is carried out by two proteinases NS2-NS3 Zinc-dependent 
metalloproteinase and NS3 serine proteinase located at the N-terminal region of the NS3 protein. 
The NS2-NS3 proteinase is responsible for cleavage of the NS2/NS3 region of the viral 
polyprotein only. In contrast, the NS3 serine proteinase together with its cofactor NS4a releases 
the remaining proteins from the viral polyprotein complex (Moradpour and Penin, 2013, Penin et 
al., 2004, Moradpour et al., 2005).  
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Figure 14. Graphic representation of the Hepatitis C viral genome structure. The HCV genome consists of two non-translated regions (5’ 
and 3’ NTR and a single polyprotein encoding for structural (red) and non-structural (yellow) proteins. During the co- and post-
translational processing, the polyprotein is cleaved to generate ten proteins. C- structural core protein, E1 and E2 – viral glycoproteins 
responsible for attachment and entry, NS1 (p7) – viroporin, NS2-3 – viral proteinases, NS4a- NS3 cofactor, NS5b – RNA-dependant RNA 
polymerase. 
Source: http://stanford.edu/~ncho/AR_2.html 
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3.1.3 The lifecycle of Hepatitis C  
HCV enters the target cell through interactions with specific membrane receptors such as CD81 or 
SR-BI that are suggested to play crucial roles in viral binding (Figure 15). Upon attaching itself 
to the host’s receptors, the viral lipid envelope is fused with the target cell’s membrane and this is 
followed by release of the viral nucleocapsid into the cell cytoplasm. Attachment and fusion is 
mediated by viral surface glycoproteins (E1-E2) and can take place at either the host’s plasma 
membrane or inside the endosomes followed endocytosis (Kim, 2016, Kato, 2000, Barth et al., 
2006). 
As previously mentioned, Hepatitis C virus stores its genetic material in a form of single-stranded, 
positive sense RNA molecule. The HCV genome can be used as a direct template for translation 
into viral proteins. Once the viral protein synthesis is complete, the NS4b protein stimulates 
Figure 15. Graphic representation of the Hepatitis C life 
cycle. 
Source: 
http://www.abcam.com/index.html?pageconfig=reso
urce&rid=13135 
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formation of membrane vesicles, known as membranous web, which acts as a viral RNA 
replication machinery (Behrens et al., 1996, Elazar et al., 2003). The NS5b is then employed for 
the synthesis of the complementary to the viral genome, anti-sense strand ((-) RNA) which in turns 
serves as a template for synthesis of the viral ssRNA genome. Subsequently, upon synthesis of all 
the viral protein and its genetic material, assembly of new virons is carried out followed by their 
excretion from the host’s cell via exocytosis (Ashfaq et al., 2011).  
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3.1.4 Hepatitis C diversity and classification  
The HCV virus has recently been divided into seven distinct genotypes (1-7) based on the variation 
in the nucleotide sequence of all the known HCV genomes (Figure 16) (Kato, 2000, Alter, 2007). 
On average, each of these genotypes differ in 30-35% in their nucleotide sequence when the entire 
genomes where taken into consideration. It has been reported that the vast majority of the variation 
seen between different HCV genotypes are concentrated in the regions encoding for the E1 and E2 
glycoproteins (Simmonds, 1995, Simmonds et al., 1993, Cuypers et al., 2015).  
Furthermore, according to the more recent reviews of the HCV genotype / subtype classification, 
approximately 67 subtypes of the virus were identified (genotype number followed by a letter a, 
Figure 16. Graphic representation of the Hepatitis C phylogenetic tree showing all the currently known genotypes and the 
corresponding subtypes. 
Source: http://www.abcam.com/index.html?pageconfig=resource&rid=13135 
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b, c, etc.). Each identified subtype differs in at least 15 % in their coding region (or 20-25 % in 
their entire genome sequence) – variability is particularly dominant in the regions coding for the 
core, E1 and NS5B proteins. In addition, several strains of the same subtype have also been 
identified and reported to differ at less than 15 % in their genomic sequence (Timm and 
Roggendorf, 2007, Cuypers et al., 2015). 
3.1.5 Hepatitis C geographical distribution 
The geographical distribution of the HCV infections is complex. It has already been reported that 
certain subtypes including 1a, 1b, 2a and 3a are distributed globally and account for over 60 % of 
all HCV infections (Figure 17) (Timm and Roggendorf, 2007, Kato, 2000). Such a wide spread 
dispersal of these particular subtypes could potentially be explained by the adoption of blood 
transfusions that occurred in the 20th century (Simmonds, 2004, Kato, 2000). In addition, the use 
of unsterilized needles for injections and vaccinations (a practice that continues in many 
developing countries to-date), as well as needle sharing within drug user groups of industrialised 
countries. Many of the remaining subtypes are considered to be endemic strains, which are rather 
rare and have circulated for a much longer period of time in more restricted regions of the globe: 
1 and 2 – West Africa; 3 - South Asia; 4 – Central Africa and Middle East; 5 – Southern Africa; 6 
– South-east Asia. According to the most recent reports, only genotype 7 infection was reported in 
Canada where the strain was isolated form a Central African immigrant (Simmonds, 2004).   
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Globally, genotype 1 has been estimated to contribute to over 46 % (83.4 million) of all HCV 
infections with one-third cases located in East Asia followed by the HCV genotype 3 which 
contributed to over 30 % (54.3 million) of HCV incidents most of which occurred in South Asia. 
Genotypes 2, 4 and 6 are responsible for most of the remaining HCV infections and account for 
9.1 % (16.5 million), 8.3 % (15 million) and 5.4 % (9.8 million) cases worldwide, respectively 
(Simmonds, 2004).  Recent reports have shown that the genotype 5 contributed to less than 1 % of 
all the HCV infections where the vast majority occurred in Southern and sub-Saharan Africa. No 
apparent differences in the HCV structure, replication, transmission and the ability to establish a 
persistent infection have been observed between all the known genotypes. In addition, the wide 
spread of HCV infections in the human population suggests that each genotype is equally capable 
Figure 17. Graphic representation of the Hepatitis C geographical distribution with an emphasis on the most prevalent genotypes for 
each region. 
Source: (Hussain, 2013) https://www.intechopen.com/books/practical-management-of-chronic-viral-hepatitis/genomic-
heterogeneity-of-hepatitis-viruses-a-e-role-in-clinical-implications-and-treatment 
 
63 
 
of maintaining infections.  However, despite the phenotypic similarities between the genotypes, 
there is a growing evidence of genotype-specific differences in persistence and interactions with 
the innate cell defences and resistance to antiviral therapies. It has been shown that only 10-20 % 
and 40-50% of individuals infected with the genotype 1 HCV fully recovered when either IFN 
monotherapy or IFN (interferon-α)/ribavirin combination therapy, respectively, was used. In 
contrast, 50 % and 70-80 % of individuals infected with genotypes 2 or 3 were cured upon 
implementation of the exact same antiviral therapy (Hussain, 2013, Kato, 2000, Timm and 
Roggendorf, 2007). Furthermore, it is becoming more apparent that the variation in the coding 
regions, particularly within the E2 and NS5A, can have a significant effect in host’s immune 
responses and the resistance to the antiviral drug therapies.  
3.1.6 Molecular diagnostics of Hepatitis C 
Enzyme immunoassays (EIA / ELISA) and chemiluminescence immunoassays (CIA) have been 
the most widely used methods for screening of HCV infections in both developed and developing 
countries (Cloherty et al., 2016, Pawlotsky, 1999). Both technologies rely on detection of patient’s 
antibodies against chosen core antigens such as the core and / or NS3-5 proteins. The latest 3rd 
generation EIA/CIA, such as OraQuickHCV®, have not only been FDA-approved, but also 
recommended by the WHO to be used as the gold standard test in developing countries (Gupta et 
al., 2014). They exhibit a very high, over 95 %, accuracy and in most cases are able to detect 
antibodies within the first 2-3 weeks after the exposure (WHO, 2017). However, the success of the 
3rd generation ELI-based tests lies not only in their high sensitivity and accuracy but also can be 
contributed to their relatively low cost and simplicity in use (Abdel-Hamid et al., 2002, Marwaha 
and Sachdev, 2014). Nonetheless, due to the initial window period required for the seroconversion 
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of the infected blood prior to testing, immunoassays should not be solely relied on for blood 
screening purposes (Figure 18).  
HCV core antigen testing is yet another example of highly effective diagnostic tools for HCV 
infections. Unlike the EIA-based technologies, the diagnosis of HCV infections is performed via 
direct detection of the pathogen rather than the host’s response to infection (Freiman et al., 2016). 
In this approach, a specific matrix (either a membrane or microparticles) is coated with monoclonal 
antibodies, which are specific to the core protein that makes up the HCV nucleocapsid. Since, the 
core protein has been shown to be the most conserved protein amongst all of the HCV genotypes 
and is one of the first protein synthesised during HCV life cycle, it became the target of choice for 
the direct detection. The Architect HCV Ag assay developed by Abbott, was one of the first 
commercially available platforms in Europe that utilised this technology (Ghany et al., 2009). 
However, despite its extremely high specificity, of nearly 100%, and simplicity, it did not become 
the method of choice due to its much lower sensitivity compared to many RNA or EIA-based 
platforms. It has however, widely used as a method for confirmation of positive EIA results.      
Despite the great success of immunoassays in HCV diagnosis, nucleic acid amplification 
technologies (NAAT) have become the preferred method of choice in diagnosis of early infections, 
as well as monitoring of anti-viral therapies and been playing a crucial part in the fight against the 
spread of the disease (Ghany et al., 2009, Gupta et al., 2014).  
NAAT-based technologies rely on the detection of the circulating viral RNA and make use of 
either RT-PCR or other technologies, such as TMR or bDNA assays (Morishima et al., 2006, Chan 
et al., 2000). As previously described, the HCV genome divides into two non-translated UTR 
regions (5’ and 3’ UTRs) and a single coding open reading frame encoding for the viral 
polyprotein. The unique function of the 5’ UTR in HCV translation reflects its high conservation, 
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with nearly 90% sequence identity amongst all of the HCV genotypes (Simmonds et al., 1993, 
Kato, 2000). Thus, it is the most targeted part of the vial genome for almost all of the currently 
available commercial and in-house developed kits.  Direct detection of the viral genome, very 
much like in case of the core antigen detection technologies, enables diagnosis of pre-
seroconverted individuals. 
 
 
Figure 18. Graphic representation of the Hepatitis C screening steps. Highlighted in red are stages of the screening process where false 
negative diagnosis based on serological testing may contribute to further spread of the disease.  
Source: https://www.health.ny.gov/publications/1852/diagnosis.htm 
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Thus, greatly limiting the risks of new infections. However, unlike the direct immunoassay 
platforms, the NAAT-based detection is more accurate and highly sensitive (Firdaus et al., 2015, 
Kargar et al., 2012, Wang et al., 2011, Yang et al., 2011).  
Nonetheless, most currently available NAAT-based kits cannot fully replace the immunoassay 
screening but should rather be used in conjunction. During the development of the disease, 
particularly in the first 10 weeks of the infection, the level of HCV RNA can not only vary 
significantly, but also fall below the limit of detection of many currently available tests (Figure 
19). Thus, increasing the risks of misdiagnosis (Ghany et al., 2009, Cacopardo et al., 2009). 
   
 
Figure 19. Graphic representation of 3 main patterns of HCV viremia. A – continuous high level of detectible HCV RNA; B – spontaneous 
resolution of the disease; C – Oscillating levels of HCV RNA usually falling below the limit of detection. 
Source: http://jamanetwork.com/journals/jama/fullarticle/205592 
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In summary, HCV diagnosis begins with testing for anti-HCV markers (Figure 18) and depending 
on the result of such a test, the NAAT-based confirmation assay will be performed.    
Since even the most sensitive immunoassays available on the market, have a minimum of 2 weeks 
prior to seroconversion of the infected blood, the risks of misdiagnosis and false negative results, 
as well as asymptomatic course of the disease development, increase the risks of new infections 
and make the eradication of the disease impossible (Figure 18, red boxes)(Cacopardo et al., 2009, 
Ghany et al., 2009, Scott and Gretch, 2007). Even more so, in developing countries, such as India, 
where immunoassays are not routinely accompanied by NAAT-based tests (WHO, 2017). The 
NAAT-based platforms, could potentially generate false positive results, due to viral RNA load 
oscillations during the acute phase of the Hepatitis infection (Scott and Gretch, 2007). Thus, it is 
becoming clear that the NAAT-based platforms should be used in conjunction with immunoassays 
in order to avoid misdiagnosis and reduce the risk of new exposures.   
Several highly sensitive platforms for HCV testing have been developed with a limit of detection 
ranging between 5 to 50 IU/mL of plasma. The AMPLICOR 2.0 and Ampliscreen 2.0, both by 
Roche Diagnostics, Indianapolis, Ind as well as The VERSANT HCV RNA Qualitative Assay 
(Bayer Diagnostics, Emeryville, Calif) have been shown to reach the highest sensitivity levels in 
clinical diagnosis with over 98% accuracy. Nonetheless, due to the cost of their equipment, this 
technology cannot be utilised in most developing countries, such as India, where the HCV burden 
increases every year. Thus, despite all of the advances in HCV diagnostics, the lack of a quick, 
sensitive and affordable test continuous to be the major obstacle in the fight against HCV in the 
developing world (Suthar and Harries, 2015).     
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3.1.7 Implications of RNA structure on the efficiency of RNA assays 
3.1.7.1 Reverse transcription technology 
Reverse transcription (RT) assay, is a two-step reaction, in which RNA template is converted into 
its complementary DNA (cDNA) strand by reverse transcriptases. Subsequently, the reverse 
complimented RNA (1st strand cDNA) is then amplified by a standard LAMP reaction or other 
amplification technologies including PCR (Freeman et al., 1999, Lee et al., 2011). In addition, 
depending on the chosen RT enzyme, the initial RNA strand can either be digested during the 
cDNA synthesis by RNaseH activity (e.g. Maxima RNaseH+, ThermoFisher UK), to improve the 
yields, or remain in the assay in a form of a cDNA:RNA heteroduplex (e.g. Maxima RNaseH 
minus, Superscrip IV, THermoFisher, UK). While both methods can increase the yield of cDNA 
synthesis, they also carry disadvantages depending on the type of template and amplification 
technology used. For instance, RT enzymes with intrinsic RNaseH activity have been reported to 
reduce the overall efficiency of cDNA synthesis, when reverse transcribing longer amplicons, 
since many of those enzymes can cut RNA templates during pausing (Kotewicz et al., 1988). Thus 
resulting in premature termination and synthesis of shorter products. In contrast, enzymes lacking 
this activity have been shown to have an increased processivity and therefore the capability of 
transcribing longer, up to 20 kb, templates (Maxima RNase H minus, ThermoFisher, UK). 
However, since the initial RNA target forms highly stable cDNA: RNA hetero duplex, these 
structures can potentially impair primer invasion and thus reduce the efficiency of initiation and 
consequently the overall amplification reaction, particularly in LAMP-based assays (Lesnik and 
Freier, 1995, Chien and Davidson, 1978). PCR-based technologies are less likely to be affected by 
those structures, since each amplification cycle involves a 95 °C denaturation step.  
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Although the RT assays are two-step reactions, many of the currently available RT kits carry out 
those reactions in a single-tube format (One-Taq RT-PCR kit, NEB, UK; SuperScript III RT-PCR 
system, ThermoFisher, UK). However, despite the single-tube format, most of the RT-PCR 
reactions involve a pre-PCR isothermal reverse transcription step carried out isothermally at a 
lower, more suitable for the enzyme, temperature, followed by RT inactivation and template 
denaturation. In contrast, RT-LAMP utilises a highly stable RT enzymes capable of withstanding 
up to 65 °C thus allowing maintaining constant assay temperature throughout (Maxima RNaseH 
+/minus, SuperScript IV, ThermoFisher, UK). In addition, several dual-function enzymes have 
also been developed to further optimise and simplify the RT process. For instance Bst 3.0 recently 
developed by NEB have been shown to exhibit not only an increased displacement activity but 
also the capacity to use RNA and DNA as templates for DNA synthesis.    
3.1.7.2 RNA structures can affect the efficiency of oligonucleotide hybridisation 
The biological function of many RNA molecules, including the HCV RNA genome, relies on their 
substantial folding into secondary or even tertiary structures such as hairpins and pseudoknots as 
well as interaction between them (Smith et al., 2002, Smith and Wu, 2004). In fact, replication and 
translation of the HCV genomic RNA relies solely on the conformation of the 5’ and 3’ UTR 
regions (Smith et al., 2002, Jubin, 2001, Berry et al., 2011). While this structural function ensures 
a high degree of conservation between different genotypes and subtypes, it also simplifies the 
primer design for inclusivity, it can pose a significant barrier for primers and probes hybridisation 
greatly reducing the efficiency of amplification and detection. 
Anato et al. reported how sequence variations between different RNA hairpin structures can have 
direct effects on their thermostability (Antao et al., 1991). For instance, he demonstrated that loop 
structures containing UUCG motifs neighbouring with cytosine and guanine at the 5’ and 3’end, 
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respectively exhibited an increased thermostability with an average Tm of over 70 °C. In contrast, 
the same motif neighbouring with guanine at the 5’ end reduced the stability of this hairpin by over 
10 °C.  However, Anato and co-workers not only concluded that RNA hairpin structures varied in 
their thermal stability depending on the loop sequence but also showed that RNA hairpins are 
significantly more stable than corresponding DNA hairpins. He showed that the difference 
between thermal stability of certain RNA and DNA secondary structures could be as much as         
20 °C.   
Although, several factors can affect amplification performance including template integrity, 
chemistry or efficiency of chosen enzymes, primer binding is crucial for successful target detection 
(Forsell et al., 2015, Stadhouders et al., 2010). Thus, due to such a great variations in 
thermostability observed between different hairpin motifs, careful consideration has to be taken 
while designing primers for RT assays.  
Currently, a wide range of primer design tools are available on the market and online databases, 
but most of these tools utilise DNA template as the matrix for primer and as a consequence do not 
consider the conformational structure of the chosen target (PrimerQuest Tool, IDT, USA, 
GenScript Primer design tool). Similarly, in PCR-primer designs, the potency of secondary 
structures on the impairment of primer binding is often underestimated, as displacement is 
achieved by DNA template denaturation during the thermocycle. As most reverse transcription of 
RNA are performed between 45-60 °C the secondary and tertiary structures of the template may 
need to be negotiated in the RT primer design. This is true for PCR that goes through a denaturing 
step and isothermal amplification like LAMP that operates at assay temperatures ranging between 
60-65 °C. 
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3.2 Aims and objectives 
The main focus of this study was to develop a highly optimised RT-LAMP assay for diagnosis of 
Hepatitis C infections with a careful consideration of the target’s secondary structures and their 
implications on the primer design and the efficiency of the target detection.  
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3.3 Results 
3.3.1 HCV RT-LAMP primer design 
HCV RT-LAMP primer sets were designed according to the specifications listed in the methods 
section. The HCV sequence data retrieved from the HCV sequence database [URL: 
https://hcv.lanl.gov/content/sequence/NEWALIGN/align.html] was aligned and the region with 
the highest degree of similarity across all of the known HCV genotypes was used (Figure 20). As 
described throughout the literature, the 5’ UTR region of the HCV genome was the most conserved 
amongst all of the seven HCV genotypes and numerous subtypes characterised and deposited in 
GenBank [URL: https://www.ncbi.nlm.nih.gov/nuccore/?term=HCV] (Figure 20 – red box). 
In-depth in silico analysis of the sequence and the characterisation candidate primer binding 
positions resulted in the generation of three HCV primer sets that were analysed in terms of, 
potential primer interactions and orientation with respect to RNA template secondary structure.   
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Figure 20. Graphic representation of a HCV genome alignment containing representative sequences from all 7 genotypes and several 
subtypes. The most conserved region of the HCV genome across all of the retrieved sequences is highlighted in red.  
Source: https://hcv.lanl.gov/content/sequence/NEWALIGN/align.html 
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Table 2 lists the HCV primer sets designed according to the parameters described in the methods 
section, along with two published sets (Nyan and Swinson, 2016, Young et al., 1993). Primer sets 
13-40 were designed in-house. For LAMP primers, two Tm were calculated, where each 
corresponds to the F/B1 and F/B2 respectively.  
primer identifier Sequence (5’->3’) Tm [°C] 
PCR-LGC-F GCAGAAAGCGTCTAGCCATGGCGT 70.5 
PCR-LGC-R ctcgcaagcaccctatcaggcagt 69.8 
   HCV001-DN3-F3 GGCGACACTCCACCATGAAT 64.6 
HCV002-DN3-R3 ctatcaggcagtaccacaaggc 64.4 
HCV003- DN3-FIP cactatggctctcccgggagTTTTCGTCTAGCCATGGCGTTAG 65.4/62.1 
HCV004-DN3-BIP GGAACCGGTGAGTACACCGGTTTTcccaaatctccaggcattga 66.1/62.5 
HCV005- DN3-LF aggctgcacgacactcata 63.3 
HCV006- DN3-LB GACCGGGTCCTTTCTTGGA 63.5 
   HCV013-LF CCTTGTGGTACTGCCTGATA 61.2 
HCV014-FIP CCGAGTAGTGTTGGGTCGggtctacgagacctccc 61.4/59.6 
HCV015-F3 aggtttaggattcgtgct 58.4 
HCV016-BIPv1 ggctgcacgacactcataACTACTGTCTTCACGC 61.7/55.2 
HCV018-B3 GAATCACTCCCCTGTG 55.6 
   HCV019-BIP caccggttccgcagaCGGGAGAGCCATAGTG 61.0/57.9 
HCV013-LF CCTTGTGGTACTGCCTGATA 61.2 
HCV014-FIP CCGAGTAGTGTTGGGTCGggtctacgagacctccc 61.4/59.6 
HCV015-F3 aggtttaggattcgtgct 58.4 
HCV020-B3 AGTATGAGTGTCGTGC 55.3 
   HCV-034 FIP TGCCTGGAGATTTGGGCccctatcaggcagtacca 62.0/60.0 
HCV-035 BIP aaaggacccggtcgtTGGTCTGCGGAACCGGTGAG 59.6/68.0 
HCV-036 LoopF GAGTAGTGTTGGGTCG 55.1 
HCV-038 F3 gtgcacggtctacgaga 60.6 
HCV-039 LoopB cctggcaattccggtgta 61.8 
HCV-040 B3 TCCCGGGAGAGCCAT 61.6 
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3.3.2 HCV 5’UTR secondary structure analysis 
Since, the Hepatitis C virus genome is a single-stranded RNA, most of the currently available 
nucleic acid amplification technologies, involve a reverse transcription step that results in the 
production of cDNA that is subsequently re-amplified by a DNA polymerase. It is well known that 
single-stranded nucleic acid molecules, particularly RNAs, have an extremely high tendency to 
fold into various stable motifs, such as hairpins or pseudoknots.  
The secondary structure of the 5’UTR sequence, typical of HCV genotype 1 was assessed in silico, 
to understand any imposition that could interfere with primer annealing, particularly the proposed 
FIP and reverse displacement priming positions necessary for the initiation of reverse transcription. 
Figure 21 shows a graphic representation of the secondary structure of the first 400 nucleotides of 
the 5’UTR region. An online software was applied in order to generate the most probable 
secondary structure output of the chosen fragment at the assay temperature (60 °C). The data was 
displayed in a form of a graphical model and a colour-coded sequence alignment.  
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The 5’UTR region of the HCV genome is highly structured with numerous hairpins and 
pseudoknots exhibiting various levels of stability. According to the colour-coded sequence, highly 
stable secondary structures are dispersed throughout the UTR region. Each colour represents the 
probability of a stable base pairing with the warmer (Red, orange and yellow) colours being the 
Figure 21. Graphic representation of  the HCV 5’UTR folding prediction performed by Vienna online RNA folding tool. A – 2-D RNA folding 
structure with double-stranded stems and open loops highlighted in green and blue/orange, respectively. B – HCV 5’ UTR sequence output  
(5’  3’ ) with highlighted probabilities of forming secondary structures. Red, orange and yellow represent highly structured regions whereas 
green, and blue indicate the likelihood of open loop formation.    
Source: http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi  
 
GCCAGCCCCCUGAUGGGGGCGACACUCCACCAUGAAUCACUCCCCUGUGAGGAACUACUGUC 
UUCACGCAGAAAGCGUCUAGCCAUGGCGUUAGUAUGAGUGUCGUGCAGCCUCCAGGACCCCC
CCUCCCGGGAGAGCCAUAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCAGGACGAC
CGGGUCCUUUCUUGGAUAAACCCGCUCAAUGCCUGGAGAUUUGGGCGUGCCCCCGCAAGACU
GCUAGCCGAGUAGUGUUGGGUCGCGAAAGGCCUUGUGGUACUGCCUGAUAGGGUGCUUGCGA
GUGCCCCGGGAGGUCUCGUAGACCGUGCACCAUGAGCACGAAUCCUAAACCUCAAAGAAAAACC
AAAC 
A
B
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most stable. The position of red and orange bases are indicative of structures extremely difficult 
to melt and invade by primers that rely solely on the displacement activity of the polymerase. A 
substantial amount of open and weak secondary structures indicated by the green and blue bases 
were also be detected. This analysis is rarely afforded by primer design tools, and was enabling 
allowing for RT primer designs that would not only account for inclusivity, but also consider the 
efficiency of primer binding with respect to target structure. 
3.3.3 Effects of secondary structures on HCV 5’UTR RT-LAMP-BART 
Three in-house designed HCV RT-LAMP primers sets (Table 2 – Set 13-18; 13-20 and 34-40) 
were designed to be highly inclusive for all of the known HCV genotypes with a particular 
emphasis on the genotypes 1-3 due to their high clinical relevance. Prior to experimental 
assessment, each primer set was analysed in silico in order to determine potential primer 
interactions that could result in mis-amplification.  
Despite the fact that the in silico analysis of the primer interactions did not predict any significant 
primer-dimers, only the HCV 34-40 primers amplified the target RNA sequence specifically 
(Figure 22A-B). Consequently, the binding positions of each primer set was analysed with respect 
to the RNA secondary structure of the UTR template, in order to determine the possible cause of 
amplification failures. Similar analysis was then performed on two published primer set for 
reference purposes.   
Figures 23-24 show a colour-coded output of the in silico sequence analysis using the Vienna 
software for the first 400 nt of the 5’UTR region. Primer binding positions were underlined for 
visual clarity.  
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Figure 22.  LAMP-BART profiles generated using in-house designed HCV LAMP primers. A – HCV assay using 10^4 cps of synthetic 5’UTR 
DNA and the 34-40 primer set; B – HCV assay using 10^4 cps HCV 5’UTR RNA fragments and the 34-40 primer set; C – HCV assay using 
10^4 cps HCV 5’UTR RNA fragments and the 13-18 primer set; D – HCV assay using 10^4 cps HCV 5’UTR RNA fragments and the 13-20 
primer set. 
Note that red curves represent the reactions containing the target template. Black profiles were generated from the NTC control 
reactions (no Template) 
Refer to protocol 2 
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Figure 23. HCV 5’ UTR sequence output (5’  3’) generated by the Vienna RNA fold software with highlighted probabilities of forming 
secondary structures. Red, orange and yellow represent highly structured regions whereas green, and blue indicate the likelihood of 
open loop formation. A – HCV 5’ UTR sequence output with highlighted published DN3 primer binding sites. Each separate primer 
binding site was highlighted in bold and underlined in a specific order: 5’ – B3, B2, LoopB, B1, F1, LoopF, F2, F3 – 3’. Note that certain 
sites were separated by a “-“ for visual clarity due to the proximity to the other recognition sites.  B -  HCV 5’ UTR sequence output with 
highlighted published LGC primer binding sites in a specific order : 5’ – Forward, Reverse primer – 3’   
Source: http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi  
 
GCCAGCCCCCUGAUGGGGGCGACACUCCACCAUGAAUCACUCCCCUGUGAGGA
ACUACUGUCUUCACGCAGAAAGCGUCUAGCCAUGGCGUUAGUAUGAGUGUCGU
GCAGCCUCCAGGACCCCCCCUCCCGGGAGAGCCAUAGUGGUCUGCGGAACCGG
UGAGUACACCGGAAUUGCCAGGACGACCGGGUCCUUUCUUGGAUAAACCCGCU
CAAUGCCUGGAGAUUUGGGCGUGCCCCCGCAAGACUGCUAGCCGAGUAGUGUU
GGGUCGCGAAAGGCCUUGUGGUACUGCCUGAUAGGGUGCUUGCGAGUGCCCCG
GGAGGUCUCGUAGACCGUGCACCAUGAGCACGAAUCCUAAACCUCAAAGAAAA
ACCAAAC 
A
B
GCCAGCCCCCUGAUGGGGGCGACACUCCACCAUGAAUCACUCCCCUGUGAGGA
ACUACUGUCUUCACGCAGAAAGCGUCUAGCCAUGGCGUUA-
GUAUGAGUGUCGUGCAGCCUCCAGGACCCCCCCUCCCGGGAGAGCCAUAGUGG
UCUGCGGAACCGGUGAGUACACCGGAAUUGCCAGGACGACCGGGUCCUUUCUU
GGAUAAACCCGCUCAAUGCCUGGAGAUUUGGGCGUGCCCCCGCAAGACUGCUA
GCCGAGUAGUGUUGGGUCGCGAAAGGCCUUGUGGUACUGCCUGAUAGGGUGCU
UGCGAGUGCCCCGGGAGGUCUCGUAGACCGUGCACCAUGAGCACGAAUCCUAA
ACCUCAAAGAAAAACCAAAC 
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As expected, all of the publish RT-LAMP primer sets that were analysed here, known to target the 
least structured regions of the 5’UTR amplified very efficiently. Both, the F3 and FIP primers of 
the RT-LAMP DN3 primer set, as well as the reverse RT-PCR primer of the LGC set, landed 
GCCAGCCCCCUGAUGGGGGCGACACUCCACCAUGAAUCACUCCCCUGUGAGGA
ACUACUGUCUUCACGCAGAAAGCGUCUAGCCAUGGCGUUAGUAUGAGUGUCGU
GCAGCCUCCAGGACCCCCCCUCCCGGGAGAGCCAUAGUGGUCUGCGGAACCGG
UG-AGUACACCGGAAUUGCCAGG-
ACGACCGGGUCCUUUCUUGGAUAAACCCGCUCAAUGCCUGGAGAUUUGGGCGU
GCCCCCGCAAGACUGCUAGCCGAGUAGUGUUGGGUCGCGAAAGGCCUUGUGGU
ACUGCCUGAUAGGGUGCUUGCGAGUGCCCCGGGAGGUCUCGUAGACCGUGCAC
CAUGAGCACGAAUCCUAAACCUCAAAGAAAAACCAAAC 
GCCAGCCCCCUGAUGGGGGCGACACUCCACCAUGAAUCACUCCCCUGUGAGGA
ACUACUGUCUUCACGCAGAAAGCGUCUAGCCAUGGCGUUAGUAUGAGUGUCGU
GCAGCCUCCAGGACCCCCCCUCCCGGGAGAGCCAUAGUGGUCUGCGGAACCGG
UGAGUACACCGGAAUUGCCAGGACGACCGGGUCCUUUCUUGGAUAAACCCGCU
CAAUGCCUGGAGAUUUGGGCGUGCCCCCGCAAGACUGCUAGCCGAGUAGUGUU
GGGUCGCGAAAGGCCUUGUGGUACUGCCUGAUAGGGUGCUUGCGAGUGCCCCG
GGAGGUCUCGUAGACCGUGCACCAUGAGCACGAAUCCUAAACCUCAAAGAAAA
ACCAAAC 
GCCAGCCCCCUGAUGGGGGCGACACUCCACCAUGAAUCACUCCCCUGUGAGGA
ACUACUGUCUUCACGCAGAAAGCGUCUAGCCAUGGCGUUAGUAUGAGUGUCGU
GCAGCCUCCAGGACCCCCCCUCCCGGGAGAGCCAUAGUGGUCUGCGGAACCGG
UGAGUACACCGGAAUUGCCAGGACGACCGGGUCCUUUCUUGGAUAAACCCGCU
CAAUGCCUGGAGAUUUGGGCGUGCCCCCGCAAGACUGCUAGCCGAGUAGUGUU
GGGUCGCGAAAGGCCUUGUGGUACUGCCUGAUAGGGUGCUUGCGAGUGCCCCG
GGAGGUCUCGUAGACCGUGCACCAUGAGCACGAAUCCUAAACCUCAAAGAAAA
ACCAAAC 
C
B
A
Figure 24. HCV 5’ UTR sequence output (5’  3’) generated by the Vienna RNA fold software with highlighted probabilities of forming 
secondary structures. Red, orange and yellow represent highly structured regions whereas green, and blue indicate the likelihood of 
open loop formation. A – HCV 5’ UTR sequence output with highlighted in-house designed 34-40 primer binding sites. Each separate 
primer binding site was highlighted in bold and underlined in a specific order: 5’ – B3, B2, LoopB, B1, F1, LoopF, F2, F3 – 3’. Note that 
certain sites were separated by a “-“ for visual clarity due to the proximity to the other recognition sites.  B - HCV 5’ UTR sequence 
output with highlighted in-house designed 13-18 primer binding sites. Each separate primer binding site was highlighted in bold and 
underlined in a specific order: 5’ – B3, B2, LoopB, B1, F1, LoopF, F2, F3 – 3’. C - HCV 5’ UTR sequence output with highlighted in-house 
designed 13-20 primer binding sites. Each separate primer binding site was highlighted in bold and underlined in a specific order: 5’ – 
B3, B2, LoopB, B1, F1, LoopF, F2, F3 – 3’. 
Source: http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi  
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within either very mild secondary structures or open regions of the target (Figure 23A-B). 
Interestingly, the reciprocal priming positions for the RT-LAMP DN3 (BIP) and LGC RT-PCR 
forward primer, did show mild to heavy secondary structure. Similarly, the current HCV 34-40 
RT-LAMP primer set, which showed satisfactory amplification efficiency, (Figure 22A-B), 
annealed to sequence devoid of secondary structure. In fact, it was shown that both key reverse 
transcribing LAMP primers avoided RNA secondary structure altogether (Figure 24A). 
In contrast, primer sets 13-18 and 13-20, both landed within either mild or heavily structured 
regions of the 5’ UTR (Figure 24B-C). In both cases, the sequences targeted by the FIP and BIP 
primers showed increased folding probability. Initial evaluation of these sets, under the same 
amplification chemistry as the HCV 34-40 primer set, showed no detection of the target RNA 
(Figure 22C-D).  
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3.3.4 HCV assay optimisation 
Amongst all of the novel RT-LAMP primer sets designed for this study, only the HCV 34-40 set 
showed satisfactory performance during the initial evaluation, thus it was moved forward for 
further assay optimisation studies.  
3.3.4.1 Effect of DNA polymerases on the RT-LAMP HCV assay performance 
The performance of two different versions of the Bst DNA displacement polymerase (isolated 
from Bacillus stearothermophilus), ‘Bst 2.0’ and ‘Bst 2.0 Warm Start’ (from NEB), and GSP-SSD 
(isolated from Geobacillus sp.) (from Optigene) enzyme were compared in this study.  
The results presented in the Figure 25A-C shows RT-LAMP-BART profiles generated using 
appropriate DNA polymerases and various amounts of the target 5’UTR HCV RNA template. 
Among all the DNA polymerases tested, the assays containing the GSP-SSD enzyme performed 
noticeably better, regardless of the amount of the target RNA used. However, a significant 
reduction in the time-to-max (TTM) was observed with increasing copy number per reaction, when 
the GSP-SSD was compared with the other two enzymes assessed here (p value < 0.05, t-test). In 
contrast, at a lower copy numbers, no significant difference in TTM was detected between the 
GSP-SSD and Bst 2.0 (p values > 0.05, t-test; table 3). However, a slight increase in mis-primed 
amplifications was observed when utilising the Bst 2.0 enzyme.   
Inclusion of Bst 2.0 WS had a detrimental effect on the performance of the HCV assay with a 
significant increase in TTM and a significant reduction in the overall RT-LAMP sensitivity, when 
compared to the other two displacement polymersaes at the same specific activity; only reactions 
containing higher copy numbers of the HCV template amplified (p value < 0.05; figure 25C). On 
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average, a 13 min increase in TTM was detected at the 10^4 copies (final copy number of IVT in 
the assay) when the Bst 2.0 WS enzyme was used (Table 3).  
The sensitivity of the chosen DNA polymerases were also assessed by scoring amplification 
frequencies at various copy numbers and determining the number of false positive reactions 
detected during a pre-determined time-frame. The initial comparison of Bst 2.0 and the GSP-SSD 
polymerase did not show any significant effect on the amplification frequencies and the 
reproducibility of the HCV test, regardless of the copy number of the target RNA used (p value > 
0.05, t-test; table 3). In contrast, when the reactions containing the Bst 2.0 WS were assessed, a 
dramatic reduction in both sensitivity and reproducibility of the test was observed with respect to 
the other enzymes tested. No detection below 1000 copies of the target was achieved and a 
significant deterioration in reproducibility was observed between the replicates analysed at both 
10^ 4 and 10^3 copies of IVT per assay.   
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Figure 25.  Comparison of LAMP-BART profiles generated using HCV 5’UTR RNA fragments, 34-40 primer set and three chosen DNA 
polymerases. A – HCV assay using Bst 2.0 DNA polymerase; B – HCV assay using GSP-SSD DNA polymerase; C – HCV assay using Bst 2.0 
WarmStart DNA polymerase. 
Note that each concentration of the HCV RNA used was colour coded as follows: Red – 10^4 cps; Orange – 10^3 cps; Green – 10^2 cps; 
Blue – 50 cps; Yellow – 10 cps; Black – NTC (No template) 
Refer to protocol ## 
 
85 
 
Table 3 showing summary of the data presented in the figure 25. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
 
 
Similar observations were made when the chosen DNA polymerases were tested on a TB assay 
developed by ERBA Molecular, targeting 23s ribosomal RNA (rRNA).  
Figures 26-27 show LAMP-BART profiles generated using four different DNA polymerases 
according to the protocol 8 (see Appendix 8). 
Note that the number of units of each of the tested DNA polymerases differed due to differences 
in unit’s definition used by the manufacturer. For each comparison assay the most optimal amount 
of each DNA enzyme was used according to the previous optimisation studies performed by 
Lumora LTD (data not shown).   
As expected, the reactions utilising the GSP-SSD DNA polymerase performed noticeably better 
than all the other assays tested, in terms of both the sensitivity and amplification speed (Figure 
DNA polymerase RNA [cp/rxn] Mean [min] STDev Amp. Freq. [%]
10^4 16 0.6 100
10^3 17 0.0 100
10^2 21 0.5 100
50 20 3.9 100
10 26 2.5 100
NTC 90 100
10^4 30 3.3 100
10^3 42 9.7 100
10^2 0
50 0
10 0
NTC 117 100
10^4 18 1.1 100
10^3 20 0.9 100
10^2 23 0.5 100
50 25 2.7 100
10 30 4.0 100
NTC 88 100
GSP
BST WS
BST 2.0
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26A, C). Amplification of the M. bovis genomic DNA (gDNA) was significantly faster when GPS-
SSD was used in comparison with the assays containing Bst Large fragment and Bst 2.0 WS 
(Figure 27C), regardless of the amount of the target present (p value < 0.05, t-test). On average, 
the GSP-SSD reactions amplified the target 2 min faster than those containing Bst 2.0WS and Bst 
Large fragment. However, no significant difference in the reaction speed was noticed when Bst 
2.0 DNA polymerase was assessed (p value > 0.05, t-test). Nonetheless, the overall performance 
of the assays utilising the GSP-SSD enzyme was better when the sensitivity data was taken into 
consideration.  
All of the tested assays achieved full detection of the target DNA when 1000 cp/rxn was added. 
However, at 100 cp the reactions utilising Bst 2.0 failed to detect 1 out of 6 replicates whereas all 
other assays reached 100 % detection (Table 4).  
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Figure 26.  Comparison of LAMP-BART profiles generated using TB assay model system. A – TB assay using GSP-SSD DNA polymerase 
and M. bovis gDNA; B – TB assay using Bst Large fragment DNA polymerase and M. bovis gDNA; C – TB assay using GSP-SSD DNA 
polymerase and M. bovis 23s rRNA; D – TB assay using Bst Large fragment DNA polymerase and M. bovis 23s rRNA. 
Note that each concentration of the M. bovis NA used was colour coded as follows: Orange – 10^3 cps; Green – 10^2 cps; Black – NTC 
(No template) 
Refer to protocol ## 
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Similarly, when the RNA assays were assessed, the reactions utilising GSP-SSD enzyme 
performed noticeably better (Figure 26C). On average, the GSP-SSD assays detected the target 2 
min faster than those using Bst LF and Bst 2.0 when 1000 cp of the RNA was added. However, 
GPS-SSD reactions performed significantly faster when compared to the Bst LF assays only (p 
value < 0.05, t-test, table 4A). In contrast, at 100 cp of the target RNA, no significant difference 
in the amplification speed was noticed when Bst LF, Bst 2.0 and GSP-SSD assays were assessed. 
However, the reactions utilising the GSP-SSD enzyme generated data with noticeably higher 
reproducibility than all the other DNA polymerases tested. 
Furthermore, the assay sensitivity data showed that only the reactions utilising the Bst LF and the 
GSP-SSD enzymes reached satisfactory level of overall sensitivity. Both, GSP-SSD and Bst LF 
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Figure 27.  Comparison of LAMP-BART profiles generated using TB assay model system. A – TB assay using Bst 2.0 DNA polymerase and 
M. bovis gDNA; B – TB assay using Bst 2.0WS DNA polymerase and M. bovis gDNA; C – TB assay using Bst 2.0 DNA polymerase and M. 
bovis 23s rRNA; D – TB assay using Bst 2.0WS DNA polymerase and M. bovis 23s rRNA. 
Note that each concentration of the M. bovis NA used was colour coded as follows: Orange – 10^3 cps; Green – 10^2 cps; Black – NTC 
(No template) 
Refer to protocol ## 
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assays managed to amplify 83 and 100 % of the target RNA when 100 and 1000 cps were added, 
respectively (Table 4A). In contrast, the reactions containing the Bst 2.0 detected 1 out of 6 
replicates containing 100 cps and 6 out of 6 with 1000 cps of the target. In addition, the assays 
utilising the Bst 2.0 WS enzyme failed to detect any level of the target RNA (Table 4B).  
 
Table 4 showing summary of the data presented in the figure 26-27. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
 
  
 
 
 
DNA pol. Template NA conc. [cp/rxn] TTM [min] Stdev Amp.Freq. [%]
1000cp 9 0.6 100
100cp 10 0.6 100
1000cp 11 0.4 100
100cp 14 2.1 83
1000cp 11 0.6 100
100cp 12 0.6 100
1000cp 13 0.0 100
100cp 16 3.6 83
GSP-SSD
DNA
RNA
Bst LF
DNA
RNA
DNA pol. Template NA conc. [cp/rxn] TTM [min] Stdev Amp.Freq. [%]
1000cp 10 0 100
100cp 11 0.6 83
1000cp 13 2.3 100
100cp 14 17
1000cp 11 0.4 100
100cp 12 0.4 100
1000cp 0
100cp 0
DNA
RNA
Bst 2.0
DNA
RNA
Bst2.0WS
A
B
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3.3.4.2 Effect of reverse transcriptases on the RT-HCV assay performance 
In this evaluation, two versions of Maxima reverse transcriptase (Maxima RNaseH- and Maxima 
RNaseH+), as well as a new Superscript IV reverse transcriptase, were assessed for utility in the 
isothermal RT-LAMP reactions. The three scripts were assessed in terms of their impact on 
amplification speed, reproducibility and sensitivity.  
Figure 28-29, shows RT-LAMP-BART profiles generated using GSP-SSD DNA polymerase and 
all three reverse transcriptases.  
The overall performance of the assays containing Maxima RNaseH- were deemed to amplify more 
efficiently than the other enzymes tested. The speed and reproducibility was improved in Maxima 
lacking the RNaseH, resulting in a significant reduction in both the TTM and improved 
reproducibility at each of the RNA copy numbers tested (p values < 0.05, t-test; figure 28B). The 
overall difference in speed of each tested set up increased with reducing quantities of 5’UTR RNA 
was marked, demonstrating the importance in choice of enzyme on the amplification of HCV 
RNA. At lower copy numbers (10 copies RNA / assay), the sensitivity of detection with Maxima 
RNaseH (-) was greater than similar assays performed with Maxima H (+) (Table 5). This could 
be attributed to the overall amplification efficiency and speed that also resulted in greater numbers 
of mis-primed amplifications that were also associated with the use of Maxima RNaseH(+) enzyme 
(Figure 28A).  
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Table 5 showing summary of the data presented in the figure 28. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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Maxima RNA [cp/rxn] Mean [min] STDev Amp. Freq. [%]
10^4 23 0.4 100
10^3 27 0.6 100
10^2 40 9.9 100
50 43 10.2 100
10 77 5.7 50
NTC 122 41.7
10^4 21 0.0 100
10^3 24 0.6 100
10^2 32 0.9 100
50 33 1.3 100
10 41 8.7 83
NTC 115 50
RNaseH(+)
RNaseH(-)
Figure 28.  Comparison of LAMP-BART profiles generated using HCV 5’UTR RNA fragments, 34-40 primer set and two chosen Reverse 
transcriptases. A – HCV assay using Maxima RNase H +; B – HCV assay using Maxima RNase H - 
Note that each concentration of the HCV RNA used was colour coded as follows: Red – 10^4 cps; Orange – 10^3 cps; Green – 10^2 cps; 
Blue – 50 cps; Yellow – 10 cps; Black – NTC (No template) 
Refer to protocol 4 
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Table 6 showing summary of the data presented in the figure 29. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
 
 
 
 
 
Figure 29.  Comparison of LAMP-BART profiles generated using HCV 5’UTR RNA fragments, 34-40 primer set and two chosen Reverse 
transcriptases. A – HCV assay using Maxima RNase H -; B – HCV assay using SuperScript IV 
Note that each concentration of the HCV RNA used was colour coded as follows: Orange – 10^3 cps; Green – 10^2 cps; Yellow – 10 cps; 
Pink – 1 cps; Black – NTC (No template) 
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RT enzyme RNA [cp/rxn] Mean [min] STDev Amp. Freq. [%]
10^3 18 0.0 100
10^2 20 0.0 100
10^1 24 1.2 100
10^0 32 2.3 55.6
NTC 82 100
10^3 18 0.0 100
10^2 21 0.6 100
10^1 25 1.2 100
10^0 29 4.0 55.6
NTC 83 100
Maxima
SuperScript
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Since all experiments with Maxima reverse transcriptase demonstrated that the HCV RT-LAMP 
had a preference for the RNaseH deficient version of this reverse trascriptases, a new version of 
SuperScript RT enyme SuperScript IV also deficient in reverse transcriptase was tested. According 
to the supplier (Thermofisher), SuperScript IV was highly resistant to inhibition from various 
matrixes, and possessed a wider thermal range that may also be suited to this assay (45-60 °C).  
Figure 29, shows the RT-LAMP-BART profiles generated using the chosen reverse transcriptases 
and GSP-SSD DNA polymerase. Assays performances were compared with respect to 
amplification sensitivities, speed, reproducibility and specificity.  
No significant difference in the performance of the tested assays were observed (p value < 0.05, t-
test; figure 29). Neither the sensitivity, reproducibility nor the speed of the assays using the 
SuperScript IV were affected when compared to amplifications benchmarked using the standard 
HCV LAMP protocol, which utilised the Maxima RNaseH- RT enzyme; both scripts achieved the 
same sensitivity of 10 copies / reaction with 100% amplification and single copy detection was 
achieved in 55% of the amplifications tested (Table 6).  
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3.3.4.3 Effects of different assay chemistries on the amplification performance. 
In this study, two different reaction buffers (i.e. Thermopol and Isothermal buffer), suitable for 
isothermal amplification, were compared. Figure 30 shows the LAMP-BART profiles generated 
using GSP-SSD DNA polymerase and both reaction buffers on HCV assay.  
In this experiment, a range of HCV 5’ UTR RNA dilutions was used to assess the performance of 
the HCV LAMP assay in terms of both the speed and sensitivity as well as NTCs formation, under 
different buffering conditions. Firstly, 100 % amplification frequency was achieved for all of the 
RNA titrations tested, regardless of the reaction buffed used. However, the reactions containing 
the Isothermal buffer showed a significant improvement in both the speed of amplification and the 
reproducibility (p values < 0.05, t-test). All of the reactions containing 10 cp of the template 
amplified under 30 min when the Isothermal buffer was used whereas nearly 40 min was required 
for the corresponding template concentration to be amplified under the Thermopol buffering 
conditions.  
Moreover, on average, over 9 min difference in TTM was detected between the two assessed 
reaction set ups, regardless of the amount of the template used. However, the differences in TTM 
between the two tested reaction set ups was noticed to increase with reducing amount of the 
template used.  
In addition, the STDev was noticeably lower, for the reactions utilising the Isothermal buffer, 
showing a much higher reproducibility. However, unlike the Isothermal buffer, the reactions under 
the Thermopol buffering conditions showed no NTCs throughout the run. 
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Table 7 showing summary of the data presented in the figure 30. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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Figure 30.  Comparison of LAMP-BART profiles generated using HCV 5’UTR RNA fragments, 34-40 primer set and two chosen reaction 
buffers. A – HCV assay using Thermopol buffer; B – HCV assay using Isothermal (ISO) buffer. 
Note that each concentration of the HCV RNA used was colour coded as follows: Red – 10^4 cps; Orange – 10^3 cps; Green – 10^2 cps; 
Blue – 50 cps; Yellow – 10 cps; Black – NTC (No template) 
 
RNA [cp/rxn] Mean [min] STDev Amp. Freq. [%]
10^4 16 0.0 100
10^3 18 0.0 100
10^2 21 0.6 100
50 23 0.4 100
10 26 2.0 100
NTC 93 100
10^4 25 0.6 100
10^3 29 0.7 100
10^2 35 1.6 100
50 35 2.9 100
10 38 3.4 100
NTC 0
ISO buffer
Thermo Buffer
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3.4 Discussion 
3.4.1 Impact of RNA structure on assay performance 
Although, formation of secondary and tertiary structures by most RNA genomes and transcripts 
can often be attributed to biological function, very limited consideration is given to possible steric 
hindrance, in commercial software packages used to design, RT-PCR and RT-LAMP primers 
(Jubin, 2001, Lukavsky, 2009). Moreover, despite a wide range of bioinformatics tools available 
for RNA folding analysis, such as Vienna or RNAFold, secondary structure analysis prior to 
primer design for RNA amplifications is not yet common practice. Several publications have 
reported formation of highly stable RNA hairpins, with melting temperatures (Tm) of 70 °C or 
more (Antao et al., 1991, van der Werf et al., 2013, Chen and García, 2013). Despite the 
widespread understanding of the thermostability of such RNA structures, the impact of this on 
reverse transcribed priming is limited in the scientific press. Although, it is often assumed that RT-
PCR assays are immune to this limitation in primer design, these assays must also undergo a low 
temperature RT step, therefore, cannot make the use of the denaturation step characteristic for this 
type of DNA amplification. cDNA synthesis by reverse transcription occurs isothermally, 
irrespective of the technology used and reverse transcription cannot make use of high melting 
temperatures to delineate RNA secondary structures. Since the RT step initiates all subsequent 
activity in RT-PCR amplifications it is of paramount importance to nurture this activity with 
respect to RNA secondary structure that can now be more reliably predicted with software as was 
observed.  
In this study, we attempted to assess the effects of RNA structure on the performance of HCV 
RNA detection by using an online RNA folding software, Vienna. Our in silico analysis of 5’ UTR 
RNA folding showed a high degree of secondary structures predicted by the software. This was to 
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be expected, since the initiation of the HCV RNA translation relies on formation of IRES. 
Nonetheless, certain regions of the sequence used also showed mild to no folding indicated by the 
green and blue colour code (see the Vienna alignment), thus these regions of the sequence were 
more suited for primer design. All of the designed RT-LAMP primer sets performed efficiently, 
where the RNA secondary structure with respect to primer design had been careful considered and 
negotiated (Set 34-40). Both, the F3 and FIP primers of the 34-40 primer set, landed in a highly 
open region of the HCV UTR sequence. Conversely, the B3 and BIP primer targeted fragments 
with mild folding. All primers of RT-LAMP designs 13-18 and 13-20, were annealed to RNA with 
a high level of complexity, and performance suffered as a consequence. In an RT- LAMP 
amplification, the FIP and F3 are crucial primers for initiating reverse transcription, since they 
bind to the target RNA directly. Both set primer sets 13-18 and 13-20 shared common F3 and FIP 
primers and since no amplification was observed in any of the reactions utilising those primers, 
one could conclude that the heavily structured region of the HCV 5’UTR RNA targeted by the F3 
and FIP were simply inaccessible. The same RT primers of RT-LAMP set 13-20 utilised B3 and 
BIP primers targeting significantly more open regions of RNA than those used by the 13-18 primer 
set. However, since the B3 and BIP binding relied on the first strand cDNA synthesis, no difference 
in performance between those primer sets, was observed. Thus, we concluded that the FIP and F3 
binding positions were crucial for the initiation and therefore fundamental to the success when 
amplifying from RNA.  
Furthermore, we also assessed the role of B3 and BIP primers in the overall performance of RT-
LAMP. Both, published DN3 and currently designed 34-40 primer sets, amplified the target HCV 
RNA with satisfactory performance. However, to our knowledge, the 34-40 set performed 
noticeably better and achieved a higher degree of sensitivity. We contributed this increased 
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performance to the role of B3 and BIP primers. We noticed that both B3 and B2 part of the 
published BIP primer (DN3) landed within highly structured region of the HCV 5’UTR, whereas 
our designed primer set targeted more open structures at these annealing positions. We concluded 
that the accessibility of the BIP and B3 primers to the template may affect the amplification 
performance but to a much lower extent and limited to DNA templates. We assume that once the 
first cDNA strand is synthesised from FIP and F3 extension, it can either be displaced or the 
original RNA template is digested resulting in formation of a single-stranded cDNA fragment. 
Thus, due to the single-stranded nature of the generated target, one could also conclude that folding 
of this structure would also occur; although the affinity of bases may not be quite the same as the 
original template RNA (Antao et al., 1991). DNA secondary structures are known to be less stable 
than their corresponding RNA hairpins, primer invasion by B3 and BIP may not be impaired by 
structure to the same extent as the FIP and F3 on the original RNA target (Chen and García, 2013).  
Although, many factors affect performance of polymerisation, the in silico analysis does not 
always reflect the true primer interactions, on template and with each other; our study indicates 
that RNA folding must be considered in the RT-PCR / RT-LAMP design as it can significantly 
impair reverse transcribed polymerisations.  
3.4.2 Optimisation of the HCV RT-LAMP amplification  
Since changes in the chemistry of any amplification technology can have a dramatic effect on their 
performance and sensitivity, a lot of effort has been put into creating highly optimised methods for 
nucleic acid synthesis, a wide and growing range of enzymes and their buffers is constantly being 
developed and improved upon (Freeman et al., 1999, Godfrey and Kelly, 2005, Estes et al., 2012). 
It is often the case that different amplification mechanisms and reporter systems require completely 
different chemistries (Balmer, 20072007, Kramer and Coen, 2006). In this study, two versions of 
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the Bst large fragment DNA polymerase were compared to ‘a new, highly displacing enzyme, 
GSP-SSD’ to evaluate any differences in performance that could be attributed to displacement 
polymerases in an RT-LAMP amplification. 
In general, the Bst DNA polymerases used (i.e. Bst 2.0 and 2.0 Warm Start) have been shown to 
be much more active and less sensitive to inhibitory substances such as potassium and sodium salts 
when compared to the Bst large fragment (NEB [URL: https://www.neb.com/products/m0537-bst-
20-dna-polymerase]). The kinetics, as well as inhibitor sensitivity, were factors most likely 
changed, by either introducing alternate amino groups into the original version of the DNA 
polymerase or by coupling the enzyme with additional subunits (e.g. DNA binding proteins or 
nucleic acid aptamers) giving the new version of the enzyme additional or improved properties 
(Elshawadfy et al., 2014, Lahr and Katz, 2009, Bedford et al., 1997). For example, according to 
the supplier’s specifications, the active site of the Bst 2.0 Warm Start was modified by a reversible 
binding of additional components in order to maintain the enzyme inactive at room temperature. 
Furthermore, improved performance of the Bst 2.0 have been shown to have a tremendous impact 
on the overall time of amplification reactions, where over 10 % decrease in TTM values between 
Bst 1.0 and 2.0 were recorded (data not shown). This work does not substantiate the supplier’s 
claims; Rather than the improved assay performance promised by the supplier, the utilisation of 
Bst 2.0 Warm Start had a negative impact on the overall performance of both the HCV RT-LAMP-
BART and TB RT-LAMP-BART assays. It was previously described that the warm start version 
of the Bst 2.0 could significantly increase the performance of DNA synthesis under isothermal 
conditions, as this version of the enzyme would help to control unwanted primer extensions 
(Tanner and Evans, 2014, Tang et al., 2016). Indeed, we saw an improvement in amplification 
kinetics of the reactions containing the WS version of Bst 2.0 when compared to the performance 
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of the Bst Large fragment (Table 4). However, the nucleic acid detection of both HCV and TB 
assays was significantly impaired by the addition of the modified DNA polymerase. It was 
assumed that the poor performance on RNA amplifications was attributed to the aptamer 
introduced into Bst 2.0 as this enzyme was demonstrated to amplify efficiently when used in its 
absence. It was very evident that the aptamer only inhibited the reverse transcription process as 
the TB DNA assay remained unaffected.   
Of all of the DNA polymerases tested, GSP-SSD proved to be the most optimal for the current 
RT-LAMP HCV assay. This polymerase not only increased the kinetics of the amplification, but 
also generated far fewer NTCs compared to Bst 2.0. Primer dimerization, is a very well-known 
cause of such non-template amplification events and when combined with increased enzyme 
activity, increased rates of non-specific amplification are more likely to occur (Friedberg et al., 
2000, Poritz and Ririe, 2014). Despite GSP-SSD higher polymerisation efficiency, priming 
specificity was maintained, which would tend to contradict Friedberg et al. However, the disparity 
between the polymerisation efficiency and the observed NTC formation could be contributed to 
the reduced activity of the GSP-SSD at lower temperatures. In contrast, the Bst 2.0 enzyme is well 
known to retain partial activity at room temperature which drove the development of Bst 2.0WS. 
Nonetheless, it is highly likely that an improved RT-LAMP for HCV diagnosis could be developed 
if the GSP-SSD polymerase is used. Most of polymerases used in isothermal nucleic acid 
amplifications, utilise enzyme that can either synthesise DNA from DNA templates (DNA 
polymerases) and enzymes that reverse transcribe RNA into a cDNA (RT enzymes). GSP-SSD as 
well as other recently developed dual-function enzymes including Bst 3.0 (NEB) or rtTh Taq 
(Cosmo Bio) are unique enzymes, possessing both polymerase activities, which allows initiation 
of amplification from RNA and recopying of cDNA and higher order amplification products 
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(Optigene [URL: http://www.optigene.co.uk/reagent_type/dna-polymerase-enzymes/]). GSP-SSD 
was the most optimal for the RT-LAMP-BART. 
Evaluation of three reverse transcriptases was also performed to determine the most suitable 
enzyme for the RT-LAMP HCV chemistry. As shown in Figure 28B, the Maxima RNaseH- was 
proven to be the most optimal generating significantly faster and more reproducible amplification 
kinetics regardless of the RNA concentration tested. DNA synthesis via LAMP utilise a 
displacement polymerase to open up the DNA in preparation for synthesis, unlike PCR that uses 
denaturing temperatures to melt the double helix. We therefore hypothesised that RNaseH 
deficient reverse transcriptase’s would preserve the original RNA molecule throughout the 
synthesis process, and increase in performance of the RT-LAMP amplification. Since the original 
RNA molecule would not be digested during the reverse transcription process, it would remain 
available for cDNA synthesis throughout the duration of the assay. Utilising these RNaseH 
negative enzymes could potentially result in an accumulation of cDNA, which would benefit the 
assay sensitivity. In addition, the inherited ability of LAMP to strand invade and displace, would 
then ensure production of single-stranded DNA molecules required for the cycling and elongation 
steps without compromising on the overall performance of the assay. Furthermore, it is well known 
that the reverse transcriptase enzymes with intrinsic RNAseH activity can prematurely terminate 
cDNA synthesis as a consequence of template restriction and polymerase pausing (Kotewicz et al., 
1988). This could also be the cause of the observed differences in performance between the reverse 
transcriptases tested.  
Comparisons of the Maxima RNaseH- and the Superscript IV showed no significant difference in 
performance. This was likely due to the fact that both enzymes were deficient in RNase H activity. 
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However, according to the supplier, the latter had the potential to be highly resistant to a wide 
range of inhibitory substance and perform better in a wider range of temperatures. 
Furthermore, additional optimisation of the HCV LAMP-BART assay involved comparison of two 
commonly used reaction buffers: Thermopol and Isothermal buffer. As predicted, the reactions 
containing the isothermal buffer performed significantly faster, generating highly reproducible 
peaks. However, an increase in NTCs formation was observed when the isothermal buffer was 
used whereas no non-specific amplifications were detected with the thermopol buffer. The 
difference in performance could be contributed to the fact that isothermal buffer contains 40 mM 
more KCl than the thermopol buffer. It has previously been reported that the amount of salt can 
significantly affect the overall Tm of given primers, where a positive correlation between the 
concentration and the Tm was described. Since an increase in Tm of given primers, would result 
in a stronger binding their target, it could also result in a stronger non-specific binding of the 
primers either to the target DNA or the primers themselves which in turns could lead to an increase 
in NTCs formation.    
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3.5 Perspective 
This research has demonstrated the importance of not only highly optimised chemistry and the 
right choice of enzymes but also showed the requirement for choosing RT primers that negotiate 
RNA secondary structure and polymerases which can adequately displace RNA and DNA 
molecules in isothermal reactions. This work resulted in a RT-LAMP assay that was highly 
sensitive and capable of detecting, as little as 40 copies of 5’UTR through the workflow with an 
analytical LoD of less than 5 cps. Despite this success further evaluations are needed to optimise 
this assays chemistry and to assess its performance when challenged with RNA extracted from 
clinical samples, and when challenged with classical polymerase chain inhibitors. 
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Chapter 4 
4 Inhibition of RT-LAMP assays 
4.1 Introduction 
4.1.1 PCR inhibition 
One of the major drawbacks of PCR amplification is its sensitivity to inhibitory substances which 
can result in either a reduction in the efficiency of amplification or a complete failure in detection 
(Bustin and Nolan, 2004, Schrader et al., 2012). Thus inhibitory substances pose a real risk, 
particularly in the field of molecular diagnostics, where an amplification failure can lead to a 
misdiagnosis and have a direct effect on patients’ wellbeing (Huggett et al., 2008, Drosten et al., 
2002).  
PCR inhibitors’ are highly heterogeneous substances that can originate from the tested sample 
itself or be introduced during sample processing and nucleic acid extraction procedure (Lim et al., 
2016, Schrader et al., 2012). Matrixes such as faeces or soil samples, may contain a wide range of 
inhibitory substances from inorganic salts to more complex organic constituents, such as humic 
acid. Additionally, many of these inhibitors can be found in a variety of different matrices (Sidstedt 
et al., 2015, Braid et al., 2003, Bessetti, 2007).  
The most well-known and encountered inhibitors are organic compounds such as bile salts, urea, 
phenol, sodium dodecyl sulphate, collagen, haem, polysaccharides and carrier nucleic acid (Opel 
et al., 2010, Wilson, 1997, Gieffers et al., 2000). However, commonly found inorganic inhibitors 
affecting PCR like inorganic salts or calcium ions also affect many isothermal amplification 
technologies (Gieffers et al., 2000, Bessetti, 2007).  
105 
 
The concentration of these inhibitory compounds play a crucial role in their inhibitory effect.  For 
instance, potassium chloride is widely used for preparation of amplification buffers, however at 
concentrations exceeding 100 mM it is documented to be inhibitory to PCR and LAMP 
(Montgomery and Wittwer, 2014, Bessetti, 2007). In addition, collagen and calcium ions are 
components of connective tissue and bone and are often co-extracted from food samples but only 
significantly inhibits PCR amplification when their concentration is too great (>8 µg/rxn) to be 
overcome by the polymerases activity (Opel et al., 2010, Kim et al., 2000, Bickley et al., 1996a). 
Isothermal amplification-based assay inhibition has not been as widely studied, although inhibitory 
effects similar to PCR have been reported. LAMP has been shown to exhibit an increased 
resistance in inhibition when compared to the standard PCR assays (Kiddle et al., 2012, Edwards 
et al., 2014).  
4.1.1.1 Mechanism of inhibition 
Inhibitory substances can interfere with several components of an amplification reaction including 
nucleic acids, enzymes or other constituents such as Mg ions or dNTPs (Bessetti, 2007). For 
instance, DNA can be absorbed onto the polymeric surfaces of the reaction tubes used during 
sample processing and nucleic acid extraction, resulting in a loss of sensitivity due to poorer yields 
(Butot et al., 2007, Fox et al., 2007). DNA or RNA templates can also be severely degraded by 
nucleases if the samples were not properly preserved and the extraction procedure failed to remove 
any such activity (Zhang et al., 2010b, Kreader, 1996a, Wiedbrauk et al., 1995). Thus, many 
nucleic acid extraction methods include a Proteinase K step in order to ensure the inactivation of 
any residual nuclease activity originating from the sample (Hilz et al., 1975, Rossen et al., 1992). 
However, if co-extracted into the final reaction mixture, it can inactivate any enzymatic activity 
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required to carry out successful amplification reaction (Rossen et al., 1992, Powell et al., 1994, 
Wilson, 1997, Mertens et al., 2014).   
Several publications have reported that phenolic compounds can not only denature polymerases 
and other protein-based reaction components, but also can cross-link RNA under oxidising 
conditions and thus impair RNA isolation (Smart et al., 1999, Schrader et al., 2012).  In addition, 
it has also been found that the presence of polysaccharides during purification of sample extracts 
can significantly reduce the efficiency of RNA re-suspension, affecting the final yield and 
subsequently reducing detection sensitivity (Sipahioglu et al., 2006, Schrader et al., 2012).  
Annealing of the primers have also been reported to be affected by certain inhibitory substances, 
such as humic acid (HA), that are capable of binding to DNA, thus obstructing the binding sites 
(Opel et al., 2010). Opel et al. (2010) found that primers with higher melting temperatures were 
less affected by the inhibition, suggesting that the nucleic acid sequence may have a direct effect 
on inhibition and indicates the competitive nature of nucleic acid hybridisation. 
Although amplification inhibition is thought to be the result of many factors, research has mainly 
focused on the inhibition of DNA polymerase function (Opel et al., 2010, Al-Soud and Rådström, 
2001). 
To date, a wider range of inhibitory substances affecting DNA polymerases have been 
characterized and include substance that either affect the enzymatic activity directly by interfering 
with the template or indirectly via other reaction components (Opel et al., 2010, Schrader et al., 
2012, Bessetti, 2007).  As mentioned previously, proteases (like proteinase K) and detergents can 
denature DNA polymerases, RT enzymes and BART components. For instance, urea and phenols 
have been shown to directly interfere with DNA polymerases by degrading the enzyme whereas 
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collagen, calcium or haematin inhibit its activity (Opel et al., 2010, Khan et al., 1991, Wilson, 
1997). Melanin has been shown to bind to DNA polymerases and RT enzymes in a reversible 
manner causing competitive inhibition (Opel et al., 2010, Eckhart et al., 2000). Polysaccharides 
have been found to indirectly affect the activity of DNA polymerases by mimicking DNA 
structures thus resulting in sequestration of the enzymes (Kiddle et al., 2012, Opel et al., 2010, 
Schrader et al., 2012). Humic acids have been found to have a dual function as inhibitory 
compounds (Tebbe and Vahjen, 1993, Opel et al., 2010). Their phenolic structures have been 
shown to directly bind to the DNA polymerases causing denaturation of the protein. It has also 
been reported that HA can interact with the templates obstructing amplification reactions causing 
premature termination or initiation failure by competing for the primer binding sites (Opel et al., 
2010, Zipper et al., 2003, Saeki et al., 2011).    
Other substances have been found to react with co-factors of DNA polymerases or RT enzymes. 
High concentrations of calcium ions can compete with magnesium for the binding sites of both 
proteins, disrupting their ability to carry out their enzymatic reactions (Bickley et al., 1996a, 
Funes-Huacca et al., 2011). In contrast, tannic acids or bicine can act as a chelating agent and thus 
deplete the magnesium available (Nakon and Krishnamoorthy, 1983, L. Lawson et al., 2003). 
Nonetheless in both cases the amount of free magnesium binding to the enzyme is greatly impaired, 
resulting in a reduction of amplification efficiency or a complete failure.  
Nucleic acids themselves can also act to inhibit the amplification of a target.  High concentrations 
of nucleic acid can sequester polymerases and primers, thus inhibiting amplification.  This puts an 
upper limit on the total amount of nucleic acid that can be added to an amplification reaction.   
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Substrate(s) Inhibitor(s) Mode of inhibition Facilitator(s) Reference 
     
Faeces and plants 
Bile salts and complex 
polysaccharides 
Interaction with DNA template (sequestration of DNA) BSA, gp32, sample dilution 
(Rouhibakhsh et al., 2008) 
(Radstrom et al., 2004) 
Bones and connective 
tissues 
Collagen Binds to DNA template 
Sample purification, use of less 
sensitive Taq polymerases, addition of 
Mg2+ 
(Burkhart et al., 2002)    
(Opel et al., 2010) 
Bones Calcium ions Competitive inhibitor of Mg2+ required for Taq activity 
Sample dilution, chelation, addition of 
Mg2+ 
(Opel et al., 2010)      
(Bickley et al., 1996b) 
Clothing dyes (e.g. indigo) Dyes 
Affects DNA template by incorporating into DNA 
structure. 
Sample purification, 
(Larkin and Harbison, 
1999) 
Lactoferrin and 
haemoglobin(Blood) 
Iron ions (From 
lactoferrin and 
Heamoglobin) 
Competitive inhibitor of Mg2+ required for Taq activity 
Sample dilution, chelation, addition of 
Mg2+ 
(Radstrom et al., 2004) 
Blood Haem 
Binds to Taq polymerases causing dissociation of the 
DNA-polymerase complex 
BSA, gp32 
(Kreader, 1996b)            
(Akane et al., 1994) 
Hair and skin Melanin Binds to DNA Sample purification, sample dilution 
(Opel et al., 2010)      
(Eckhart et al., 2000) 
Soils and bones Millard Products 
DNA trapped in complex polysaccharide-rich matrix 
(inaccessible to Taq polymerases) 
Sample purification (repeated silica 
extraction) 
(Alaeddini, 2012) 
Environmental samples 
containing soil 
Phenolic compounds (e.g. 
humic, fulvic and tannic 
acids) 
Chelating with  Mg2+ , 
Humic acids have also been reported to directly affect 
Taq polymerases and DNA through sequence specific 
binding of DNA, reducing the amount of amplifiable 
template 
Retardation of phenolic migration in 
PVP-containing agarose gel 
electrophoresis, sample dilution, 
addition of Mg2+, ion-exchange 
chromatography, 
(Mayer and Palmer, 1996) 
(Herrick et al., 1993)    
(Tebbe and Vahjen, 1993) 
(Tsai and Olson, 1992) 
Semen swabs from sexual 
assaults, microorganisms 
found in environmental 
samples 
Vaginal microorganisms, 
non-target DNA 
DNA sequestration, reduction of primer concentration 
by non-specific binding to non-target DNA molecules 
Sample dilution, gel filtration, (Lienert and Fowler, 1992) 
Urine Urea Denaturation of Taq polymerases Sample dilution, addition of Taq 
(Abu Al-Soud and 
Radstrom, 1998) 
Table 8. Common inhibitory substances and their mode of inhibition encountered during DNA amplification as well as methods of overcoming PCR inhibition. 
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4.1.2 Current methods of nucleic acid purification for molecular diagnostics assays 
Currently most molecular diagnostic kits rely on the quality and purity of extracted DNA or 
RNA for successful diagnosis of disease (Wink, 2011). Due to the wide range of potentially 
inhibitory substances present nucleic acid purification has become one of the most routinely 
used procedures in molecular biology and the diagnostic field (Rudi and Jakobsen, 2006, 
Niemz et al., 2011).  In general, every nucleic acid extraction procedure known to date, can be 
divided into four main steps: 1) cell disruption; 2) removal of protein and lipid membranes, 
other cell components and non-target nucleic acid; 3) binding/purification of the target nucleic 
acid and 4) nucleic acid release and concentration (Tan and Yiap, 2009).  
Cell disruption is the break down the membranes and cell walls enabling release of the cell 
content and can be achieved via either physical or chemical means (Tan and Yiap, 2009, Brown 
and Audet, 2008). Disruption procedures vary and are often dependent on the type of sample 
used where physical methods might be more suited than chemical means, and vice versa. For 
instance, many nucleic acid extraction kits from plant tissue involve physical cell disruption 
step such as grinding, due to the highly resistant cellulose-based cell wall (Tsugama et al., 
2011). In contrast, most purification methods used for nucleic acid extraction from blood or 
cell cultures involve chemical lysis to prevent shearing of the target (Robe et al., 2003). Those 
methods often combine chemical lysis using detergents such as sodium dodecyl sulphate 
(SDS), chaotropic agents like salts and enzymes as well as elevated temperatures to facilitate 
the process (Tan and Yiap, 2009, Krsek and Wellington, 1999). 
In most cases, cell disruption and the break down of cellular debris and protein occurs 
simultaneously, where one reaction component might be suitable for both steps. Proteinases 
have been widely used to facilitate not only disintegration of the cell membranes by disrupting 
protein components, but also to liberate nucleic acids from their protective protein coating such 
as histones (Goldenberger et al., 1995). Lithium dodecyl sulphate (LDS) has also been used 
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commercially to improve cell lysis as well as inactivate cellular nucleases ensuring the integrity 
of the extracted nucleic acids (Cook, 1984)(ERBA Molecular, UK).  
The Phenol/chloroform method is one of the oldest techniques in molecular biology for the 
purification of nucleic acids (Chomczynski and Sacchi, 1987, Sambrook and Russell, 2006). 
The technique/methodology takes advantage of the differences in the solubility of DNA, RNA, 
protein and other cellular components. In principle, due to the organic hydrophobic nature of 
phenol-chloroform mixture, once mixed with aqueous solution containing cellular lysates, two 
distinct phases are formed upon centrifugation. The upper aqueous phase contains the cellular 
nucleic acids and other soluble components, whereas the bottom organic phase consists mostly 
of hydrophobic lipids and precipitated proteins (Figure 31). Furthermore, by modulating the 
pH of the aqueous phase, either a total pool of nucleic acid can be extracted or a preferential 
purification of RNA can be performed in acidic conditions.      
      
 
 
 
 
Figure 31. Graphic representation of phenol:chloroform nucleic acid purification procedure.  
Source: https://www.genetargetsolutions.com.au/product/5prime-phase-lock-gel/ 
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However, due to the time consuming and toxic nature of this technique, phenol/chloroform 
extraction is no longer the method of choice in molecular diagnostics (Lahiri and Nurnberger 
Jr, 1991, Tan and Yiap, 2009). 
Most of the currently used purification kits rely on binding of DNA or RNA to a solid matrix, 
such as silica membranes, followed by various wash steps introduced to remove protein, 
cellular debris and inhibitory substances (Vandeventer et al., 2012). Many industry standard 
kits (Qiagen) utilise spin columns with a silica based sieve to capture nucleic acids of certain 
size during the centrifugation process followed by nucleic acid release using various 
reconstitution buffers (Figure 32). Other methods employ magnetic beads coated with silica 
matrix enabling automation of the entire sample preparation procedure, greatly reducing the 
risks of sample contamination as well as increase productivity and throughput (MagJET, 
ThermoFisher; MagAttract, Qiagen) (Berensmeier, 2006).  
Although such methods have been proven to be extremely useful, depending on a sample type 
used, they might pose severe disadvantages. For instance, extraction of total nucleic acid 
carried out by either spin columns of silica based magnetic beads, from sputum samples may 
cause severe inhibition of RNA detection due to significant content of non-target DNA or RNA 
(He et al., 2017, Adams et al., 2015).  
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Thus, some researchers prefer a more selective method of nucleic acid purification offered by 
capture probes. In general, a capture method involves labelling of a solid phase with an 
oligonucleotide probe that is complementary to the target of interest. Thus the vast majority of 
extracted nucleic acid consists of the target of interest by ensuring conditions favouring 
hybridisation (Figure 33). While this method generates lower yields, the specificity of the 
target extraction have been reported to significantly increase the overall sensitivity of a 
diagnostic assay, particularly in the samples containing large amounts of non-target nucleic 
acids.      
 
 
Figure 32. Graphic representation of a typical spin-column based nucleic acid purification technique.  
Source: https://shop.roche.com/wcsstore/RASCatalogAssetStore/Articles/HTML%20Articles/High-Pure-Technology.html 
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4.1.3 Summary 
Although co-extraction of inhibitory substances and their mode of DNA polymerisation 
inhibition have been widely studied and reported throughout the literature, little is known about 
the effects of those substances on the reverse transcription, a key step in most RNA detection 
kits. 
Furthermore, nucleic acid extraction procedures have been reported to significantly improve 
the quality and purity of isolated nucleic acid. However, since different types of samples such 
as faeces, blood or sputum can significantly differ in their biochemical composition, a careful 
consideration should be taken as to what nucleic acid extraction procedure is most suitable.     
Figure 33. Graphic representation of a magnetic bead with capture probes- based nucleic acid purification methods.  
Source: http://pubs.rsc.org/en/content/articlelanding/2001/an/b106343j/unauth#!divAbstract 
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4.2 Aims and objectives 
The main focus of this study was to determine the inhibitory effects of key components of 
sample preparation chemistries associated with the extraction of DNA or RNA from samples. 
In particular, the work focused on in-house technologies for the extraction of TB, HIV, HBV 
and HCV where the associated buffers had potassium and sodium salts and LDS as key 
components.  Further, the nature of the clinical samples means that significant amounts of non-
target nucleic acids could be present.  The aim was to quantify the effects of these substances 
on the RT-LAMP assay using HCV and TB model assays.  
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4.3 Results 
4.3.1 Effects of inhibitory substances on the performance of nucleic acid amplification 
Co-extraction of inhibitory substances during nucleic acid purification is the most common 
cause of amplification failure when a sufficient amount of the target template is present. 
However, the choice of DNA polymerase and RT enzyme or the nature of the target and the 
detection method can react to inhibitory substances differently.  
4.3.1.1 Effects of sample-prep derived inhibitors on the performance of NAAT assays.  
In this study, the effects of various components of the in-house developed nucleic acid 
purification method(s), on the performance of TB detections, was assessed.  
Figure 34 shows LAMP-BART profiles generated using a standard TB assay challenged with 
various amounts of LDS detergent according to the protocol 9 (see Appendix 9). 
As expected, the TB assay was inhibited by the presence of LDS detergent (Figure 34B-C). 
However, unlike most inhibitory substances, LDS affected the amount of light emitted to a 
much higher extent than the amplification itself, and is reflected by a reduction in peak heights. 
At 0.05 % LDS, the amount of emitted light was reduced by over 50 %, in comparison with 
the non-inhibited samples, without significantly affecting the average TTM for the reactions 
containing 1000 copies of the TB target RNA (p value > 0.05, t-test) (Figure 34A and C) 
(Table 9). In addition, an apparent decline in the base line was observed at 0.05 % LDS, 
suggesting that BART was affected/ inhibited irrespective of the DNA polymerase and RT 
performance.  
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Table 9 showing summary of the data presented in the figure 34. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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LDS [%] TB RNA [cp/rxn] TTM [min] Stdev Amp.Freq. [%]
0% 1000cp 22 7 100
100cp 22 1 50
0.01% 1000cp 25 11 83
100cp 21 17
0.05% 1000cp 20 5 50
100cp 0
Figure 34. LAMP-BART profiles generated using the TB assay model system and various amounts of M. bovis positive control 23s 
rRNA. A – amplification profiles generated with non-inhibited reactions; B – amplification profiles generated with reactions 
containing 0.01 % LDS; C – amplification profiles generated with reactions containing 0.05 % LDS.  
Note: orange curves correspond to the reactions containing 1000 cps of the target; green curves show reactions containing 100 cps of 
the target; black curves represent NTC (No template control)  
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As previously shown in this study, buffers can affect amplification kinetics (p. 94) and different 
amplification chemistries can significantly affect the performance of nucleic acid synthesis or 
NTC formation. However, the choice of reaction buffer can modulate the inhibitory effect of 
LDS on assay kinetics.  
Figure 35 shows LAMP-BART profiles generated using a modified TB protocol where either 
12.5 or 125 mM bicine buffer was used in the absence of both loop primers. 
Similarly to the previous LDS inhibition data (p. 115), the addition of 0.05 % LDS to the TB 
reactions caused a significant reduction in light emission without affecting the average TTM, 
regardless of the buffer used  (p value > 0.05, t-test) (Figure 35E). The characteristic decline 
of the base line was also observed in the challenged samples confirming the previous findings. 
Nonetheless, when the average peak heights of the challenged and un-challenged samples were 
compared, the inhibitory effect of LDS was more apparent in the reactions utilising the 12.5 
mM bicine buffer. However, it was also observed that the non-inhibited reactions containing 
the 12.5 mM bicine buffer generated less light than those with the higher concentration of 
bicine thus a direct comparison between the two buffers could not be performed. Nevertheless, 
the relative difference in light emission, between the two buffers with either presence or 
absence of inhibition, revealed interesting effects of buffering on the impact of LDS on BART 
(Table 10).  
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Figure 35. LAMP-BART profiles and summary bar charts generated using the TB assay model system various amounts of M. bovis 
positive control 23s rRNA under two different buffering chemistries. 
 A – amplification profiles generated with non-inhibited reactions and 125 mM 1x Bicine buffer; B – amplification profiles generated 
with non-inhibited reactions and 12.5 mM 1x Bicine buffer; C – amplification profiles generated with reactions containing 0.05 % LDS 
and 125 mM 1x Bicine buffer; D – amplification profiles generated with reactions containing 0.05 % LDS and 12.5 mM 1x Bicine 
buffer; E – bar chart showing the effects of LDS and chosen reaction buffers on the average peak height. 
Note: orange curves correspond to the reactions containing 100000 cps of the target; green curves show reactions containing 10000 
cps of the target; black curves represent NTC (No template control)  
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Table 10 showing summary of the data presented in the figure 35. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq) (A) 
as well as light emission (RLU) (B). 
 
In the non-inhibited samples utilising 100,000 copies of the target TB RNA, the average peak 
height generated by 125 mM bicine was 1.4 x higher than those with the low bicine. Similarly, 
when the reactions containing 10,000 copies of the target were assessed, in the absence of the 
inhibitor, the reactions utilising the 125 mM bicine produced peaks 1.35 x brighter. However, 
when the challenged samples were evaluated, the reactions containing 125 mM bicine buffer 
generated 1.7 and 1.95 x brighter peaks than those utilising lower bicine for 100,000 and 10,000 
copies of the target RNA, respectively.  
 
 
 
 
 
Inhibitor Bicine Buffer RNA conc. [cp/rxn] Mean [min] Stdev Amp.Freq.[%]
10000 39 9.7 83
100000 24 1.2 100
10000 34 3.6 100
100000 27 1.6 100
10000 29 1.0 100
100000 25 1.0 100
10000 33 1.8 100
100000 27 0.8 100
0.05% LDS
No LDS
12.5 mM 
125 mM 
12.5 mM 
125 mM 
Inhibitor Bicine Buffer RNA conc. [cp/rxn] Mean [RLU] Stdev 
10000 2335 882.4
100000 4700 461.7
10000 4561 840.9
100000 7897 1622.6
10000 12703 1371.8
100000 13785 1045.5
10000 17190 3323.5
100000 19653 1018.9
0.05% LDS
12.5 mM 
125 mM 
No LDS
12.5 mM 
125 mM 
A
B
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In this study, the effects of three inorganic salts; sodium chloride, potassium chloride and 
potassium acetate, were assessed on the performance of nucleic acid amplification. Figure 36 
shows LAMP-BART profiles generated using HCV RNA assay challenged with various 
amounts of potassium chloride and potassium acetate, in addition to salts already present in the 
assay. The assays were prepared according to the protocol 6 (see Appendix 6). 
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Figure 36. LAMP-BART profiles generated using the HCV assay model system, 2000 cps of HCV 5’UTR RNA fragments and two chosen 
DNA polymerases challenged with various amounts of KCl and KAc. 
 A – amplification profiles generated with reactions containing Bst 2.0 and various amounts of KCl; B – amplification profiles 
generated with reactions containing GSP-SSD and various amounts of KCl; C – amplification profiles generated with reactions 
containing Bst 2.0 and various amounts of KAc; D – amplification profiles generated with reactions containing GSP-SSD and various 
amounts of KAc. 
Note: red curves correspond to the non-inhibited reactions; black curves show reactions containing 10 mM additional potassium salt; 
orange curves represent reactions containing 31.25 mM additional potassium salt; blue curves shows reactions challenged with 50 
mM additional potassium salt.   
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Inhibition of the nucleic acid synthesis was observed for both assays regardless of the inhibitor 
used. The reactions utilising the DNA polymerase GSP-SSD were more sensitive to higher 
concentrations of the salts tested (Table 11). However, the inhibition coming from potassium 
chloride (KCl) affected these assays to a much higher extent when compared to the reactions 
containing potassium acetate (KAc). A 5 minute increase in TTM was observed when 50 mM 
of KCl was added whereas only 2 minute difference was detected in the reactions containing 
50 mM of the KAc salt. In contrast, only 3 and 2 minute increases in TTM was detected in the 
reactions containing the Bst 2.0 DNA polymerase, when challenged with the same amounts of 
the KCl and KAc salts, respectively (Table 11). 
Interestingly, the addition of 10 mM of either salt improved the speed of the assay, when 
utilising the Bst 2.0 DNA polymerase, by at least one minute. However, a similar improvement 
on the amplification speed of the assay containing the GSP-SSD DNA polymerase was only 
seen upon the addition of 10 mM KAc.    
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Table 11 showing summary of the data presented in the figure 6. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
Note that the concentrations of the tested potassium salts shown, correspond to the amounts of 
additional salt added, not the final concentration used in the assay (Isothermal buffer used 
contained 50 mM KCl at 1x concentration). 
 
 
 
 
 
 
 
 
 
DNA pol Salt conc. [mM] Mean [min] STDev Amp. Freq. [%] Inhibitor
0 17 0.44 100
10 16 0.44 100
31.25 17 0.44 100
50 20 0.55 100
0 16 0.00 100
10 16 0.00 100
31.25 17 0.44 100
50 21 0.00 100
0 17 0.00 100
10 16 0.44 100
31.25 17 0.44 100
50 18 0.59 100
0 16 0.00 100
10 15 0.44 100
31.25 16 0.00 100
50 18 0.56 100
Bst2.0
GSP-SSD
KCl
Bst2.0
GSP-SSD
KAc
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Furthermore, the initial assessment of the effects of sodium chloride on the HCV assay 
performance revealed similar responses to inhibition when GSP-SSD and Bst 2.0 DNA 
polymerases were tested.  
Figure 37 shows LAMP-BART profiles generated using HCV assay utilising either Bst 2.0 or 
GSP-SSD DNA polymerases, challenged with various amounts of sodium chloride, again in 
addition to the salt already present within the assay.  
 
 
 
 
The assay when utilising the DNA polymerase GSP-SSD was more sensitive to the tested salt, 
as the addition of 30 mM NaCl resulted in an increase in TTM by at least 1 minute. In contrast, 
no sign of inhibition was observed for the reactions using Bst 2.0 when 10-30 mM of sodium 
chloride (NaCl) was added. In addition, a 3 minute increase in TTM was observed when 50 
mM of NaCl was added to the reactions containing the GSP-SSD enzyme, whereas only 2 
minute difference was detected in the reactions utilising Bst2.0 when compared to the non-
inhibited samples (p value < 0.05, t-test)(Table 12).  
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Figure 37. LAMP-BART profiles generated using the HCV assay model system, 2000 cps of HCV 5’UTR RNA fragments and two chosen 
DNA polymerases challenged with various amounts of NaCl. 
 A – amplification profiles generated with reactions containing GSP-SSD and various amounts of NaCl; B – amplification profiles 
generated with reactions containing Bst 2.0 and various amounts of NaCl;  
Note: red curves correspond to the non-inhibited reactions; black curves show reactions containing 10 mM additional potassium salt; 
orange curves represent reactions containing 30 mM additional potassium salt; blue curves shows reactions challenged with 50 mM 
additional potassium salt.   
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In contrast to the previous experiment, addition of 10 mM NaCl did not result in improvement 
in the assay kinetics, regardless of the DNA polymerase used.  
 
Table 12 showing summary of the data presented in the figure 37. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
Note that the concentrations of the tested NaCl shown, correspond to the final concentration 
used in the assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DNA pol. Salt conc. [mM] Mean [min] STDev Amp. Freq. [%] Inhibitor
0 18 0.55 100
10 18 0.00 100
30 18 0.00 100
50 20 0.00 100
0 16 0.00 100
10 16 0.57 100
30 17 0.55 100
50 19 0.00 100
Bst2.0
NaCl
GSP-SSD
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4.3.1.2 Effects of sample-derived inhibitors on the performance of NAAT assays. 
In this study the effect of variety of different inhibitory substances, found in blood and sputum, 
on the performance of NAAT assays, was assessed. In particular we looked at non target 
nucleic acids commonly abundant in most samples. 
Figures 38 show LAMP-BART profiles generated using the TB RNA and DNA assays 
challenged with various amounts of carrier DNA (salmon sperm DNA). 
As expected, all assays managed to detect the target, regardless of the type of nucleic acid 
tested. However, full detection was seen only when M. bovis gDNA was used at 1000 and 100 
copies. In the non-inhibited samples, a slight reduction in sensitivity was detected when RNA 
was used for amplification. At 100 copies of the target RNA only 5 out of 6 replicates showed 
positive amplification profiles whereas full detection was observed when DNA template was 
used. Moreover, similarly to our previous data, an increase of 2-3 minute in TTM was observed 
in the assays containing the positive control RNA when compared with the same reactions 
utilising gDNA target.  
Furthermore, addition of 1000 ng of carrier DNA caused severe inhibition of the TB assay 
regardless of the type of template used. However, the RNA assay was observed to be far more 
sensitive to inhibition than the reactions utilising gDNA as the template for amplification. 
Firstly, the presence of carrier DNA significantly impeded the amplification of gDNA (p value 
< 0.05, t-test). On average, a 3 and 7 minute delay in detection was observed in the challenged 
reactions containing 1000 and 100 copies of the DNA target, respectively (Table 13). 
However, no effects on the assay sensitivity was observed, even at limit of detection of 100 
copies of the gDNA.  
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Table 13 showing summary of the data presented in the figure 38. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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Template Carrier DNA [ng/rxn] NA conc. [cp/rxn] TTM [min] Stdev Amp. Freq. [%]
0 ng 1000 cps 13 0.6 100
1000 ng 1000 cps 16 0.9 100
0 ng 100 cps 17 0.9 100
1000 ng 100 cps 24 4.5 100
0 ng 1000 cps 16 0.8 100
1000 ng 1000 cps 19 17
0 ng 100 cps 19 1.4 67
1000 ng 100 cps 24 17
gDNA
rRNA
Figure 38. LAMP-BART profiles generated using the TB assay model system and various amounts of M. bovis positive control 23s rRNA 
or genomic DNA (gDNA). A – amplification profiles generated with non-inhibited reactions containing gDNA template; B – 
amplification profiles generated with non-inhibited reactions containing 23s rRNA template; C – amplification profiles generated with 
reactions containing gDNA template and 1000 ng of salmon sperm carrier DNA; D – amplification profiles generated with reactions 
containing 23s rRNA template and 1000 ng of salmon sperm carrier DNA.  
Note: orange curves correspond to the reactions containing 1000 cps of the target; green curves show reactions containing 100 cps of 
the target; black curves represent NTC (No template control)  
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Nonetheless, the overall performance of the DNA assay was noticeably impaired due to both, 
reduction in amplification speed and reproducibility at 100 copies.  
Secondly, carrier DNA had similar effects on amplification speed and sensitivity when the 
target nucleic acid was RNA rather than gDNA. However, the observed inhibition was far more 
severe than that of the previously showed DNA assays.   
Similarly to the DNA assays, addition of the carrier DNA caused significant amplification 
delays, regardless of the amount of target TB RNA used (p value < 0.05, t-test). On average, 3 
and 7 minute delays in detection were observed when 1000 and 100 copies of the target RNA 
was used. However, unlike the inhibition of the TB DNA assays, the sensitivity of RNA 
detection in the presence of the carrier DNA was greatly reduced, regardless of the amount of 
template used. At both 1000 and 100 copies of the target, only 1 out of 6 replicates showed 
positive amplification profiles when challenged with the inhibitor.  
Note that full detection of 100 copies of the target RNA, in the non-inhibited conditions, was 
not achieved. Nonetheless, clear reduction in the assay sensitivity was still observed when 
compared to the non-inhibited reactions.   
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4.4 Discussion 
Amplification inhibitors are highly heterogeneous substances that can act on different 
components of a diagnostic test leading to either reduction in the sensitivity of the assay or a 
complete amplification failure (Bessetti, 2007, Zhang et al., 2010b, Schrader et al., 2012, 
Huggett et al., 2008, Speers, 2006).  For instance, we showed that both the carrier DNA and 
LDS could reduce the overall sensitivity of the TB assay leading to a number of false negative 
results. However, the observed inhibitory mechanism differed significantly between the two 
tested substances. LDS showed to have no effect on the speed of amplification, regardless of 
the amount of template and inhibitor used. We suggest LDS interferes with the BART 
components rather than the polymerisation reaction, since a significant reduction in the light 
output was detected in the inhibited samples. It is likely that the observed inhibition of light 
was a direct result of the sensitivity of the Luciferase enzyme to either LDS or pH changes 
caused by the detergent (Kitayama et al., 2003, Gabriel and Viviani, 2014, Imani et al., 2010).  
In contrast, carrier DNA caused significant delays in amplification of the target M. bovis RNA 
without affecting the light emission. Although, the presence of high amounts of non-target 
DNA is unlikely to directly interfere with the enzymatic properties of the polymerases or RT 
enzymes, it has been reported that sequestration of enzymes and primers onto non-target 
templates can significantly reduce assay performance (Kiddle et al., 2012, Morata et al., 1998, 
Rohrman and Richards-Kortum, 2015). In addition, several researchers have shown that DNA 
molecules can bind magnesium ions in order to stabilise their own structure, therefore resulting 
in a reduction of the amount of free magnesium available for DNA polymerase and RT enzyme 
activity (Robinson et al., 2000, Serec et al., 2016).  
Furthermore, we have also demonstrated that the assay chemistry and the type of target nucleic 
acid can impact the inhibitory effects of certain substances such as LDS or carrier DNA.  LDS 
was showed to reduce the overall light emission by 60 % in the reactions utilising the 125 mM 
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1x bicine buffer. In contrast almost 70 % reduction in the light intensities was observed in the 
samples containing the 12.5 mM 1x bicine buffer. Since LDS is a highly potent acidic 
detergent, the most likely explanation for the observed behaviour of BART could be simply 
associated with a lower buffering capacity of the 12.5 mM bicine buffer. Nonetheless, our data 
indicates that the choice of reaction chemistries can play a key part in the extent of inhibition.  
Furthermore, our analysis on the effects of carrier DNA on amplification of both DNA and 
RNA templates, revealed interesting correlations between the type of nucleic acid and the 
degree of inhibition coming from non-target nucleic acids. Although, carrier DNA inhibition 
has been widely reported across the literature, limited consideration have been made in regards 
to the effects of such contaminants on RNA assays. We demonstrated that despite a significant 
increase in the TTM of the reactions containing genomic M. bovis DNA, the presence of carrier 
DNA had no effect on the overall assay sensitivity, regardless of the amount of template used 
for each reaction. In contrast, almost 90 % reduction in detection was observed when the M. 
bovis rRNA target was being amplified in the presence of the same inhibitor and inhibitor load.   
Reverse transcription, a crucial step in most RNA detection systems, has been reported to be a 
less efficient process when compared to the DNA synthesis step (Bustin and Nolan, 2004, 
Sanders et al., 2013). Thus, one can conclude that inhibitory substances can further impact this 
process. As mentioned previously non-target DNAs can sequester primers and enzymes 
including RTs thus further reduce the efficiency of reverse transcription. In addition, RT steps 
have been reported to have an increased requirement for magnesium ions, thus can be highly 
sensitive to changes in the amounts of available free magnesium (Goldschmidt et al., 2006). 
Consequently, the choice of nucleic acid purification method can have a significant effect on 
the performance of the downstream detection. As mentioned previously, more a selective 
purification using target capture technology, could prevent RT inhibition by favouring 
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extraction of the target RNA over other carrier nucleic acids (Chandler et al., 2000, Wu et al., 
2015).   
Furthermore, we showed that not only the type of inhibitory substances present but also its 
concentration are key elements of the overall potency of the inhibitory effect. As an example, 
we showed different responses of our model HCV assay to certain salts such as NaCl, KCl or 
KAc. We showed that all assays containing greater than 100 mM of total salt were significantly 
inhibited, regardless of the type of salt tested. However, when 10 mM additional salt (total 60 
mM) of either KCl or KAc was added to the assays, a noticeable improvement of the 
amplification speed was observed. Since KCl and similarly KAc, have been reported to 
stabilise the primer-template interaction by reducing the repulsion of negatively charged DNA 
backbones, one could conclude that the observed improvement was caused by optimisation of 
this effect through increasing of the salt concentration. However, whilst optimal salt 
concentration can facilitate primer binding and therefore improve the initiation step of 
amplification reactions, greater salt amounts have also been shown to significantly increase the 
Tm of longer DNA molecules. Although, higher salt concentrations have been shown to be 
beneficial when very short sequences are targeted, it can also impede primer invasion due to 
increased stability of DNA helixes and secondary structure of RNA molecules (de Vega et al., 
2010). Moreover, the counter ion chlorine has also been suggested to negatively affect DNA 
polymerases by binding to their active sites, leading to temporary inactivation and thus 
resulting in impaired binding to the target templates.  
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4.5 Perspective 
Although, we demonstrated different nature of chosen inhibitory substances and their effects 
on detection of DNA and RNA templates, our amplification models have not been challenged 
with some key inhibitory substances commonly found in biological samples such as haem or 
heparin, due to time limitations. Moreover, since RT assays rely on the performance of both 
DNA polymerases and RT enzymes, the observed inhibitory effects were most likely a 
combined inhibitory effect of the two enzymes rather than solely contributed to the RT 
efficiency.   
In addition, since very little is known about the direct effects of inhibitory substances on reverse 
transcriptases, it would be of great benefit to screen a wider range of inhibitors in regards to 
their effects on different RTs.  
Moreover, it has been reported in this study, that assay chemistry could potentially affect the 
potency of certain inhibitors, thus it is recommended to further test this hypothesis using a 
wider range of buffers including Thermopol and Isothermal buffers (NEB, UK).  
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Chapter 5 
5 Development of internal amplification controls for RT-LAMP 
assays 
5.1 Introduction 
During the last 20 years, nucleic acid purification technologies have advanced dramatically, 
resulting in significant improvements that affect the reliability of down-stream applications 
that are dependent upon quality preparations (Tan and Yiap, 2009). Despite these 
improvements. co-extraction of inhibitory substances affecting nucleic acid amplifications 
(NAAT) and reporter chemistries can still occur (Bessetti, 2007, Bickley et al., 1996a, Funes-
Huacca et al., 2011, Opel et al., 2010). Thus, it has becoming more common to control 
polymerised chain reactions by qualifying the inhibitory nature of the extracted samples in 
order to eliminate the risks of misdiagnosing false negative amplifications (Hoorfar et al., 
2004b, Hoffmann et al., 2006).  
In any NAAT-based diagnostic approach, a negative result could be unreliable if such an 
inhibitor control is not included in the test; as this result could be due to amplification failure 
caused by inhibitory substances, sub-optimal amplification efficiency, problematic detection 
chemistries, or faulty equipment (Rådström et al., 2008). In general, amplification controls 
(IACs) should consist of a pre-defined input copy number of nucleic acid or microorganism, 
and the amplification should run in parallel with the true positive (Rosenstraus et al., 1998, 
Hoorfar et al., 2004b, Malorny et al., 2003). By comparing the detection parameters of these 
controlled amplifications, with those performed under non-challenged conditions, an 
estimation of the inhibitory nature of the samples can be made.  In practice, two main types of 
controls can are used – external and internal amplification controls (Lion, 2001). 
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The external control is added at the very start of the sample preparation and purification 
process. Thus, controlling the extraction processes such as cell lysis, nucleic acid binding and 
recovery, as well as the amplification (Kalle et al., 2013). External controls for microorganisms 
can be ‘synthetic mimics’ comprising of encapsulated nucleic acid (such as Armoured RNA or 
DNA), that resemble the true target organism, and are extracted from the same matrix (Meng 
and Li, 2010, Yu et al., 2008, Pasloske et al., 1998). These controls are used to simplify a 
single-tube assay design and reduce the complexity of primer design (often a problem 
encountered for IAC) and the risks of potential, unwanted interactions (Hoorfar et al., 2004b). 
The external controls can be extremely beneficial for evaluating integrated workflows of 
diagnostic assays, where sample preparation, nucleic acid purification and detection are 
performed in a single module / device or consumable (Hata et al., 2011). However, these 
controls provide no information with respect to the cause of potential detection failure.  
In contrast, internal amplification controls (IACs), are added to the amplification chemistry, 
and control for the amplification and its detection. The IAC, therefore gives meaningful 
information about the cause of amplification failure and can be used to effectively judge the 
nature of inhibition with respect to the sample and its effect on the polymerase activity. There 
are currently two main strategies adopted for use of IACs in molecular diagnostic assays, and 
each depends on the level of competition between the target diagnostic chemistry and the 
detection of IAC targets.  
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5.1.1 Competitive vs. non-competitive IAC systems 
Generally, a non-competitive IAC system relies on separate primer sets targeting the IAC 
template and the target of interests, and can be performed together with the target amplification 
or in a separate tube (Selvey et al., 2001).  Some commercial platforms, such as Illumigene, 
adopted this approach, where each tested sample is ran as a set of two reactions; one for 
detection of the potential disease and one IAC (Lucchi et al., 2016). However, this approach 
increases the overall cost of an assay as well as require an increased amount of the biological 
sample to accommodate the IAC reactions.  
In contrast, the competitive IAC involves the utilisation of a single primer set that can amplify 
the true target and IAC template simultaneously in the same tube. Both strategies are somewhat 
similar, and competitive inhibition of the true amplification can occur if a single tube is used 
for both true and IAC reactions. There is always a risk that the IAC amplification will compete 
for the amplification precursors, (dNTPs / primers) and enzymes required for the true 
amplification (Hoorfar et al., 2004b, Dingle et al., 2004). This competition would be reported 
regardless of the detection system used. As many isothermal amplifications require the use of 
multiple and long primers (such as LAMP) that span large template regions, the use of 
additional primer sets for IACs may be necessary to reduce competitive inhibition, but this 
poses challenges related to non-specific priming (Kiddle et al., 2012, Lee et al., 2015). All IAC 
strategies require precise optimisations that favour the detection of the true target without 
compromising the overall sensitivity of the control assay (Abdulmawjood et al., 2002, Cubero 
et al., 2002, Kleiboeker, 2003). 
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5.2 Aims and objectives 
The main focus of this study was to develop a reverse transcribed internal amplification control 
for RT-LAMP assays that used delayed competitive IACs. We aimed to reduce the level of 
competition for primers, enzymes and precursors by impeding the amplification of the IAC 
with respect to limiting copy numbers of true target nucleic acid. This would be achieved by 
using a synthetic template, akin to the target of interest, albeit with eliminated and altered 
primers annealing positions designed to hinder amplification. Manifestations of this IAC would 
be reportable by BART and a specific probe that would allow differentiation between positive 
amplifications and those initiated from the IAC. 
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5.3 Results 
5.3.1 Development of Internal Amplification Control for monitoring assay inhibition 
In this section, a step-by-step approach for generating a single-tube IAC will be realised.  It has 
been demonstrated that certain primers and modifications can perturb amplification kinetics. 
These primer modifications were exploited as a way of impeding the initiation and propagation 
of IAC amplifications, thereby reducing the competition with the core RT-LAMP.   
5.3.1.1 Impeded RT-LAMP assay as a model for IAC generation 
As shown in a different study, loop primer elimination and LAMP primer mutations with 
respect to the true target, could cause severe delays in amplification without affecting the 
sensitivity of the assay (see Appendix 39). Thus, it was decided to explore similar approaches 
in this study.  
Figure 39 shows LAMP-BART profiles generated using the standard TB assay as a model. 
Since it is well established that loop primers significantly improve the amplification speed, 
they were removed from the RT-AMP TB 23S primer set used in this study (Nagamine et al., 
2002).  
In addition, the number of introduced mismatches differed depending on the LAMP primer 
used. It was necessary to maintain similar melting temperatures for complementary regions, to 
enable direct comparison of the effects of mutated primer melting temperatures and priming 
positions on the performance the TB assay.  
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Table 14 shows all of the tested versions of the TB LAMP primers with introduced mismatched 
bases highlighted in red. The shown Tm values represent the melting temperatures of the 
mutated priming regions that maintained complementarity with the target, unless otherwise 
stated.  
 
The introduced mismatches significantly affected the amplification of the M. bovis positive 
control rRNA (p value < 0.05, t-test) (Figure 39). In general, the lower Tm’s of the mutated 
LAMP primers impeded the amplification from target RNA; the more bases mutated the greater 
the observable impact. However, the biggest impact on amplification kinetics was seen when 
using the MutFIPv2-4 and MutBIPv2-4 (Table 14-15). These primers generated both highly 
delayed and reproducible amplifications. Over a 15 to 30 min delay in time-to-peak was 
achieved with the MutFIPv2 and MutBIPv2 primers. Interestingly, despite the differences to 
which the amplification times were delayed, the Tm of these primers are calculated to be highly 
similar (separated by 1 °C). Furthermore, the reactions containing the MutFIPv3-4 and 
MutBIPv3-4 produced peaks at 82-64 min and 70-74 min, respectively (Figure 39A, C). 
However, the reproducibility of those reactions suffered a noticeable loss in amplification 
efficiency when compared to either the assays utilising the WT primers or version 2 of the RT-
LAMP primers tested (Table 15). The standard deviation in time to maximum varied between 
Primer Tm [°C]
WT BIP B1-60.2 B2-61.4
WT FIP F1-58.6 F2-65.2
M utFIPv2 F1-44.0 F2-65.2
M utFIPv3 F1-37.3 F2-65.2
M utFIPv4 F1-30.2 F2-65.2
M utFIPv5 F1-58.6 F2-58.0
M utFIPv6 F1-58.6 F2-46.8
M utFIPv7 F1-58.6 F2-37.7
M utBIPv2 B1-45.5 B2-61.4
M utBIPv3 B1-37.3 B2-61.4
M utBIPv4 B1-29.0 B2-61.4
M utBIPv5 B1-60.2 B2-50.6
M utBIPv6 B1-60.2 B2-45.4
M utBIPv7 B1-60.2 B2-36.9
ACTCGCAGGCTCATTCTTTTTaggGGAGGAGGGTGG
ACTCGCAGGCTCATTCTTTTTaggcGAGGAGGGTGG
ACTCGCAGGCTCATTCTTTTTaggcctGGAGGGTGG
5'→3' sequence
AAGGTTAACCCGTGTGGTTTTgcgcacaGGGTCGCC
ACTCGCAGGCagtaagaTTTTTCCGGAGGAGGGTGG
ACTCGCAGGgagtaagaTTTTTCCGGAGGAGGGTGG
ACTCGCAGcgagtaagaTTTTTCCGGAGGAGGGTGG
ACTCGCAGGCTCATTCTTTTTTCCGGAGGAGGGTGG
AAGGTTAACCCGTGTGGTTTTCGCGTGTGGGTCGCC
AAGGTTAACCCGacaccTTTTCGCGTGTGGGTCGCC
AAGGTTAACCgcacaccTTTTCGCGTGTGGGTCGCC
AAGGTTAACCCGTGTGGTTTTgcCGTGTGGGTCGCC
AAGGTTAACCCGTGTGGTTTTgcgcaGTGGGTCGCC
AAGGTTAACCCcacaccTTTTCGCGTGTGGGTCGCC
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5 to 10 min, whereas only 2 min difference was observed in the average TTM of reactions 
performed with version 2 primers. LAMP primer, variants 5-7 also caused significant delays 
in amplification (p value < 0.05, t-test) (Table 15). Together with the overall delay in 
amplification caused by LAMP primers, there were also noticeable differences in the assays 
performance between the affected BIP and FIP primers.  
Mutagenesis resulting in the reduction in Tm of the B2 position within the back inchworm 
primer (BIP; MutBIPv5-7) caused mild delays in amplification speed, compared with all the 
other reactions tested (Figure 39D). Surprisingly, only a 7 min difference in the time to 
maximum light output (TTM) was detected between reactions containing the WT and the 
mutant versions (v5-7) of the BIP (Table 15). MutBIPv5 and v7 generated BART curves with 
similar TTM although reactions utilising the MutBIPv7, suffered a noticeable reduction in 
reproducibility. The overall reproducibility of the TB amplification, was highly comparable 
between the above BIP variants. The MutBIPv6 and the MutBIPv2 designs resulted in almost 
identical calculated Tm but showed a prominent difference in amplification performance. 
When mismatches were introduced to the B1 site of the BIP primer a 30+ min delay in 
amplification was achieved, whereas only a 4 min difference in TTM was observed when the 
B2 side was mutated by the same temperature difference (Figure 39C).  
Similar reductions in the Tm on the F2 region of the forward inchworm primer (FIP), had a 
completely different impact on the assay (Figure 39B). On average, these reactions amplified 
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10 min slower than those containing similar mutations within the BIP. The amplification 
reproducibility was affected to a much greater extent than any of the mutated variants tested.  
 
Table 15 showing summary of the data 
presented in the figure 39. Each set of 
reactions was analysed using average 
TTM (Mean), reproducibility (STDev) 
and sensitivity (Amp.Freq). 
 
 
 
 
 
Primer Mean [min] Stdev Amp.Freq.[%]
TB mutFIPv2 51 2.2 100
TB mutFIPv3 82 6.9 100
TB mutFIPv4 64 6.5 83
WT FIP 35 1.1 100
TB mutFIPv5 46 6.3 100
TB mutFIPv6 45 11.0 83
TB mutFIPv7 48 15.9 33
WT FIP 32 0.5 100
TB mutBIPv2 61 2 100
TB mutBIPv3 70 10 83
TB mutBIPv4 74 5 50
WT BIP 31 1 100
TB mutBIPv5 37 0.8 100
TB mutBIPv6 34 0.6 100
TB mutBIPv7 37 2.6 100
WT BIP 30 0.9 100
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Figure 39. Comparison of LAMP-BART profiles generated using mutated versions of TB LAMP primers. A – amplification profiles 
generated suing FIP primer with altered F1 site; B – amplification profiles generated using FIP primer with altered F2 site; C – 
amplification profiles generated using BIP primer with altered B1 site; D – amplification profiles generated using BIP primer with 
altered B2 site 
Each version of LAMP primers was colour-coded as follows: red – WT primer; Green – version 2; Blue – version 3; Orange – version 4; 
Black – version 5; Yellow – version 6; Purple – version 7 
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5.3.1.2 Internal amplification control template design 
In order to maintain similarity between the IAC template and true amplifications the 23s rRNA 
targeted by the RT-LAMP, was used as a template for the IAC design. Figure 40B shows the 
consensus region targeted by the 23s Mycobacterium bovis rRNA with highlighted RT-LAMP 
primers and the capture probe binding sites used for its extraction.  
Table 16 contains colour-coded primer sites corresponding to each binding position shown in 
the Figure 40.  
 
Figure 40A shows the IAC template design generated from the 23S rRNA sequence along with 
the mutated and altered primer annealing positions that were introduced (black box). 
To accommodate the proposed IAC design and reduce the cost of synthesis, the entire sequence 
was truncated to remove unnecessary bases. The loop priming positions were substituted for 
probe sites; this would serve to decelerate the amplification significantly and allow for 
alternative specific fluorescent detection of the IAC. The substitution of the loop primer 
annealing position did not affect the overall length of the target sequence. Finally, to further 
impede the IAC amplification, base substitutions were introduced to the B2 binding site, 
mimicking the alterations within the MutBIPv2.  
 
 
 
Primer sequence 5' -> 3'
LAMP B (BIP) ACTCGCAGGCTCATTCT-TTTT-TCCGGAGGAGGGTGG
LAMP F (FIP) AAGGTTAACCCGTGTGG-TTTT-CGCGTGTGGGTCGCC
Loop B CAAAAGGCACGCCATCA
Loop F CGAAAGCGAGTCTGAATAG
Displacement B (DispB) AGAGTACCTGAAACCGTG
Displacement F (DispF) ATTCACACGCGCGTAT
Capture probe CGGGTCCAGAACACGCCAC 
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F3F2LFF1B1
B3 B2
LB Capture probe
A
B
Figure 40. showing a sequence alignment using the consensus region targeted by the TB primers and the IAC design. Each corresponding primer 
binding site was colour-coded as follows: Green – B3; Teal – B2; Yellow – Loop B; Dark yellow – B1; Dark blue – F1; Orange – Loop F; Light blue – 
F2; Pink – F3; Red – capture probe binding position.  Each highlighted sequence corresponds to a fully complementary region of the TB primers. 
Black box showing the mutated region of the IAC template. Note: A – consists of two identical IAC sequence alignments; B – WT region of the TB 
consensus sequence.  
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5.3.2 Detecting assay inhibition using the RT-LAMP IAC 
In this section, the parameters affecting the performance of the standard TB assay, including 
the IAC interference study as well as inhibition, were assessed.  
5.3.2.1 Assessing the performance of the in-house developed IAC assay 
In the first instance, the performance of the newly designed IAC template was evaluated using 
the in-house freeze-dried 50 uL RT-LAMP 23S TB assay, which contained all the chemistry 
and primers required for true positive and IAC amplifications. 
Figure 41 shows LAMP-BART profiles (A) and summary bar charts (B) generated using the 
50 uL standard TB assay. 
The positive control 23s rRNA and the IAC in vitro transcribed (IVT) RNA successfully 
amplified under the RT-LAMP conditions used. However, the amplification of the IAC RNA 
was significantly delayed compared to the target 23s RNA (p value < 0.05, t-test) (Figure 41B). 
Over a 20 min difference in TTM was achieved between the two amplification mechanisms, 
good reproducibility was observed for both amplifications at the copy numbers tested. 
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Figure 41. Comparison of LAMP-BART profiles (A) and summary bar chart (B) generated using standard TB 50 uL reactions containing 
full primer set. Each tested template was colour-coded as follows: Green – 10^5 cps of 23s M. bovis rRNA; Red – 10^6 cps of the in-
house IAC RNA; Black - NTC 
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5.3.2.2 DNA contamination in the IAC IVT RNA. 
As the IAC IVT RNA was synthesised from a DNA template it was important to account for 
any contaminating DNA that may affect our interpretation of DNA and RNA polymerised 
events later in this chapter. 
Figure 42 RT-LAMP and LAMP-BART profiles generated using in the presence and absence 
of reverse transcriptase.  
All reactions conducted with Maxima RNaseH+ amplified, the reproducibility and speed was 
comparable to the previously generated data for 10^6 cp of the IAC (data not shown). 
Surprisingly, the reactions deficient in Maxima RNaseH+ also exhibited exceptionally good 
amplification efficiency, and reproducible detection at all copy numbers tested (Figure 42B). 
Reactions with RT amplified slightly faster than those deficient in this activity. In fact, 
reactions performed at 10^8 copies of IVT RNA without the RT enzyme amplified at the same 
time as RT dependent amplifications containing 10^7 copies of the target IVT (Table 17). This 
suggested the IVT RNA was contaminated with 10 % of its parental DNA template.  
In order to further confirm the DNA contamination levels, the amplification performance of 
the IAC RNA assay lacking the RT enzyme was compared with a sample standard generated 
from an IAC DNA PCR product quantified using qPCR and Agilent by ERBA Molecular (data 
not shown).  
Figure 43 shows LAMP-BART profiles generated using a standard TB assay (no 
MaximaRH+) and various amount of either IAC RNA or positive control DNA. The average 
TTM for each sample dilution was then used to estimate the contamination levels in the RNA 
samples.  
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Table 17 showing summary of the data presented in the figure 42. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq).  
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10^7 33 1.5 100
10^8 31 1.7 100
10^6 51 7.5 100
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Figure 42. Comparison of LAMP-BART profiles generated using standard TB 20 uL reactions containing full primer set and various 
amounts of IAC RNA. A – represents reactions containing the reverse transcriptase (MaximaRNaseH+); B – showing amplification 
profiles generated in the absence of RT. 
Concentrations of the IAC RNA used were colour-coded as follows: Red – 10^8 cps; Blue – 10^7 cps; Green – 10^6 cps; Black - NTC 
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Table 18 showing summary of the data presented in the figure 43. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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Figure 43. Comparison of LAMP-BART profiles generated using standard TB 20 uL reactions containing full primer set and various 
amounts of IAC targets. A – represents reactions amplifying the positive control IAC DNA; B – showing amplification profiles 
generated using the ivt IAC RNA. Note that none of these reactions contained RT enzyme. Bst Large fragment was also used.  
Concentrations of the IAC templates used were colour-coded as follows: Red – 10^8 cps; Orange – 10^7 cps; Blue – 10^6 cps; Green – 
10^5; Black - NTC 
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As expected, successful amplification of the target was achieved on both the DNA and RNA 
templates without the standard RT enzyme, confirming the presence DNA contamination 
(Figure 43A-B). Similarly to our previous findings, the contaminations levels were estimated 
to be approximately 10 %. Table 18, shows TTM values for each DNA and RNA titration used. 
In general, the amplification of IAC DNA was observed to be significantly faster than of 
corresponding RNA amount (p value < 0.05, t-test). However, the comparison of TTM between 
the samples containing the IAC DNA and a corresponding 10-fold dilution of the RNA target 
showed no significant difference in amplification speed (p value > 0.05, t-test). On average, 
the reactions containing 10^5 cps of the IAC DNA amplified in 63 min whereas 69 min was 
required to detect 10^6 cps of IAC RNA. Similarly, when the reactions utilising 10^6 cps of 
the IAC DNA were compared to the assays containing 10^7 cps of the IAC RNA, highly 
comparable amplification times were detected (Table 18). In fact, the same pattern was noticed 
across all of the DNA and RNA titrations tested.  
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5.3.2.3 RT-LAMP - IAC interference study 
Due to the single-tube format of the 23S rRNA RT-LAMP / IAC amplification and knowledge 
that the true and control reactions utilise the same primer set and substrate, it was crucial to 
determine any potential effects that the IAC amplification may have on the RT-LAMP-BART. 
Figure 44 23S rRNA RT-LAMP-BART profiles generated using the standard reaction 
conditions protocol 14 (see Appendix 14), spiked with a final load of 10^6 copies of the IVT 
IAC RNA 
No significant differences in amplification speed were perceived between those reactions 
containing purely the 23S rRNA and reactions spiked with the IAC RNA (p value > 0.05, t-
test; Table 19). Amplifications containing various titrations of 23S RNA and IAC IVT all 
amplified faster than those containing the IAC RNA alone (Figure 44A NTC+IAC). All of 
the reactions containing 100 cp of the 23S rRNA target, amplified prior to the IAC IVT RNA 
Figure 19. Interestingly, a slight improvement in true target amplification sensitivities were 
detected when the IAC IVT RNA was present in the reaction. In the spiked samples containing 
100 cps of the 23S rRNA target, 5 out of 6 replicates showed positive amplification profiles, 
whereas only 3 out of 6 reactions were detected in the absence of the IAC IVT RNA (Figure 
44B).  
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Table 19 showing summary of the data presented in the figure 44. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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10000cp 14 0.9 100
1000cp 17 1.5 100
100cp 19 1.6 50
10000cp + 10^6 IAC 14 0.7 100
1000cp + 10^6 IAC 17 2.9 100
100cp + 10^6 IAC 19 5.6 83
IAC RNA 10^6 43 2.8 100
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Figure 44. Comparison of LAMP-BART profiles generated using standard TB 20 uL reactions containing full primer set and various 
amounts of TB target. A – represents reactions spiked with 10^6 cps of IAC RNA; B – showing amplification profiles generated in the 
absence of IAC template.  
Concentrations of the TB target 23s rRNA used were colour-coded as follows: Red – 10^4 cps; Orange – 10^3 cps; Green – 10^2; Black 
– NTC. 
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5.3.2.4 The effects of probing on the performance of IAC and 23S RT-LAMP-BART 
As already described earlier in this chapter the TB loop priming positions were forsaken for 
non-TB probe sequences that may be used as an alternative reporter for the detection of IAC 
IVT amplification. The effect of ROX-labelled loop probes on the performance of IAC RNA 
amplification were therefore assessed.  
Figure 45 23S RT-LAMP-BART profiles and summary bar charts generated using a modified 
TB assay conditions according to the protocol 15 (see Appendix 15). Amplifications were 
tested in the presence of probe designed to target the recombinant loop position of the IAC IVT 
RNA and either BstLF (B) or GSP-SSD (A) 
A significant difference in amplification performance was detected between reactions 
containing GSP-SSD and Bst LF polymerase, irrespective of the presence of the ROX loop 
probes (p value < 0.05, t-test). On average, reactions utilising the GSP-SSD amplified over 10 
min faster than those containing the Bst LF (Table 20). In addition, over a 30 min difference 
in TTM was observed between those containing the ROX probes compared to those without. 
The presence of the ROX probes had a detrimental effect on amplification kinetics, regardless 
of the DNA polymerase used. However, the degree of inhibition realised was greater in 
reactions containing the Bst LF compared to similar reactions with GSP-SSD. On average, only 
an 11 min difference in amplification of the IAC target was observed between reactions 
containing the ROX probes and the controls (Figure 45 dotted red curves) when the GSP 
enzyme was used. In contrast, this difference increased to over 30 min when the Bst LF enzyme 
was added (Table 20).  Furthermore, the presence of the ROX-probes seemed to reduce the 
level of non-specific amplification. In general 50% NTC’s amplified in reactions containing 
the GSP-SSD and no probe compared to 15% in its presence. The same improvement was true 
for reactions with BstLF. 
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Table 20 showing summary of the data presented in the figure 45. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
Addition or ROX loop probe was indicated with “P”. 
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NTC 79 8.3 100
NTC +P 89 33
10^6 IAC RNA 38 5.1 100
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Figure 45. Comparison of LAMP-BART profiles generated in a presence or absence of ROX loop probe using a modified TB 20 uL 
reactions containing full primer set. A – represents reactions utilising GSP-SSD enzyme ; B – showing amplification profiles generated 
using Bst LF. 
Note that dotted lines represent the samples lacking the ROX probe (P), whereas solid curves show amplification profiles generated 
in the presence of the ROX probe. Red – samples containing 10^6 cps of IAC RNA; Black – NTC  
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5.3.2.5 Assessing the effects of inhibitory substances on the performance on 23S RT-LAMP 
and IAC RNA amplification. 
The inhibitory effect of sodium chloride, carrier DNA and RNA, humic acid and sodium 
hydroxide/mucin would be assessed on the 23S RT-LAMP / IAC. 
Figure 46 RT- LAMP-BART profiles generated using a modified assay according to the 
protocol 16 (see Appendix 16) challenged with various amounts of sodium chloride. Each 
reaction contained both the target 23S rRNA and the IAC RNA at a concentration of 10^6 cps 
per reaction, unless otherwise stated and a titration of NaCl (Ranging from 0 to 40 mM 
additional salt) 
The NaCl showed an inhibitory effect on the performance of the integrated IAC IVT RNA 
amplification and the RT-LAMP-BART designed to detect the M. bovis 23s rRNA. Overall, 
the TTM of the true positive samples (M. bovis 23S rRNA) and the IAC IVT RNA differed 
noticeably between the amounts of inhibitor used. A 5 min difference in TTM was observed 
between the uninhibited samples containing 100 copies of the target 23S rRNA (and an 
additional 10^6 copies of IAC IVT RNA) and the corresponding reactions spiked with 40 mM 
NaCl. Similarly, for the reactions containing 1000 copies of the 23S rRNA, a significant 
increase in TTM was observed between the uninhibited reactions and the samples containing 
40 mM NaCl, where over a 5min difference in amplification speed was detected (p value< 0.05, 
t-test). Interestingly, the salt did not cause reduction in the sensitivity of the 23s rRNA assay.  
A significant shift in TTM was also observed when the performance of IAC amplification was 
considered across all of the tested amounts of inhibitor (p value < 0.05, t-test) (Table 21). 
Within the time frame of the assay (60 min), full detection of IAC target was lost when assays 
were challenged with 30 and 40 mM of the NaCl (Figure 46C).  
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Table 21 showing summary of the data presented in the figure 46. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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Sample M. bovis  RNA conc. [cp/rxn] NaCl conc. [mM] Mean [min] Stdev Amp.Freq. [%]
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30 24 3.7 50
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Figure 46. Comparison of LAMP-BART profiles generated using a modified TB 20 uL reactions containing full primer set challenged 
with various amounts of NaCl. A – represents reactions containing 100 cp of the 23s rRNA  spiked with 10^6 cps IAC RNA; B – showing 
amplification profiles generated using 1000 cps of the 23s rRNA spiked with 10^6 cps IAC RNA; C – amplification profiles generated 
using 10^6 cps of the IAC RNA. 
Amounts of NaCl added to each reaction were colour-coded as follows: Green – 0 mM; Blue – 20 mM; Orange – 30 mM; Red – 40 
mM.  
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Figure 47 RT- LAMP-BART profiles generated using a modified reaction chemistry according 
to the protocol 17 (see Appendix 17) Amplification reactions were challenged with various 
amounts of salmon sperm DNA (ranging from 0 to 1000 ng). Each reaction contained both the 
target 23S rRNA and the IAC IVT RNA at a concentration of 10^6 cps per reaction, unless 
otherwise stated.  
The salmon sperm DNA caused inhibition of the 23S RT-LAMP amplification which was very 
apparent at the lowest copy number tested here (100 copies per assay). Over 50% reduction in 
amplification detections at 100 copies per reactions were observed in the presence of 1000 ng 
salmon sperm DNA, compared to the control (Table 22). When 1000 cps of the target 23S 
rRNA, were challenged with 500 and 1000 ng of the salmon sperm DNA a significant 
deterioration in amplification kinetics was realised. The amplification profiles of the IAC IVT 
RNA were also affected by the presence of the carrier DNA. Mirroring the RT-LAMP, a 
significant decrease in amplification speed of almost 10 min was observed, between reactions 
containing 1000 ng ssDNA and the control reactions (p value < 0.05, t-test) (Figure 47C). As 
little as 500 ng of the carrier DNA was potent enough to negatively impact upon amplification 
kinetics. Contrasting with NaCl inhibition, where no effect on the assay sensitivity was 
detected, carrier DNA caused a significant reduction in detection at the lowest copy number 
tested here. On average, every 10-fold increase in the concentration of the salmon sperm DNA, 
resulted in a 15% loss of sensitivity at 100 copies. Furthermore, concentrations of carrier DNA 
that caused a failure to detect 100 copies of 23S rRNA were not reflected by a failure full detect 
the IAC IVT RNA, just a reduction in the overall amplification efficiency.  
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Table 22 showing summary of the data presented in the figure 47. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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Figure 47. Comparison of LAMP-BART profiles generated using a modified TB 20 uL reactions containing full primer set challenged 
with various amounts of salmon sperm DNA. A – represents reactions containing 100 cp of the 23s rRNA  spiked with 10^6 cps IAC 
RNA; B – showing amplification profiles generated using 1000 cps of the 23s rRNA spiked with 10^6 cps IAC RNA; C – amplification 
profiles generated using 10^6 cps of the IAC RNA. 
Amounts of salmon sperm DNA added to each reaction were colour-coded as follows: Red – 0 ng; Green – 50 ng; Blue – 500 ng; 
Orange – 1000 ng.  
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Figure 48 23S RT-LAMP-BART profiles and bar charts generated using a modified reaction 
chemistry challenged with various amounts of tRNA.  
In this experiment, the target 23S RNA and the IAC RNA were amplified separately under the 
same inhibitory conditions.  
The 23S RT-LAMP and IAC IVT RNA amplification suffered from a reduction in performance 
when assays were challenged with 500 to 1000ng of tRNA, causing significant delays in 
amplification compared to the non-inhibited reactions (p value < 0.05, t-test) (Figure 48A-B). 
However, as was previously seen, the effects of carrier DNA, affected the 23s rRNA 
amplification to a much higher extent.   
A dramatic reduction in the sensitivity of the 23S RT-LAMP was detected when challenged 
with 1000 ng of the tRNA, yet none of the carrier RNA concentrations affected the sensitivity 
of the IAC IVT RNA amplifications. Furthermore, the reproducibility of the 23S-RT-LAMP 
containing 500 ng of carrier tRNA was compromised compared to the control reactions, 
whereas the IAC IVT RNA amplifications were unperturbed. At 50 ng of carrier tRNA, the 
amplification speed and reproducibility of 23S RT-LAMP was noticeably improved (Table 
23).  
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Table 23 showing summary of the data presented in the figure 48. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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Figure 48. Comparison of LAMP-BART profiles generated using a modified TB 20 uL reactions challenged with various amounts of 
carrier tRNA. A – represents reactions containing 100 cp of the 23s rRNA; B – showing amplification profiles generated using 10^6 cps 
IAC RNA; C – amplification profiles generated in the absence of both the 23s rRNA and IAC template. 
Amounts of the carrier RNA added to each reaction were colour-coded as follows: Red – 0 ng; Green – 50 ng; Blue – 500 ng; Orange – 
1000 ng.  
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Figures 49 23S-RT-LAMP-BART profiles and bar charts generated using various amounts of 
mucin / sodium hydroxide. A mucin stock was prepared according to the protocol 40 
(Appendix 40), the mucin therefore contained contaminating levels of sodium hydroxide. Each 
template titration was prepared using the corresponding inhibitory solution as diluent. 
Tables 24 show the amounts of mucin used to challenge both, the TB and IAC assay and the 
concentrations of sodium hydroxide expected in each mucin titration.  
An inhibitory effect of the mucin / sodium hydroxide solution on the IAC IVT RNA 
amplification performance was detected (Figure 49A, C). At the 400ng mucin containing 
approximately 1.3 mM NaOH, reduced the amplification speed by 3 min (p value < 0.05, t-
test) (Table 24). Once more, the RT-LAMP assays were more prone to inhibition by the 
inhibitor. The mucin / sodium hydroxide caused a 40% reduction in amplification sensitivity 
without affecting the amplification speed. Both the 400ng mucin and 1.3 mM sodium 
hydroxide affected the amplifications equally suggesting the latter to be the main cause of 
inhibition.  
Further investigation of mucin inhibition showed no apparent effect on neither the TB IAC nor 
the target TB 23s rRNA amplification (Figure 50).  
In that experiment, both the target TB 23s rRNA and the IAC RNA were amplified in a single-
tube format, where the two templates were spiked directly into the reaction mix followed by 
an addition of the appropriate inhibitory solution, unlike previously described in the Figure 49.  
When challenged with as much as 700 ng of mucin solution, which contained approximately 
2.3 mM NaOH, no significant change to either assay sensitivity or kinetics was detected when 
compared to the non-inhibited samples (p value > 0.05, t-test). Both reactions generated highly 
reproducible peaks with a TTM of 13 min and reaching over 80 % detection. In fact, similar 
effects were seen across all of the mucin and NaOH amounts used.  
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Note that in this set up 20 min threshold was chosen as a cut off point for true positive 
amplification. Thus, any profiles generated after that time were scored as IAC amplification.  
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Figure 49. Comparison of LAMP-BART profiles generated using a modified TB 20 uL reactions challenged with various amounts of 
mucin / NaOH. A – represents reactions containing 100 cp of the 23s rRNA challenged with mucin solution; B – showing amplification 
profiles generated using 100 cps of the 23s rRNA challenged with NaOH only; C – amplification profiles generated using 10^6 cps of 
the IAC template challenged with mucin solution; D – amplification profiles generated using 10^6 cps of the IAC template challenged 
with NaOH only. 
Amounts of mucin added to each reaction were colour-coded as follows: Red – 0 ng; Blue – 50 ng; Orange – 200 ng; Green – 400 ng; 
Black - NTC.  
The reactions containing 1.3 mM NaOH only are shown in red. 
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Table 24 showing summary of the data presented in the figure 49. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
 
 
 
 
 
  
 
 
 
Target Mucin [ng/rxn] NaOH [uM] TTM [min] Stdev Amp.Freq. [%]
0ng 0uM 23 0.4 100
50ng 175uM 24 0.9 100
200ng 675uM 24 0.4 100
400ng 1333uM 26 1.0 100
0ng 1333uM 24 1.1 100
0ng 0uM 15 1.2 50
50ng 175uM 13 1.4 67
200ng 675uM 12 1.2 50
400ng 1333uM 13 17
0ng 1333uM 14 17
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Table 25 showing summary of the data presented in the figure 50. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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0ng 13 1.5 80
400ng 13 1.2 80
500ng 13 1.8 100
700ng 13 1.2 100
1333 uM 12 0.6 90
1667 uM 14 1.7 100
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Figure 50. Comparison of LAMP-BART profiles generated using a modified TB 20 uL reactions challenged with various amounts of 
mucin / NaOH. A – represents reactions containing 100 cp of the 23s rRNA challenged with mucin solution; B – showing amplification 
profiles generated using 100 cps of the 23s rRNA challenged with NaOH only. 
Amounts of mucin added to each reaction were colour-coded as follows: Red – 0 ng; Orange – 400 ng; Blue – 500 ng; Green – 700 ng.  
Amounts of NaOH added were colour-coded as follows: Orange – 1.3 mM; Blue – 1.7 mM; Green – 2.3 mM.  
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5.3.3 IAC detection 
In the current RT-LAMP / IAC amplifications that utilise BART, differential detection of 
multiple amplifications in the same tube is not possible. Thus, two strategies were developed 
to enable differentiation between the RT-LAMP amplification and the IAC IVT RNA 
amplification. To this end the suitability of BART or fluorescent probing, would be assessed.  
5.3.3.1 Bioluminescent Assay Real-time (BART) as a method of IAC detection 
Although, the current BART reporter cannot distinguish between two simultaneous 
amplifications, the TTM, amplification frequency or peak shape could hypothetically enable 
this differentiation.  
Figure 51 23S-LAMP-BART profiles generated using a modified chemistry according to the 
protocol 18 (see Appendix 18). In this experiment, the effects of reaction volume on both 
amplification speed and reproducibility, were tested. A single reaction mix was made which 
contained 10^7 copies of the IAC IVT RNA per 50 ul. Two sets of reactions containing either 
50 or 10 uL of that reaction mix were then tested in order to determine the effects of 
concentration and reaction volume on the amplification performance.  
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The reaction volume had little effect on the speed, sensitivity or reproducibility of the IAC 
amplification. Both reaction volumes amplified in less than 20min, achieving comparable 
reproducibility and identical sensitivity. Peak height was the only parameter tested that differed 
significantly between the two sets of reactions (p value < 0.05, t-test) (Figure 51).   
When the reactions containing a challenging amount of the 23S rRNA were assessed, a 
significant effect of the reaction volume on the sensitivity and reproducibility, was observed.  
Figure 52 23S-LAMP-BART profiles and bar charts generated using a modified reaction 
chemistry according to the protocol 18 (see Appendix 18). Each reaction mix was prepared 
with 100 copies of the 23S RNA target per 50 uL. Two sets of reactions containing either 50 
or 10 uL of that reaction mix were then tested.  
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Figure 51. Comparison of LAMP-BART profiles generated using a modified TB assay and 10^7 cps/50 uL of the IAC RNA.  Red curves 
represent the reactions carried out in 50 uL volume, whereas the green lines shows amplification profiles generated in 20 uL reaction 
volume. Note that both sets of reactions contained equal concentration of the target IAC RNA (2 x 10^5 cps/uL).  
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Almost 40 % reduction in the RT-LAMP detection of 23S rRNA was observed when 10 uL 
reaction volumes were compared to 50ul reaction volumes, and although no significant change 
to TTM was seen, the reproducibility was noticeably altered by the choice of reaction volume 
tested (Figure 52D). Moreover, the variability in amplification time decreased with increased 
reaction volumes (Figure 52C).  
Since significant differences in the performance of RT-LAMP and IAC amplifications were 
observed when the 10 ul volumes were used, the effects of carrier DNA inhibition on the 
performance of a combined RT-LAMP / IAC amplification would be assessed using two 
different reaction volumes. This analysis was needed to establish whether or not the BART had 
the capacity to distinguish between the IAC and RT-LAMP amplification times and 
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Figure 52. Comparison of LAMP-BART profiles and summary bar chats generated using a modified TB assay and 100 cps/50uL of the 
23s rRNA.  A – profiles generated using 50 uL reactions; B – amplification curves generated from 10 uL reactions; C – summary data 
using average TTM; D – summary data using amplification frequencies. Note that both sets of reactions contained equal 
concentration of the target RNA (2 cps/uL).  
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frequencies, under both controlled and inhibited reaction conditions, when using a lower 
reaction volume.  
Figure 53 23S-LAMP-BART profiles and bar charts generated using a modified reaction 
chemistry according to the protocol 19 (see Appendix 19). Samples containing either the 100 
cps of the 23s rRNA spiked with 10^6 cps IAC RNA or 10^6 cps IAC only, were challenged 
with 500 ng carrier DNA (salmon sperm DNA) and run at 50 anf 10 uL volumes. 
Full detection of the IAC IVT RNA was achieved under both, inhibited and uninhibited 
conditions, regardless of the reaction volume. In addition, no significant change in TTM was 
noticed between the two tested volumes (+ or – inhibitor; p-value > 0.05, t-test; Table 26). In 
contrast, the presence of 500 ng of carrier DNA, affected the IAC RNA significantly, compared 
to the uninhibited controls (p-value < 0.05, t-test) (Figure 53A-B), where over a 30 min 
increase in TTM was detected. The opposite effect was seen when a challenging amount of the 
23s rRNA template was spiked with 10^6 copies of the IAC RNA. Firstly, a significant 
reduction in sensitivity was observed between the 50 and 10 uL reactions with the lower 
volumes amplifying less frequently under the uninhibited chemistry – over a 40 % decrease in 
sensitivity was detected (Figure 53C). Secondly, unlike the IAC RNA amplification, the 
presence of carrier DNA greatly impacted upon the sensitivity of the 23s rRNA assay, where 
over a 40 % and 25 % drop in amplification frequency was observed for the 50 uL and 10 uL 
reactions, respectively (Figure 53D, F).    
However, similarly to the IAC RNA data, no effect of reaction volume on the average TTM 
was detected in the mixed samples, regardless of the presence of carrier DNA. In addition, 
similar response to the inhibitor was observed, where a significant 10 min increase in TTM of 
the reactions amplifying the 23s rRNA was detected when compared to the mixed uninhibited 
samples.  
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Note that overall full detection was observed across all of the tested assays. However, in the 
mixed samples, the profiles generated after 50 min were scored as IAC RNA amplification 
(IAC RNA3). Both the 50 and 10 uL reactions amplifying after that time generated identical 
profiles as those observed from the samples containing the IAC RNA only.   
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Figure 53. Comparison of LAMP-BART profiles and summary bar chats generated using a modified TB assay and 100 cps/50uL of the 
23s rRNA and/or 10^6 cps IAC RNA.  A – profiles generated using 10^6 cps IAC RNA amplified at 50 (red) and 10 (green) uL volumes; B 
– profiles generated using 10^6 cps IAC RNA amplified at 50 (red) and 10 (green) uL volumes, challenged with 500 ng salmon sperm 
DNA; C – profiles generated using 100 cps of the 23s rRNA spiked with 10^6 cps of the IAC RNA and amplified at 50 (yellow) or 10 
(orange) uL volumes; D – profiles generated using 100 cps of the 23s rRNA spiked with 10^6 cps IAC RNA and amplified at 50 (yellow) 
and 10 (orange) uL volumes, challenged with 500 ng salmon sper DNA; E – summary data using average TTM; F  – summary data 
using amplification frequencies.  
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Table 26 showing summary of the data presented in the figure 53. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
Samples 1-2 represent the mixed reactions whereas sample 3 was amplified in the presence of 
IAC RNA only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carrier DNA Template Rxn. Vol. TTM [min] Stdev Amp.Freq. [%]
50uL 28 0.9 100
10uL 29 0.4 100
50uL 13 0.8 100
10uL 13 2.4 58
50uL 0
10uL 28 1.9 42
50uL 61 2.3 100
10uL 61 6.0 100
50uL 22 3.0 58
10uL 24 9.5 33
50uL 59 2.5 42
10uL 61 3.1 67
IAC RNA1
M. bovis rRNA2
IAC RNA3
0ng
500ng
IAC RNA1
M. bovis rRNA2
IAC RNA3
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5.3.3.2 Fluorescent probing as a method of IAC detection 
Molecular probes were assessed as novel tools for the differential detection of RT-LAMP and 
IAC. As described in the introduction to this chapter (section 1.1.5), most of the methods used 
to detect nucleic acid amplifications rely on the 5’->3’ endonuclease activity of DNA 
polymerases, which liberate digested fluorescent tag from a specific oligonucleotide (TaqMan 
probes). Hairpin loop structures are also commonly used that ensure the close proximity of 
fluorophores to the quencher (beacons). Here we describe an original method for LAMP 
detection, whereby a loop primer is labelled with rhodamine X (ROX) and the black hole 
quencher 2 (BHQ2) at the 5’ and 3’ ends, respectively. It is believed that proximity of the 
fluorophore and the quencher is maintained on the loop oligonucleotide via static interactions 
between the functional groups, which keep the ROX fluorescence low when unbound; while 
the binding of the loop probe to amplified LAMP or IAC complimentary sequences results in 
an increased distance between the functional groups, that causes a liberation of ROX 
fluorescence. The more single stranded loop amplified the greater the fluorescence signal 
achieved. This mechanism relies on the probing of single stranded amplified product such as 
the suggested loop or even stem regions of LAMP. This method can report the amplification 
in real time and is quantifiable. The following section of this Thesis explores the possibility of 
using Loop probing to detect the IAC when duplexed with the RT-LAMP-BART. The 
mechanism makes use of a specific loop sequence that can only be probed as a consequence of 
the IAC and not the RT-LAMP amplification. 
Figure 54 shows the folding predicted of the chosen loop B probe, under typical RT-LAMP 
salt (50mM) and temperatures (60oC), performed using the IDT oligo analyser tool [URL: 
https://www.idtdna.com/calc/analyzer].  
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No secondary structure was detected in the chosen probe design. Only a small hairpin was 
predicted by the software that was thermal labile. No strong interactions were observed 
between the 5 and 3’ of this sequence. No specific design was engineered that would generate 
a highly complementary region at the 5’ and 3’ ends, which would ensure quenching of the 
probe, as is the case for molecular beacons.   
 
Figure 55 shows LAMP-ROX profiles generated using the proposed fluorescence-based 
approach, according to the protocol 21-22 (see Appendix 21-22).  
No detection of RT-LAMP amplification occurred when ROX-loop probes were eliminated 
from the amplification. BART did not cause any significant shift in the background 
fluorescence observed in the absence of the ROX-loop probes. In contrast, full detection of the 
target was achieved in all RT-LAMP amplifications that contained the ROX-loop probe, and 
Figure 54. showing a typical sequence analysis output generated using the IDT oligo analyser. The tested oligo probe showed very 
mild folding with only 2 bp stem.    
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target DNA irrespective of BART. Furthermore, BART did have an effect on the probe 
chemistry, elevating the fluorescence signal in the presence and absence of target DNA (Figure 
55D).    
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Figure 55. showing a typical LAMP-ROX profiles generated using the HBV assay model. Each reaction was amplified in either presence 
or absence of BART components.  A – amplification profiles generated in the absence of both the BART and ROX loop probes; B – 
amplification profiles generated in the presence of 0.8 uM ROX loop probe; C – amplification profiles generated in the presence of 
BART only; D – amplification profiles generated using 0.8 uM of the ROX loop probes in the presence of BART. 
Different concentrations of the HBV dsDNA used in this study were colour-coded as follows: Red – 10^4 cps; Orange – 10^3 cps; Black 
- NTC   
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Figure 56 LAMP-BART profiles and bar charts generated using the standard HBV protocol 
20 (Appendix 20). The effect of FAM and ROX labelled probes on the LAMP-BART 
performance was assessed.  
The addition of unlabelled loop primers (Figure 56 orange curves) resulted in a significant 
acceleration of amplification when compared to the reactions lacking these primers (Figure 56 
green curves). On average, a significant 4 min reduction in TTM was observed in the presence 
of unlabelled loop primers (p value < 0.05, t-test; Table 27). In contrast, a significant 5 and 6 
min increase in TTM was detected when the forward loop primer was substituted by either the 
FAM- or ROX-labelled probe, respectively (p value < 0.05, t-test). Furthermore, when 
compared to the reactions lacking both loop primers, the addition of labelled loop probes did 
not cause acceleration of amplification, but rather slowed it down, as seen previously with the 
probes tested under BART chemistry (see p.144).  
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Figure 56. showing LAMP-BART profiles (A) and summary bar chart (B) generated using the HBV model assay in a presence of 
functional Loop B and various other loop probes. Each type of loop F probes used was colour-coded as follows: Red – 5’ROX and 
3’BHQ2 labelled loop F; Blue - 5’FAM and 3’BHQ2 labelled loop F; Yellow – unlabelled loop F; Green – absence of both loop primers. 
Note that each reaction contained equal amount of the target HBV dsDNA (5 x 10^5 cps).  
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Table 27 showing summary of the data presented in the figure 56. Each set of reactions was 
analysed using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LoopF primer Mean [min] Stdev Amp.Freq.[%]
No loops 19 0.6 100
Fam-labelled 20 0.0 100
unlabelled 15 0.0 100
ROX-labelled 21 0.4 100
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Figure 57 IAC ROX and SYBR green detection using GSP-SSD or BstLF. The HIV ROX-
loop probe and SYBR green chemistry were used to detect 10^5, 10^6 and 10^7 copies of IAC 
RNA. 
The reactions performed with GSP-SSD performed noticeably better with SYBR green and 
ROX-labelled probe detection systems compared to those performed with BstLF. When GSP-
SSD was used full detection of 10^7 and 10^6 copies of the IAC was achieved using both 
reporters; 80% of the reactions containing the lowest copy number (10^5) were detected using 
both methods (Figure 57A, C). In contrast, reactions utilising the BstLF managed to fully 
detect the highest copy number only when the SYBR detection system was used, the sensitivity 
was compromised when using the ROX probe and only limited detection occurred in reactions 
that contained lower amounts of the IAC RNA (Figure 57B, D).  
The overall performance of the HIV probing was a lot lower than that observed in the HBV 
probed IAC (reported earlier; Figure 55), regardless of the DNA polymerase used. Both, the 
reproducibility and light output was noticeably higher when HBV loop probe was used (Figure 
56). The IAC makes use of two loop probe annealing positions, whereas in the HBV design, 
only one loop probe is used, which could account for the performance differences.  
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Figure 57. showing a typical LAMP-ROX/SYBR profiles generated using the IAC assay model. Each reaction was amplified in absence of 
BART components.  A – amplification profiles generated using GSP-SSD and SYBR dye; B – amplification profiles generated using Bst 
LF and SYBR dye; C – amplification profiles generated using GSP-SSD and 0.8 uM of the ROX HIV stem probe; D – amplification 
profiles generated using Bst LF and 0.8 uM of the ROX HIV stem probe. 
Different concentrations of the IAC RNA used in this study were colour-coded as follows: Red – 10^7 cps; Blue – 10^6 cps; Orange – 
10^5 cps; Black - NTC   
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5.4 Discussion 
One of the major limitations of NAAT diagnostic platforms, is the lack of amplification 
controls, which ensure the integrity of the detection system, and the inhibitory effects carried 
forward by the sample preparation procedures (Hoorfar et al., 2004a, Malorny et al., 2003). 
Without such controls, negative results can be highly misleading, as they are often attributed 
to faulty chemistry or inhibition of amplification and detection. Characterisation of false 
negatives is particularly important in the field of infectious disease diagnostics, where failings 
can affect patients well-being and prognosis, but also allow the increased spread of a disease 
(Chua and Gubler, 2013). Thus, in this study, we aimed to develop a non- or low-competitive 
IAC, to further our understanding of sample inhibition and to empathise the need for such 
controls in the diagnostic field.  
5.4.1 Development of the IAC model system 
Although, the loop mediated isothermal amplification (LAMP) technology has been shown to 
be an extremely useful and sensitive tool for nucleic acid amplification, one of the major 
limitations of this technology is the primer design (Kiddle et al., 2012, Lee et al., 2011). In 
order to achieve a high degree of specificity and sensitivity, LAMP employs up to six primers 
and 8 priming positions, but this causes increased complexity for primer design for singleplex 
assays, and severely limit the use of this technology for duplex or multiplexed amplifications. 
As a consequence of these limitations, we decided to adopt a competitive model for the 
development of internal amplification controls. This approach would not only limit the number 
of primers required for each assay, but also enable us to maintain a high level of similarity 
between the IAC and true targets sequence. Hence, factors such as GC-rich regions that can 
cause RT and DNA polymerase pausing or even secondary structure that are potentially 
limiting for primer and / or capture probe hybridisation, would have a similar effect on the two 
targets (Smith and Wu, 2004, Viguera et al., 2001).   
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Since LAMP is an extremely rapid amplification, several alterations were introduced into the 
IAC template that would ensure an impeded amplification, which in turn would avoid 
significant competition with the true positive amplification. Moreover, impediment of IAC 
amplification with respect to the core target was crucial for drawing a clear distinction with 
BART curves generated from late true positive amplifications.  
Since loop primers significantly accelerate LAMP, both annealing sites were substituted with 
alternative sequences for oligonucleotide probing of our IAC template design. This alteration 
to the IAC template served to confine the loop primed acceleration to the true LAMP 
amplification, but it also permitted fluorescent detection of the IAC amplification. 
Furthermore, as described earlier, the introduction of mismatches between a given LAMP 
inchworm primer (BIP or FIP) and its template resulted in amplification delays, which did not 
affect the overall reproducibility of the amplification time.   
All of the mismatches introduced into the BIP and FIP primers affected the performance of 
Mycobacterium complex 23s rRNA RT-LAMP amplification, regardless of the extent and the 
location of the mutations. Mutation introduced into specific poles of the inchworm primers (B1 
and F1) had a much greater impact on the amplification speed than corresponding alterations 
in F2 and B2. This difference could be correlated with distinct roles governed by each pole of 
the LAMP inchworm primers within the initiation and propagation of target sequence 
amplification. For example, the F2 site is crucial for the initiation of cDNA synthesis and the 
entire resultant amplification and therefore impacts upon the function of the BIP primers. Any 
alterations to the F2 region would therefore be expected to cause a severe reduction in 
amplification performance (sensitivity / kinetics). We did indeed observe significant 
amplification delays, along with a deterioration in the reproducibility of the RT-LAMP RNA 
amplification that utilised FIP primers, which had the F2 site mutated. In contrast, we did not 
see such severe effects of similar F2 mutations on DNA amplifications via LAMP (data not 
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shown). It is likely that the F2, has a more fundamental role in reverse transcribing the RNA in 
RT-LAMP, while, both the B2 and F2 sites have more equal roles in the initiation of 
amplification from DNA. Thus, we concluded that the increased variability in RT performance 
caused by impairment of the initiation step was responsible for this disparity.  
Mutations in the B2 sites of the BIP primer caused significant amplification delays, but these 
did not show the same potential to impede LAMP compared to corresponding F2 mismatches 
within the FIP, suggesting that primers involved in reverse transcribing RNA have a greater 
role in the initiation of LAMP from RNA than DNA. It could therefore be argued that first 
strand synthesis and displacement from RNA, are similar in nature to the second strand 
synthesised from cDNA and that amplification of the cDNA solely relies on the B2 site of BIP. 
Since it has been demonstrated that DNA hairpins are less stable than RNA, the effect of cDNA 
structure B2 primer hybridisation be mild compared to the effects of similar RNA structures 
on the F2 mutations (Antao et al., 1991). When primer carrying mismatches within the F2 or 
B2 sites are extended, newly formed amplicon will also contain sites exactly complementary 
to the introduced mutations, making the impact of these alterations less than those introduced 
into the other pole of the inchworms (B1 and F2), as is discussed. 
The B1 and F1 mutated sites caused significant amplification delays compared to their B2 and 
F2 counterparts without affecting the reproducibility of amplification time. The impact of these 
mutations is associated with their stabilising effect on the LAMP dumbbell intermediate, a 
molecule pivotal for propagation of these isothermal reactions. Mismatches introduced within 
the B1 and F1 persist throughout the amplification reaction, since they are incorporated into 
the freshly synthesised target amplicon (refer to LAMP figure 8). Thus, this mechanism 
guarantees the continued impaired interaction between these sites and their compliments on the 
dumbbell and extended concatemers. Furthermore, the impediment of amplification continues 
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throughout the course of the amplification, resulting in a greater impact upon the kinetics of 
amplification than mutations with the 3’ of the inchworm primers.   
After taking all experimental data and bioinformatics analysis into consideration, the IAC RNA 
template was designed, and this impacted upon loop primer binding sites, and alterations to the 
BIP B1 position, since this alteration to the BIP caused amplification impediment without 
affecting the reproducibility of amplification time.   
5.4.2 Performance of the IAC for monitoring inhibition of RT-LAMP. 
Our initial assessment of the designed IAC RNA assay demonstrated a significant delay in 
amplification time using our impeded LAMP mechanism, and also proved the potential of a 
test to report on the inhibitory nature of sample and sample preparation derived substances such 
as sodium chloride and carrier DNA, without affecting the core RT-LAMP amplification. It 
was noted that the 23S RT-LAMP assay could tolerate 10^6 copies of the IAC template without 
exhibiting any untoward effects. This proves that alterations to the LAMP priming mechanism, 
used to drive the impeded the amplification also served to sufficiently reduce the competition 
between the RT-LAMP and IAC. When challenged with sodium chloride or carrier nucleic 
acid, substantial delays in amplification times for the IAC were observed, proving these 
mechanisms responsiveness to inhibition. However, we did note that the inhibitor often 
affected the RT-LAMP amplification to a greater extent than the IAC when challenged with 
limiting amounts of RNA.  
Carrier DNA is a known inhibitor of PCR and isothermal assays that not only delayed the RT-
LAMP amplification, but also caused a significant reduction in the overall assay sensitivity and 
generation of detectable false negative results (Rohrman and Richards-Kortum, 2015, Kiddle 
et al., 2012). This effect was not observed when the IAC template was challenged by the same 
inhibitor, as all replicates of the target were detected even at the highest concentration of carrier 
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DNA used. Similar differences in the responsiveness of the RT-LAMP and IAC were observed 
for mucin, sodium hydroxide and carrier RNA. 
It is very likely that differences in inhibitor tolerance exhibited by both amplifications are 
associated with differences in the manifestation of the target nucleotide. The RT-LAMP assays 
are solely dependent on reverse transcriptase, as the template is known to be a highly pure 23S 
RNA preparation, while the IAC IVT RNA template is known to contain a mixture of RNA 
and DNA. To be certain of accurate scores of reverse transcribed inhibition the IAC template 
would have to be presented in a purer form, as it is likely that the susceptibility of different 
polymerases to all of the tested inhibitors has been inadvertently scored in these experiments. 
The nature of in vitro generated RNA templates showed to have a great impact on the 
performance and accuracy of IAC assays. We showed that using highly pure RNA IAC controls 
is required not only for controlling RT step, but also inhibitory substances that affect 
amplification of RNA compared to DNA. This work also shows that the reverse transcriptase 
is likely to be more rate limiting in our RT-LAMP amplifications that the DNA polymerase, 
and the tolerance of reverse transcriptase to classical PCR inhibitors may be a factor that 
significantly influences clinical sensitivity. 
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5.4.3 IAC detection systems 
The simplicity and affordability of the bioluminescent amplification reporter (BART) makes 
this detection highly competitive and very useful in low resource settings. It was however 
undefined whether BART could be used to differentiate between the impeded IAC and RT-
LAMP; the potential for this was assessed in this investigation.  
Reactions that contained limiting amounts of the target rRNA amplified significantly slower 
under inhibitory conditions than uncompromised RT-LAMP amplifications. Thus, a molecular 
diagnostic in the field, should be able to discriminate between RT-LAMP inhibition, false 
positive amplifications and true positive amplifications that amplify inefficiently due to low 
inputs of target nucleotide. An efficient method of differentiating between the IAC and 
inhibited and non-challenged true target amplification was crucial to avoid mis diagnosing 
samples. The major limitation of the BART reporter, is inability to discriminate between 
amplifications, as it responds to amplification per se and is not sequence dependent like probe 
based strategies for detection. Accordingly, a different approach had to be considered.  
The high concentration of IAC template used to control each amplification, were taken 
advantage of, to differentiate between this amplification and the RT-LAMP mechanism. It was 
envisaged that the two forms of amplification could be resolved by assessing amplification 
kinetics and frequency.  
A method was developed that made use of limiting amplification volumes and a greater number 
of analytical replicates to assess the impact of inhibitors.  The standard 50 ul reaction volume 
used for the RT-LAMP (which included the IAC target) was analysed and compared to the 
exact same reaction tested as 5x 10ul reactions. An assessment of BART timings (TTM) and 
amplification frequencies was then conducted in the presence and absence of inhibitor. 
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Thus, in the proposed approach, if all 5 of the 10ul reactions amplified within an early time 
frame, such a result would be deemed as truly positive and likely to contain large amounts of 
the target rRNA. Following on, if a smaller proportion of the 10ul reactions amplified with 
reduced kinetics, but still within a time frame known to be associated with RT-LAMP the 
overall result would still be scored as a positive diagnosis, but at the limit of detection. In 
contrast, where none of the reactions amplified in a time frame typical of LAMP, but 
corresponding to the IAC amplification times, such result would be deemed as a true negative. 
Thus using this approach, reactions containing limited copy numbers of the RT-LAMP or those 
compromised by inhibition are less likely to fully amplify within all 5 partitions. The Tmax as 
well as amplification frequencies generated by such partitioned reactions are less likely to be 
mistaken for the IAC detection profiles.  
In this chapter it was demonstrated that no difference in IAC amplification speed or 
amplification frequencies were detected when the volume of the reaction partition was reduced. 
It is thought that this result reflected the constant IAC concentration, despite varying copy 
numbers. Consequently, the likelihood of template-primer interactions remained constant for 
both sized reaction partitions. In contrast, when limited amounts of the RT-LAMP template 
RNA was used, a deterioration in amplification frequency was observed with the reduced 
reaction volume. This change in reaction volume did not affected the RT-LAMP amplification 
kinetics. It was concluded that the impeded nature of the RT-LAMP was caused by a limited 
amount of target available in the smaller reaction partition. Furthermore, when observing RT-
LAMP at its limit of detection performed with the IAC, similar observations were made. When 
RT-LAMP amplifications were conducted in 10 ul reactions, two populations of peaks were 
generated, indicating that the reduced volume affected sensitivity without impacting upon the 
detection of the IAC. It was also confirmed that the IAC amplification did not mask the effect 
that volume contributed to the RT-LAMP sensitivity.  
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5.4.3.1 Fluorescent detection system 
One of the major advantages of probe-based fluorescent detection technologies over BART is 
their sequence specificity that lends itself well to multiplexed PCR of two or more targets (Sint 
et al., 2012). Thus, we decided to explore this type of technology for detection of the IAC 
targets described above. We demonstrated that dually labelled loop primers (using fluorophores 
and quenchers) could be used for detection of LAMP products. We also proved that such probes 
cannot prime amplification and do not require hydrolysis via exonuclease activities to release 
fluorescent signal. This was an interesting finding which suggested that the TaqMan probes 
also do not require hydrolysis to release fluorescence, as suggested by the Roche patent, but 
could simply rely on the probe binding to its target.  
Secondary structure analysis of the loop probes demonstrated that the chosen loop primers did 
not form any significant 5’ to 3’ structure that would explain detection via a mechanism, similar 
to that described for molecular beacons. Several reports have suggested the potential static 
interactions between fluorophores and quenchers which could explain our finding.  
The Loop-probes were shown to work well in conjunction with BART and these could detect 
both DNA and RNA LAMP amplifications. The loop-probes could also discriminate between 
isothermal amplifications that had complementary loops in their target compared those targets 
deficient in the sequence. This made the loop-probed approach particularly well suited for the 
specific detection of the IAC. The loop-probes did not contribute to the amplification and 
delayed amplification times were observed from targets hybridising such probes; the probes 
therefore contribute to the impeded amplification required for the IAC.   
Together with functionality in the IAC, It is envisaged that this type of LAMP probing could 
allow for further multiplexing of true positivity and SNP detection.    
 
182 
 
5.5 Perspective 
It was demonstrated that the current IAC amplifies with a significant delay, compared to all 
copy numbers amplified by the RT-LAMP, this control also exhibits sensitivity to various 
inhibitory substances such as LDS, NaCl or carrier DNA. Nonetheless, despite the fact the 
current system works as an internal positive control, further optimisations are still required to 
improve upon its performance:  
a) Fluorescent probe binding site – a HIV sequence was used as a probing site in the 
current IAC TB RNA design. The use of non-human or -pathogen related sequence 
might be more suitable to avoid false positive detection from samples containing an 
abundance of this genome. 
b) IAC RNA purity – As already discussed it is important to have an IAC template specific 
for the target nucleotide of interest. Further purification of the IAC IVT is required to 
remove all DNA template, so that the full inhibitory effect on reverse transcription can 
be assessed.  
c) Further screening of inhibitory substances should be performed, including a wider 
range of substances found in clinical samples such as blood or sputum. The effect of 
these substances on reverse transcribed and DNA polymerised reactions should be 
ascertained. 
d) Although BART detection showed huge potential for differentiating between the IAC 
and RT-LAMP, further work needs to be performed, to assess this techniques limitation 
with respect to sensitivity. 
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Chapter 6 
6 Development of isothermal mechanisms of miRNA detection 
6.1 Introduction 
Micro RNA’s (miRNAs) are small, non-coding RNA molecules found in eukaryotic cells that 
average around 22 nucleotides in length (He and Hannon, 2004). These small miRNAs play a 
crucial role in regulating gene expression, in plants, animals and humans by controlling 
translation (Ambros, 2004, Bartel, 2004, Bartel, 2009). The mode of action of miRNAs as post-
transcriptional regulators involves the repression of translation, by interfering with the binding, 
promotion or the degradation of messenger RNA (mRNA) (Fabian et al., 2010, Jones-Rhoades 
et al., 2006).  
It has been reported that the human genome encodes over 1500 different miRNAs, which can 
target the translation of approximately 60% of the expressed genes (Kontomanolis and 
Koukourakis, 2015, Holland et al., 2013). miRNAs can be found in many different cell types 
and are known to regulate multiple genes associated with human cancer, neurological diseases 
and viral infections (He et al., 2012, Musilova and Mraz, 2015, Mraz and Pospisilova, 2012, 
Radhakrishnan and Alwin Prem Anand, 2016, Weber et al., 2010). Abnormal expression of 
miRNAs is commonly associated with the initiation of cancer, oncogenesis, and even tumour 
responses to treatments (Giza et al., 2014, Ardekani and Naeini, 2010, Li et al., 2016).  
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6.1.1 Function and biogenesis of miRNAs 
miRNAs are encoded in the genome in a form of long primary transcripts called pri-miRNA, 
which are mainly localised within the intron sequences of regulated genes (Rodriguez et al., 
2004, Cai et al., 2004, Weber, 2005). Although, little is known about the mechanisms of 
regulation of miRNA transcription, their localisation within the coding and non-coding regions 
of genes may indicate the host gene promotors involved in the regulation process (Rodriguez 
et al., 2004, Kim and Kim, 2007, Baskerville and Bartel, 2005).  
In animals, formation of mature miRNAs is normally carried out in two stages. Firstly, pri-
miRNAs consisting of a 5’ cap, a stem loop and a 3’ polyA tail that is transcribed by RNA 
polymerase II (Figure 58); this is then followed by cleavage events that result in the formation 
of approximately 70 bp long precursor miRNAs (called pre-miRNA), where each pri-miRNA 
may contain as much as six pre-miRNAs molecules (Lee et al., 2004, Zhou et al., 2007, Faller 
and Guo, 2008).  
The first stage of miRNA maturation occurs in the nucleus and is mediated by two core 
enzymes, Drosha and Pasha (Lee et al., 2003, Gregory et al., 2006). Pasha recognises the 
double-stranded regions of hairpin loop structures and together with an RNA restriction 
enzyme ‘Drosha’, several fragments of pre-miRNAs are formed. Each of the pre-miRNAs 
consists of a stem loop and a 2 nt long 3’ overhang, which is recognised by the Exportin-5 and 
a Ran-GTP dependent nucleo-cytoplasmic cargo transporter and translocated into the cytosol 
for further processing (Conrad et al., 2014, Auyeung et al., 2013, Ali et al., 2012, Murchison 
and Hannon, 2004).     
In the second stage of miRNA maturation, the pre-miRNA is cleaved into 20-25 nt products 
by an RNase III Dicer enzyme (Lund and Dahlberg, 2006, Park et al., 2011). The Dicer removes 
the loop structure of the pre-miRNA hairpin generating an imperfect miRNA: miRNA duplex 
185 
 
that consists of both the mature miRNA and its complementary strand. Separation of the two 
compliments is then carried out by the Dicer’s helicase domain DUF283 resulting in formation 
of single-stranded mature miRNA fragments (Mirihana Arachchilage et al., 2015, Kurzynska-
Kokorniak et al., 2016).  
 
The miRNAs main cellular function is to regulate expression of proteins via inhibition of 
translation or degradation of the target mRNAs. The exact contribution of each mechanism 
remains unclear. It is thought that post-transcriptional inhibition of translation is the most 
common mode of gene silencing found in the animal kingdom (Williams, 2008, Bazzini et al., 
2012, Maroney et al., 2006). Some reports have suggested that binding of miRNA to the 3’UTR 
regions of mRNAs affects the protein translation/release form the mRNA/ribosome complex, 
whereas others claim the disruption of translation to be the main factor (Nottrott et al., 2006, 
Petersen et al., 2006, Gu et al., 2009, Mathonnet et al., 2007).  
In plants, translational inhibition is very rare and the mode of gene silencing occurs through 
the RNA-induced silencing complex of proteins (RISC) containing Dicer and other activities 
Figure 58. Graphic representation of a typical miRNA synthesis 
pathway. 
Source:  http://www.biosyn.com/tew/gene-silencing-by-micro-
rnas.aspx 
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that facilitate the cleavage of the mRNA (Figure 59) (Zhang, 2013, Jones-Rhoades et al., 
2006). In this model, Argonaute (Ago) proteins containing PAZ and PIWI domains responsible 
for binding to the mature miRNA, help to orient the guide RNA within the RISC complex, 
which in turn binds to the target mRNA and initiates degradation (Yan et al., 2003, Schwarz 
and Zamore, 2002, Pratt and MacRae, 2009).   
It has also been suggested that the 
RISC complex plays a role in post-
transcriptional inhibition via either 
deadenylation of the 3’ polyA tail, 
thereby affecting the mRNA 
functionality, preventing translation 
factors from binding to the 5’ cap, and 
impairing the binding of the 60s 
ribosomal subunit or by encouraging 
the premature termination of 
translation (Figure 59) (Pratt and 
MacRae, 2009, Filipowicz et al., 2008, 
Wakiyama et al., 2007).  Although, miRNA-mediated mRNA degradation is well documented, 
it is still unknown whether translational repression is caused by mRNA degradation or 
inhibition of translation. 
It has recently been shown that inhibition of the translation events where the levels of mRNA 
remained unaffected, had a very modest impact on protein synthesis. In contrast, modulation 
Figure 59. Graphic representation of regulation of gene expression using 
RISC complex. 
Source:  https://www.researchgate.net/figure/miRNA-based-post-
transcriptional-gene-silencing-Briefly-endogenous-miRNA-genes-
are_fig3_235768533 
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of the mRNA stability in a miRNA-dependant manner showed a much higher reduction in the 
overall protein concentrations suggesting this mechanism  to be the main contributor in gene 
silencing (Guo et al., 2010).  
In a different study, it was found that lin-4 miRNA negatively regulated the translation of its 
lin-14 transcript without affecting its cellular concentration (Bagga et al., 2005). It was reported 
that although the lin-4 miRNA inhibited the translation of the lin-14 protein, it failed to affect 
the synthesis, polyadenylation or abundance of the lin-14 transcript. Moreover, it has also been 
proposed that depending on the level of complementarity between the miRNA and its target 
transcript, gene silencing can be achieved via translational inhibition of mRNA degradation. In 
animals, miRNAs match imperfectly with their target sequence, where typically only 2-7 
nucleotides must be conserved, to effect translational inhibition (Lewis et al., 2005, Lewis et 
al., 2003). In contrast, plants require perfect matching between the miRNA and message, in 
order to initiate degradation of the transcript (Mazière and Enright, 2007). Some miRNAs 
showed a dual function. For example, miR16 with an AU-rich element commonly found in 
unstable mRNAs, such as TMF α or GM-CSF, can either stimulate translational inhibition or 
mRNA degradation (Jing et al., 2005). It has been demonstrated that full complementarity 
between the miR16 and its target lead to mRNA degradation via Ago2 protein complex. 
However, when only partial complementarity was maintained, gene regulation was carried out 
via translational inhibition (Jing et al., 2005, Lim et al., 2003, Lim et al., 2005).  
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6.1.2 miRNAs as disease biomarkers 
Many clinically relevant human miRNAs are located within the regions associated with cancer 
or at fragile sites and control a wide range of important processes, such as cell proliferation, 
apoptosis or angiogenesis, where dysregulation of these regulatory mechanisms play a key role 
in the onset and progression of cancer (Wang et al., 2016). Numerous studies have shown 
altered miRNA profiles in a wide range of cancer types, such as breast cancer, leukaemia or 
liver cancer (Calin et al., 2004, Tam, 2008, Qi et al., 2013). In 2004, Takamizawa and co-
workers associated the levels of miRNA expression with the disease progression (Takamizawa 
et al., 2004). They found that expression of the let-7 miRNA was greatly reduced in all lung 
cancers tested and the patients exhibiting lower expression profiles had a significantly lower 
survival rate, after potentially curative resection.  
In 2005, Calin et al. showed the importance of miRNAs in diagnosing chronic lymphocytic 
leukaemia (CLL) (Calin et al., 2005).  It was reported that miRNA expression profiles could 
directly discriminate between normal B cells and the malignant disease, in patients with CLL.  
Since then, the interest in miRNA as biomarkers has grown exponentially. Although, miRNA 
biomarkers have been most widely characterised in cancer diagnostics, several reports have 
suggested the potential of miRNAs for the  diagnosis of viral infections, neurological disorders 
and even diabetes (Wang et al., 2016).  
It has been shown that miR-199a and miR-210 can reduce replication of HBV virus by binding 
to the S protein coding region (Zhang et al., 2010a). In a different study, an association between 
miR-122 and facilitation of HCV RNA replication was reported, where a knock down of miR-
122 gene caused almost complete inhibition of viral replication (Jopling et al., 2005, Scaria et 
al., 2006). Furthermore, it has been reported that over 70 % of miRNA are localised in the brain 
and frequently mutations in the miRNA processing machinery has been associated with 
numerous neurological disorders, such as amyotrophic lateral sclerosis or fragile X syndrome 
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(Cao et al., 2006). miR-9 and miR-134 have been characterised as key players regulating neural 
development (Zhao et al., 2009, Bavamian et al., 2015). It has been reported that aberrant 
expression of those miRNA significantly impaired neural differentiation and was associated 
with numerous neuro-developmental diseases such as Alzheimer’s or Parkinson’s disease, even 
schizophrenia (Perkins et al., 2007, Liu et al., 2014a). 
Upregulation of 12 miRNAs found in serum, has been linked with type 1 diabetes (Chen et al., 
2014). Similarly, miR-23a and miR-126 were reported as potential biomarkers for early 
detection of type 2 diabetes (Nielsen et al., 2012). Another three serum miRNAs, (miR-132, 
miR-29a, and miR-222), were found to be associated with gestational diabetes mellitus. miR-
278 and miR-375 were reported to regulate insulin secretion, thus these could potentially act 
as targets for pharmacological treatments of diabetes (Liu et al., 2014b, Wang et al., 2016).  
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6.1.3 miRNA detection  
Since disruption in miRNA expression profiles have been associated with a wide range of 
different diseases, efficient detection methods could provide valuable insights into disease 
progression and allow for early diagnosis.  
 
Northern blotting, quantitative real-time PCR and microarrays are currently the standard 
methods used for the detection of miRNAs (Válóczi et al., 2004, Chen et al., 2005, Li and 
Ruan, 2009). Most of these technologies have limitations, such as low sensitivity, poor 
reproducibility questionable specificities, and most are time consuming and require large 
numbers of samples.  
6.1.3.1 miRNA detection using Northern blotting 
Before the implementation of PCR or microarray hybridisations, northern blotting had been 
the most widely used method for analysis of RNA expression (Kevil et al., 1997). In principle, 
the technology relies on the separation of RNA molecules by electrophoresis. Following RNA 
separation, capillary transfer of the RNA bands to a nitrocellulose membrane is proceeded by 
a probe hybridisation and detection steps (Figure 60). Probes used in northern blot analysis 
can be either single-stranded DNA or RNA molecules that are complementary to the RNA of 
interest. Usually detection of the bound probes occurs through radioactive labelling (32P) or via 
a chemiluminescence reaction, in which alkaline phosphatase or horseradish peroxidase 
metabolise their substrates to generate a weak light signal that can be detected digitally or by 
using X-ray films.   
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A major drawback of the northern blot technique is its low sensitivity to low abundance RNAs. 
Consequently, large amounts of total RNA are required, which might be problematic when the 
cells or the source of tested tissue are limited (Streit et al., 2009, Koscianska et al., 2011).   
 
 
 
 
 
 
 
 
Figure 60. Graphic representation of a typical Northern blot workflow.  
Source:  
https://en.wikipedia.org/wiki/Northern_blot#/media/File:Northern_blot_diagram.png 
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6.1.3.2 qPCR microRNA detection 
Ever since its discovery, PCR has become one of the most widely used molecular techniques 
for studying nucleic acids, including miRNAs (Chen et al., 2005). Current PCR-based methods 
target the mature miRNA or their precursors and most commonly involves the detection of 
amplified product using Taqman probes (Benes and Castoldi, 2010, Mitchell et al., 2008). In 
principle, the miRNA molecules are targeted by stem loop primers containing a 3’-overhang 
complementary to the 5’ end of the target miRNA (Figure 61). Reverse transcription results in 
the formation of a cDNA-stem loop structure that can be detected by Taqman probing. Taqman 
probes are designed to complement the stem loop and the miRNA of interest. In the second 
step, a forward primer binds to the cDNA molecule, which initiates synthesis of the 
complementary strand and amplification results in the hydrolysis of the Taqman probe and 
emission of the fluorescent signal.  
The use of fluorescence-based systems and 
expensive thermocyclers for miRNA detection can 
significantly increase the overall cost of analysis.  
 
 
 
 
 
 
Figure 61. Graphic representation of a typical real-time PCR for 
detection of miRNAs using Taqman probes and stem-loop primer.  
Source:  https://www.researchgate.net/figure/7455286_fig1_Schematic-
description-of-TaqMan-miRNA-assays-TaqMan-based-real-time-
quantification-of 
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6.1.3.3 miRNA detection using isothermal amplification methods 
Several isothermal miRNA amplification methods have been developed over the years since 
PCR was invented, such as RCA-, SDA- or the duplex-specific nuclease-based techniques 
(Jonstrup et al., 2006, Zheng et al., 2016, Zhang et al., 2015).  Due to LAMPs complicated 
priming mechanism, the use of this technology has been greatly limited to the amplification of 
larger DNA and RNA molecules and it has not been exploited for miRNA detection, with the 
exception of Li et al, who reported a successful use of the LAMP amplification for the detection 
of miRNA (Figure 62). Li et al used the miRNA to replace a displacement primer on one 
amplification symmetry and claimed the miRNA was necessary to initiate the amplification 
within this mechanism, it was also claimed the published method was capable of discriminating 
between different miRNAs and that it could even detect SNPs (Li et al., 2011). This result is 
quite surprising, as it is well documented that LAMP FIP and BIP primers are predominating 
primers required for a successful amplification. The Loop and displacement primers only 
accessorise the LAMP amplification serving to accelerate or increase the overall sensitivity of 
these assays. Thus, it remains unclear whether the presented method was selective and would 
be able to detect low abundance miRNAs. 
  
 
 
 
Figure 62. Graphic representation of a LAMP-based miRNA detection 
approach.   
Source:  
http://pubs.rsc.org/en/content/articlelanding/2011/cc/c0cc03957h/una
uth#!divAbstract 
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6.2 Aims and objectives 
Main focus of this study was to develop an isothermal BART assay for more affordable and 
accessible detection of miRNAs.  
In this section, three alternative in-house designed methods of miRNA detection have been 
explored using loop-mediated isothermal amplification approach.  
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6.3  Results 
In this study, three in-house developed miRNA detection methods utilising the LAMP 
technology were assessed.  
6.3.1 Ligation-mediated miRNA detection 
As shown in Figure 63, the probe ligation-based miRNA detection technology involves two 
separate single-stranded probes - each containing a sequence complementary to the target 
miRNA molecules. Binding of the miRNAs to the probe results in the generation of RNA-
DNA heteroduplex with the annealed DNA stem loop probes being separated by a single 
nucleotide. The DNA stem loops can then be ligated 
to one another using SplintR ligase, which exhibits 
increased affinity for heteroduplex templates. Once 
ligated, the probes take on a dumbbell-like 
confirmation, which is an intermediate product 
generated during LAMP. Upon addition of the LAMP 
primers, the dumbbell can be propagated further 
generating pyrophosphate (PPi), which is 
subsequently detected by BART. 
 
 
Figure 63. Graphic representation of a in-house 
designed ligation-based miRNA detection method 
utilising LAMP technology.   
In this design, two probes (P1 and P2) containing the 
target miRNA recognition sites in the stem regions 
(yellow) are linked together using a heteroduplex 
bridge formed between the RNA and the probes. The 
generated nick is then sealed by a ligase resulting in 
formation of a complete dumbbell structure.  
Note that each probe consists of either forward or 
backward LAMP primer binding sites.   
 
 
P2 P1
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6.3.1.1 Assessment of the performance of the in-house developed ligation-mediated miRNA 
detection system 
Figure 64 shows LAMP-BART amplification curves generated using the detection probes and 
CAMV 35Sp LAMP primers. Each reaction component was tested in the presence or absence 
of the SPLINT R ligase (Appendix 26).   
The initial analysis showed no amplification of product in the absence of ligation (no ligation 
control (NLC)), regardless of the reaction component tested (Figure 64A). In contrast, positive 
amplifications were achieved by reactions that were successfully ligated (Figure 64B). No 
peaks were detected in the P1 and P2 reactions where only one type of the probe was used for 
each assay (Figure 64B).  Samples containing both probes gave positive peaks regardless of 
the presence of the target miRNA, where a 10 min delay was observed between the true and 
the false positives samples. 
 
 
Despite New England Biolabs clear product specification, stating that SplintR ligase, cannot 
perform ligation of single-stranded DNA molecules, it was evident that ligation of both P1 and 
P2 probes occurred in a miRNA independent manner. Nonetheless, SDS-PAGE analysis did 
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Figure 64. LAMP-BART profiles generated using the ligation-based miRNA approach. A – amplification profiles produced by the 
reactions lacking SPLINTR ligation step; B – amplification profiles produced by the reaction that undergone ligation in the presence of 
SPLINTR ligase.  
Note: blue peaks – reactions containing P1 template probe; green – reactions containing P2 template probe; orange – reactions 
containing P1 and P2 template probe; red – reactions containing P1 and P2 template probe as well as the target miRNA; black - NTC   
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not show any ligation products in the samples lacking miRNA (see Appendix 35). However, 
the amount of the ligation product generated in a miRNA-independent manner might have not 
been sufficient enough to visualise on the PAGE gels.  
6.3.1.2 Optimisation of the ligation-mediated miRNA detection system 
The initial analysis of the ligase-mediated miRNA detection system showed that non-specific 
ligation of the probes occurred in a miRNA independent manner. Thus, several ligases were 
tested in an attempt to improve the specificity of this reaction. 
Figure 65 shows the LAMP-BART profiles generated using the ligation-mediated miRNA 
method under different chemistries. Once more, no amplification profiles were generated in 
reactions deficient in ligase, proving that no prior contamination of the probes had occurred 
with the post-ligation products (Figure 65E). Only the reactions utilising Ampligase did not 
generate false positive amplifications (Figure 65D) in the absence of miRNA, within the time 
frame of analysis. The amplification observed with ampligase was significantly delayed 
compared to reactions performed with either T4 or SplintR ligase (Figure 65A-B; p values < 
0.05, t-test). The reactions containing T7 ligase showed no significant difference in observed 
polymerisation rates, whether the miRNA was included or excluded from the reaction. The T4 
and SplintR-mediated ligations worked most efficiently in the presence of the target miRNA, 
generating positive results within 17 min (Figure 65A-B). The assays utilising the SplintR 
ligase generated the quickest rates of true amplification, but also a greater delay in non-specific 
amplification (Figure 65B). In contrast, a slight difference in amplification times were noted 
between miRNA dependent and independent controls, when the T4 ligase was used (Figure 
65A).  
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Figure 65. LAMP-BART profiles generated using the ligation-based miRNA approach comparing performance of four chosen ligase 
enzymes. 
 A – T4 ligase; B – SplintR ligase; C – T7 ligase; D – Ampligase; E – No ligation control (NLC) 
Note: red curves represent reactions containing the target miRNA; orange curves shows amplification profiles generated in the 
absence of the miRNA target.    
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In this section, various attempts were made to further improve the ligation of probes, in a 
manner that was dependent on miRNA.  
Figure 66 shows BART reported LAMP amplifications during a time course study.  In this 
study, the reactions have undergone ligation (using the SplintR ligase) at room temperature for 
5 or 30 min.  
 
 
The no ligation control (NLC) reactions and the samples containing separate P1 and P2 probes 
did not generate any BART reported amplification, regardless of the duration of ligation. When 
a mixture of P1 and P2 underwent a ligation, positive BART profiles were observed, indicating 
amplification, and presumably successful ligation, although this was not dependent on the 
presence of the miRNA template (Figure 66A-B).  Moreover, when the miRNA was added to 
the ligation reactions, a 10 min reduction in the amplification time was observed, compared to 
reactions lacking the target miRNA template (p value < 0.05, t-test), suggesting an increase in 
efficiency of ligation. The duration of the ligation step did not affect the amplification kinetics 
when the probes and miRNA were present together in the reaction chemistry (p value > 0.05, 
t-test). However, a 2 min increase in the rates of positive amplification was observed between 
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Figure 66. LAMP-BART profiles generated using the ligation-based miRNA approach. A – amplification profiles produced by the 
reactions containing samples that undergone 5 min ligation using SplintR; B – amplification profiles produced by the reaction 
containing samples that undergone 30 min ligation using SplintR. 
Note: blue peaks – reactions containing P1 template probe; green – reactions containing P2 template probe; orange – reactions 
containing P1 and P2 template probe; red – reactions containing P1 and P2 template probe as well as the target miRNA; black - NLC   
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the 5 and 30 min ligation time (p value < 0.05, t-test); the increased ligation time therefore 
improves the rate of amplification (Table 28). To further increase the time differential in 
amplification kinetics observed between true and false positive polymerisations, the 
concentration of probe used in the reaction was optimised.  
Table 28 showing summary data presented in the figure 66. Each set of reactions was analysed 
using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
 
Figure 67 shows a summary bar chart of the probe concentrations used in this study. 
It may be of interest to note that the probe concentrations shown, represent the final 
concentration of each probe in the ligation reactions.   
The probe concentration did have an effect on the amplification kinetics, but this was 
independent of the template miRNA. False positive reactions were also affected by probe 
concentrations to a much greater extent than true positive reactions (Figure 67).  
A significant reduction in amplification speed of 3 min was observed for the true positive 
amplifications, between 500 nM and all the other concentrations tested (p value < 0.05, t-test) 
(Table 29). Reactions containing 1 to 50 nM of each probe did not show any significant 
difference in amplification kinetics for the miRNA dependent reaction (p value > 0.05, 
ANOVA). A further reduction in probe concentrations to 0.5 nM, did reduce the miRNA 
Ligation time [min] Sample TTM [min] Stdev Amp.Freq. [%]
P1 N/A N/A 0
P2 N/A N/A 0
P1+P2 27.2 0.6 100
P1+P2+microRNA 15.8 0.6 100
P1 N/A N/A 0
P2 N/A N/A 0
P1+P2 25.8 0.0 100
P1+P2+microRNA 15.0 0.0 100
5
30
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dependent amplification speed by 8 min compared to all other concentrations tested (p value < 
0.05, t-test).   
  
 
Table 29 showing summary data presented in the figure 67. Each set of reactions was analysed 
using average TTM (Mean), reproducibility (STDev) and sensitivity (Amp.Freq). 
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Figure 67. Summary bar chart generated using the ligation-based miRNA approach with various amounts of the P1 and P2 probes 
added during the ligation stage.  
 
Probes conc. [nM] Sample TTM [min] Stdev Amp.Freq. [%]
 +microRNA 14.18 1.40 100
 -microRNA 19.86 0.59 100
 +microRNA 17.36 0.44 100
 -microRNA 25.93 1.85 100
 +microRNA 20.61 1.97 100
 -microRNA 31.16 4.18 100
 +microRNA 17.20 7.86 100
 -microRNA 37.60 0.96 100
 +microRNA 19.53 2.30 100
 -microRNA 51.02 1.39 67
 +microRNA 28.34 0.96 100
 -microRNA 47.21 6.49 80
1
0.5
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50
5
2.5
202 
 
Similarly, when the probe concentration was reduced below 500 nM, false positive reaction 
rates reduced. Unlike the miRNA dependent amplifications, which did not show any significant 
reduction in assay kinetics between 1 and 50nM, the false positive reaction was slowed-down 
by decreasing the concentration of probe used.  
Additional reductions in probe concentration did not show any further improvements with 
respect to amplification kinetics or specificity. The probe concentration therefore significantly 
affects the rate of positive and negative amplification and reducing the amount of probe serves 
to reduce positive amplification rates, but also improves the ability to differentiate between 
BART timings resulting from true positive and nonspecific reactions. 
In summary, amongst all of the probe concentrations tested, the biggest time difference 
between the true and false amplification of over 30 min was observed in the reactions 
containing 1 nM of each probe, whereas, on average, only 5, 8, 11 and 19 min difference was 
detected in the reactions utilising 500, 50, 5, 2.5 and 0.5 nM of each of the probes, respectively.  
The sensitivity of the ligation-mediated miRNA detection system was assessed on a range of 
miRNA template concentrations (Figure 68). This experiment successfully detected as little as 
125 fM of the target miRNA; a clear difference in amplification time (of 8 min) was observed 
between the lowest copy number of miRNA tested and the template independent amplification 
time. The amplification time also decreased with increasing copies of miRNA tested, and all 
amplifications times were very reproducible at each respective concentration tested. It is also 
interesting to note that the given sensitivity represents detectible concentrations of the miRNA 
in the final LAMP-BART assay. The true analytical LoD of the ligation reaction was 50 pM 
(125 fM in the assay).  
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Figure 68. LAMP-BART profiles generated using the ligation-based miRNA approach and various amounts of the target miRNA.  
Note: red curves – 500 nM miRNA; orange – 50 nm miRNA; blue – 5 nM miRNA; purple – 500 pM miRNA; green – 50 pM miRNA; 
black – no miRNA control. 
The concentrations of target miRNA shown represent the amounts of target added to each ligation reaction not the final assay 
concentration. Analytical (assay) sensitivity is 400 x higher taking into account 100 and 4 fold dilutions of ligation mix and sample 
additions to the LAMP-BART master mix.      
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6.3.2 Endonuclease-mediated miRNA detection 
Figure 69 shows the restriction enzyme mechanism of miRNA detection in a closed-tube 
format, which involves binding of the target miRNA to a single-stranded dumbbell probe with 
the target recognition site at the 3’ end, followed by its extension by the Bst DNA polymerase. 
Synthesis of the complementary strand then generates a restriction site (between the miRNA 
and the F2 site of the forward loop; black striped rectangle), LAMP primer binding site (green 
striped rectangle); as well as the displacement primer binding site (brown striped rectangle).  
Restriction of DNA using BstUI ensures that the product of strand invasion by the LAMP 
primer will terminate at an exact predefined position, in-order to prevent miss-folding of the 
generated dumbbell structure.   
 
Figure 69. Graphic representation of an in-house designed endonuclease-based miRNA detection method utilising LAMP technology.  
Synthesis of the complementary strand is initiated by the target miRNA hybridisation to the recognition site (red rectangle). Once a 
double-stranded product is generated, the restriction site between the miRNA and the F2 binding sites (black rectangle) is recognised 
by a specific restriction enzyme (BstUI)(green arrow). The restriction digest results in generation of a double stranded DNA product 
with both LAMP and displacement binding sites (green and brown striped rectangles). Strand invasion by the two primers results in a 
formation of single stranded dumbbell. 
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6.3.2.1 Assessment of the performance of the in-house designed restriction endonuclease-
mediated miRNA detection system 
 
Performance of the restriction enzyme-mediated miRNA detection system, was assessed in this 
study. Various restriction enzymes (BssKI, BstUI, BstWI and BsaWI) were tested, in order to 
determine the most suitable candidate enzyme to couple with the LAMP-BART reaction.  
Figure 70 shows polyacrylamide gel results of a 10 min restriction digest performed using four 
restriction enzymes.  The restriction digest was tested using both, LAMP-BART and NEB 
buffering conditions in this study.  The performance of each enzyme was assessed by looking 
at the brightness of the DNA bands and fragmentation before and after digestion. Surprisingly, 
all of the restriction enzymes performed more efficiently under the LAMP-BART chemistry 
compared to NEBs recommended conditions. (Figure 70 lanes E-H). BssKI restricted the 
DNA more efficiently than the other enzymes tested under NEB recommended conditions 
(Figure 70 lanes B and F); under the LAMP-BART buffering conditions, the BstUI enzyme 
was found to be the most efficient.  
 
 
After digestion, very little evidence was left of the initial template on the polyacrylamide gel, 
with only 2 lower molecular weight bands evident, and this indicated complete digestion of the 
LGFEDCBA H
50 bp
Figure 70. Polyacrylamide gel electrophoresis showing restriction digest of 4 in-house designed double-stranded DNA probes.  
Lanes A-D show restriction digests carried out in recommended buffers; lanes E-H shows restriction digest performed under LAMP-
BART chemistry (enzyme constituents of LAMP-BART were not added). Lanes A and E – BstUI; lanes B and F – BssKI; lanes C and G – 
BsaWI; lanes D and H – BstNI; lane L contained 50bp ladder (NEB). Refer to Appendix 42 for undigested controls.         
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original template DNA. BssKI and BstWI were the least efficient of the restriction enzymes 
tested (Figure 70 lanes B and F, D and H). BsaWI generated good quantities of digested 
product but was not considered for the miRNA amplification due to its non-specific restriction 
cutting, reflected in the observed star activity and the generation of a small MW 4th band 
(Figure 70 lane G).  
Figure 71 shows LAMP-BART profiles generated using the BstUI-mediated (endonuclease) 
miRNA detection system.  
Surprisingly, positive amplification profiles were detected whether the miRNA was included 
in the reaction or not. The same amplification rates were also detected in the NTC samples, 
suggesting possible contamination of the reagents.  
 
 
A similar experimental set up, using the same aliquots of reagents, was then performed and 
comparable observations were made.  
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Figure 71. LAMP-BART profiles generated using the endonuclease-based miRNA detection system. Red curves represent the 
reactions containing the target miRNA; orange curves show profiles generated in the absence of the target miRNA; black curves 
represent reactions lacking both the miRNA and the detection probe. Note that all of the reactions contained 8 U of BstUI restriction 
enzyme and 1.6 and 0.8 uM LAMP and displacement primer, respectively. 
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Figure 72 shows LAMP-BART profiles generated using BstUI mediated miRNA detection 
chemistry. Note that the amount of enzyme in each reaction, was 5x lower than previously 
used. In addition, no BstUI was added to the NTC control samples.  
No difference in TTM was detected between the true and false positive profiles, generated 
using BstUI. Reducing the BstUI 2-fold, caused a 5 min delay in amplification time compared 
to assays utilising 1.6 U (Figure 72A-B). Despite the reduced speed no discrimination between 
miRNA dependent and independent amplifications was possible.  
 
 
 
Interestingly, when BstUI was completely eliminated, no amplification was observed in the 
reactions lacking the miRNA, yet the true positives were successfully detected (Figure 73). 
The amplifications are therefore working independently of the restriction enzyme. 
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Figure 72. LAMP-BART profiles generated using the endonuclease-based miRNA detection system. Red curves represent the 
reactions containing the target miRNA; orange curves show profiles generated in the absence of the target miRNA; black curves 
represent reactions lacking both the miRNA and the detection probe as well as the restriction enzyme. A – amplification profiles 
generated with the reactions containing 1.6 U BstUI; B – amplification profiles generated using 0.8 U BstUI 
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Figure 73. LAMP-BART profiles generated using the endonuclease-based miRNA detection system. Red curves represent the 
reactions containing the target miRNA; orange curves show profiles generated in the absence of the target miRNA; black curves 
represent reactions lacking both the miRNA and the detection probe. Note that the BstUI restriction enzyme was not present. 
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6.3.3 Nickase-mediated miRNA detection 
As shown in figure 74, the nicking enzyme mediated method is very similar to the previously 
described miRNA detection technique (Figure 69). Instead of removing the fragment of 
miRNA bound to the dumbbell probe, a single-stranded nick is generated between the miRNA 
and the F2 site (red and black striped rectangles, respectively (Figure 74)). DNA polymerase 
then binds to the nick site and proceeds with extension and displacement of the synthesised 
strand which now contains the LAMP and the displacement binding sites. From this point 
onwards, the DNA synthesis proceeds as described in the endonuclease-mediated miRNA 
detection method (see above for details). In contrast with the previous method, nicking enzyme 
should allow continuous generation of single-stranded complementary to the probe DNA 
fragments that can be targeted by the LAMP and displacement primers. This could increase the 
sensitivity of the entire system since several dumbbell structures could be generated from a 
single miRNA binding event.  
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Figure 74. Graphic representation of an in-house designed nickase-based miRNA detection method utilising LAMP technology.  
Synthesis of the complementary strand is initiated by the target miRNA hybridisation to the recognition site (red rectangle). Once a 
double-stranded product is generated, the nickase recognition site between the miRNA and the F2 binding sites (black rectangle) is 
recognised by the chosen enzyme (green arrow) which introduces a single stranded break (a nick). Bst DNA polymerase binds to the 
nicks initiating synthesis of the complementary strand resulting in generation of a double stranded DNA product with both LAMP 
and displacement binding sites (green and brown striped rectangles). Strand invasion by the two primers results in a formation of 
single stranded dumbbell. This process can potentially be repeated throughout the duration of the assay since the miRNA 
recognition site is not removed upon nicking. 
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6.3.3.1 Assessment of the performance of the in-house developed nickase-mediated miRNA 
detection systems  
The performance of the nicking enzyme-mediated miRNA detection was then tested. The 
mechanism described earlier is known to be similar to the restriction mediated miRNA 
mediated detection method that could not differentiate between the reactions containing 
miRNA and the false positives (see Figure 75). 
 
Figure 76 shows LAMP-BART profiles generated using the standard nickase-mediated 
miRNA reactions prepared in the presence or absence of the Nb.BsmI nicking enzyme. All 
reactions contained equal amounts of detection template. Amplifications were not observed in 
the NTCs (no detection template, no nicking enzyme), nor in the reactions lacking the Nb.BsmI 
nickase. In contrast, reactions containing the miRNA were detected when nickase was added.  
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Figure 75. LAMP-BART profiles generated using the nickase-based miRNA detection system. Red curves represent the reactions 
containing the target miRNA; orange curves show profiles generated in the absence of the target miRNA. Note that each 
amplification reaction was performed in the presence of 1 U of Nb.bsmI nickase. 
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Figure 77 shows LAMP-BART profiles generated using the standard nickase-mediated 
miRNA assay. In this experiment, the nicking enzyme was heat-inactivated in order to exclude 
possible contamination. No amplification was observed suggesting the requirement for an 
active nicking enzyme to generate false positive amplification profiles.  
Further investigations demonstrated that the false positive amplification profiles was nickase-
dependant, but also required a DNA polymerase. In addition, false positive amplification was 
found to be independent of primer, detection template and miRNA.  
Figure 78 shows LAMP-BART profiles generated using the nickase-mediated miRNA assay 
in either the presence or absence of the Bst2.0 DNA polymerase. All assays were performed in 
the absence of miRNA. No detectable amplification was observed in reactions lacking Bst 2.0 
DNA polymerase; this data suggests that the formation of the false positive amplifications 
requires the both the nickase and DNA polymerase.    
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Figure 76. LAMP-BART profiles generated using the nickase-based miRNA detection system. Red curves represent the reactions 
containing the target miRNA and 1 U Nb.bsmI nickase; orange curves show profiles generated with the reactions containing miRNA in 
the absence of the nicking enzyme; black curves represents reactions lacking both the miRNA and the nicking enzyme.   
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Figure 77. LAMP-BART profiles generated using the nickase-based miRNA detection system. Red curves represent the reactions 
containing the target miRNA and 1 U of heat-inactivated Nb.bsmI nickase; orange curves show profiles generated with the reactions 
containing miRNA in the absence of the nicking enzyme; black curves represents reactions lacking both the miRNA and the nicking 
enzyme.   
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Figure 78. LAMP-BART profiles generated using the nickase-based miRNA detection system. Red curves represent the reactions 
containing Bst 2.0 DNA polymerase and 1 U Nb.bsmI nickase; orange curves show profiles generated with the reactions containing 
the nicking enzyme only. 
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Figure 79 shows LAMP-BART amplification curves generated using further controls of the 
nickase-mediated miRNA assay, where no detection template, primers and the target miRNA 
was added to the reactions.  
 
In this study, the nicking enzyme was pre-incubated in a LAMP-BART reaction mixture, in 
the absence of Bst2.0, for 60 min at 60 °C followed by a heat-inactivation step. Two sets of 
reactions were then investigated, under a standard LAMP-BART set up (including Bst 2.0) 
where either the non-treated or the inactivated version of the nickase was used. It was already 
demonstrated, the reactions containing the non-treated version of the nickase showed typical 
amplification profile generated in a template- and miRNA-independent manner. Interestingly, 
positive amplifications were also detected in the samples utilising the heat-treated version of 
the nickase, although the amplification profiles differed considerably. The amplification in 
these controls were not only noticeably delayed, but also exhibited much slower assay kinetics 
with only gradual increases in BART over the course of the assay. In contrast, the BART switch 
off was extended with respect to a typical BART when the active version of the nickase was 
used.  
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Figure 79. LAMP-BART profiles generated using the nickase-based miRNA detection system. Red curves represent the reactions 
containing active Nb.bsmI nicking enzyme; orange curves show profiles generated with the reactions containing the inactive version 
of the nicking enzyme that undergone pre-incubation; black curves represent reactions lacking Nb.bsmI nickase 
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Due to the non-specific effect that BstUI and Nb.BsmI nickase had on the BART reporter, a 
number of different endonucleases were tested under non-primer and detection template 
conditions. 
Figure 80A-B demonstrates LAMP-BART profiles generated using the endonuclease / 
nickase-mediated miRNA assay using either Bst 1.0 (A) or Bst 2.0 (B) and six chosen 
endonucleases.  
All of restriction and nicking enzymes showed similar non-specific activities to that already 
observed. Despite the lack of primers and the detection template, all of the reactions containing 
these enzymes generated positive amplification profiles, and this was also regardless of the 
type of the Bst DNA polymerase used. In addition, the reactions containing the DNA 
polymerase only (NTC) or lacking both the endonucleases and DNA polymerases (NEC), 
showed no signs of reactivity.    
 
 It was evident from this data that the type of DNA polymerase used did not affect the potential 
of each restriction or nicking enzyme to cause mis-amplification events. However, small 
differences in kinetics were observed between the profiles generated using Bst 1.0 and Bst 2.0 
with the latter producing slower and shorter peaks. 
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Figure 80. LAMP-BART profiles generated using the endonuclease-based miRNA detection system. A – represents the reactions 
utilising Bst large fragment and various endonucleases; B – represents reactions containing Bst 2.0 and various endonucleases. 
Tested endonucleases were colour-coded as follows : yellow – BsaWI; orange – BssKI; dark blue – BstNI; red – BstUI; green – Nb.bsmI; 
light blue – Nt.bstNBI; black solid curves – No enzyme control (NEC); black dashed lines – no endonuclease 
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6.4 Discussion 
Recent advances in nucleic acid amplification technologies have resulted in a wide range of 
isothermal techniques being commercialised as molecular diagnostic assays (Craw and 
Balachandran, 2012). Of all the well-known isothermal amplification technologies, LAMP 
assays are the most prolific and well suited for a variety of diagnostic applications (Kiddle et 
al., 2012, Njiru, 2012, Li et al., 2011). The very design of the LAMP, and its reliance on a 
number of priming positions, makes this technology highly specific for the target of interest, 
but paradoxically prone to false positive backgrounds that can be caused by non-template 
amplifications (Tan et al., 2008). LAMP is highly sensitive and capable of detecting very small 
amounts of target template and is not prone to interference from non-template carrier DNA 
present in extracted samples, which makes this technology particularly suitable for GM 
detection, where the target concentration can be very limiting in high backgrounds of DNA 
(Kiddle et al., 2012). Since traditional LAMP requires a highly complex primer design, the 
adaption of this technology for miRNA screening has been immensely challenging, as will be 
discussed.  
6.4.1 Ligation-based miRNA detection system 
The results presented earlier demonstrate that it is possible to generate a LAMP intermediates 
(dumbbell-like structure) via a probe ligation-mediated strategy. This not only eliminates the 
need for a complex primer design, but also affords this technique reasonable analytical 
sensitivity. To test the viability of this and other miRNA detection systems lin-4 miRNA (one 
of the first discovered miRNA expressed by Caenorhabditis elegans) was selected and 
artificially synthesized as a model template (Esquela-Kerscher, 2014). Although the initial 
assessment of the ligation detection method showed this technology capable of detecting the 
target lin-4 microRNA, false positive results were routinely obtained. 
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It was demonstrated that the amplification efficiency and specificity was dependent on the 
efficiency of the ligation, the ligase used and the amount of probe in the reaction. The time 
difference of the LAMP-BART profiles generated by the true and the false positive samples 
ranged between 4 to 6 min, which had a significant impact on the dynamic range of this 
amplification mechanism. Several steps were taken to determine the cause of the false positive 
amplifications and to design methods for their control. Figure 64 shows LAMP-BART profiles 
generated using different ligation reactions containing various combinations of the probes. It 
was demonstrated that only when both probes (with or without the target miRNA) were present 
during the ligation step, false positive peaks could be detected, suggesting the possibility of 
ligation events occurring in the absence of miRNA. As the proposed mechanism was entirely 
dependent on a miRNA driven ligation further work was undertaken to improve the specificity 
of the technique. Reducing the concentrations of each probe had a significant effect on the mis-
amplification (Figure 67), a result that may be explained by the effect of molecular crowding 
on probe proximity and efficiencies of the miRNA independent ligation. Dilution of the probes 
prior to the ligation step had little effect on the detection time for the samples containing the 
target miRNA and this consequently increased the dynamic range of the method (Figure 67-
68).  
Our current probe ligation-mediated methodology, successfully detected as little as 125 fM of 
the target RNA within 40 min. Despite the analytical sensitivity demonstrated, biological 
samples, such as blood will pose additional problems for this type of technology, as the amount 
of available miRNA may be far more limiting than tested here (Parasramka et al., 2012). This 
technology may however afford increased resistance to inhibition compared to PCR based 
approaches, as LAMP and its associated displacement polymerase tolerate classical sample 
derived PCR inhibitors, such as haem, collagen or salts far more effectively than Taq 
polymerase (Kiddle et al., 2012).  
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In 2016, a ligation-based LAMP miRNA detection method was published by Du et al. that was  
based on a very similar ligation approach (Du et al., 2016). In his design, the dumbbell structure 
was also generated via ligation of two separate probes using a miRNA target, as a linker 
template. However, unlike our design, Du’s method required the reverse transcription of the 
miRNA in order to successfully carry out the ligation. Thus, this method incorporated an 
additional step into the workflow, which increased the overall time required for detection 
compared to our assays.  Similarly, to our findings, false positive results were also obtained in 
the reactions containing LAMP probes only suggesting miRNA-independent ligation events 
have occurred.   
Although we showed that our current probe ligation-based system can successfully detect 
picomolar concentrations of miRNAs further optimization is required in order to enhance its 
sensitivity and specificity, as well as establishing its performance on template extracted from 
relevant biological samples.  
6.4.2 Endonuclease-based microRNA detection 
Unfortunately, both the restriction endonuclease and nickase-mediated methods for miRNA 
detection assessed failed to detect the target miRNA within a satisfactory time frame. Both 
restriction and nicking enzyme methods generated false positive results regardless of the 
presence of the miRNA.   
Nonetheless, our work has shown a unique feature of both DNA polymerases when used in 
conjunction with endonucleases, as this coupling of activities appears to be capable of de novo 
DNA synthesis in the absence of templates and primers. There are several reports in the press 
regarding the same de novo synthesis, although it is unclear how the process is initiated 
(Antipova et al., 2014, Liang et al., 2004). For instance, Liang et al, suggested a potential 
mechanism of de novo amplification. In his model, short DNA fragments containing 
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palindromic repetitive sequences are de novo synthesised and then elongated by strand 
displacing DNA polymerases, which form long repetitive stretches of double-stranded DNAs. 
Those long molecules are then subjected to restriction or nicking digest that in turn generates 
more substrate for elongation. In concordance with our findings, Liang and co-workers have 
shown that DNA synthesis was not affected by nuclease treatment of any of the components 
used, suggesting a de novo origin of the template rather than a result of a pre-existing 
contamination of the enzymes used. Liang hypothesised that the DNA polymerase used in his 
studies was responsible for the de novo synthesis. Consequently, he showed that incubation of 
Vent DNA polymerases in the presence of dATP and dTTPs for 3 days could generate 
detectible amounts of short DNA fragments. Moreover, Ramadan et al. found that human DNA 
polymerase λ or deoxyribonucleotidyl transferase could synthesise DNA fragments de novo 
even in a presence of a single type of nucleotide such as dTTP (Ramadan et al., 2004).   
The rate of de-novo synthesis described was extremely slow and could not explain the kinetic 
profiles generated in our experiments. Furthermore, each of the tested endonucleases required 
a unique recognition site in order to initiate either double- or single-stranded breaks. Even if 
we assume that the de novo synthesis originates from the DNA polymerase through synthesis 
of random stretches of repetitive sequences, the likelihood of synthesising perfect recognition 
sites in a quick and efficient manner that would allow generating such fast amplification 
profiles, is rather low. There is however a real possibility that due to imperfect chemical 
conditions, each of the tested endonucleases exhibited a star activity that resulted in non-
specific cutting.  
In contrast with the previously mentioned reports regarding de novo synthesis, our findings 
suggest an alternative origin of the synthesised DNA. However, it is evident that the native 
version of endonuclease enzyme is needed for this artefact, as we saw no amplification profiles 
when a heat-denatured version of the Nb.bsmI nickase was used. However, when the chosen 
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nickase was pre-incubated in typical LAMP buffering conditions, containing a full set of 
dNTPs, prior to heat-denaturation, amplification profiles were detected.  
Following on, if Ling et al postulation that DNA polymerases were indeed responsible for de 
novo DNA synthesis observed in our experiments, we would expect to see no difference in 
amplification performance between reactions that utilise a heat-inactivated nickase and those 
that have undergone a pre-incubation step utilising nickase prior to heat denaturation. Instead, 
we saw full detection in the reactions containing the pre-incubated, inactive nicking enzyme. 
It is evident from this work that DNA is more likely to have originated from the endonuclease 
solution and/or the LAMP-BART components present during the pre-incubation step, which 
then was readily amplified by the DNA polymerases and this accelerated the overall miRNA 
detection mechanism in an unpredicted manner. In fact, we saw distinctly different BART 
amplification curves, when comparing reactions using the native nickase, compared to control 
reactions containing the denatured enzyme; this suggests that both are required for efficient 
amplification of the generated DNA.   
Furthermore, to our understanding, the de novo synthesis phenomena was not limited to a few 
endonucleases, but is rather a common feature amongst of these enzymes, as over 10 different 
restriction and nicking enzymes were tested, all demonstrating a capacity for de novo DNA 
synthesis.  Further work is now needed to prove our hypothesis. Particularly since successful 
incorporation of strand displacement DNA polymerases and nicking enzymes have been 
reported (SDA, EXPAR). However, most of these technologies utilise probe-based detection 
systems thus are immune to the non-specific backgrounds.    
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Chapter 7 
7 Discussion and conclusions 
7.1 Development of RT-LAMP assays 
The advent of reverse transcription technologies has empowered scientists to study gene 
expression and these have proved extremely useful in the field of molecular diagnostics. 
However, despite their widespread use, there is little working knowledge of their optimisation 
in the literature. It is well established that all single stranded RNA molecules are prone to a 
high degree of secondary and tertiary structure that is often attributed to biological function, 
yet primer design rarely accounts for RNA folding (Jubin, 2001, Lukavsky, 2009), and to-date 
no specific RT primer design software is publicly or commercially available. 
In chapter 3, different factors affecting reverse transcribed LAMP is explored, including 
enzymology, reaction chemistry and primer design. This research demonstrated the importance 
of a highly optimised chemistry and the right choice of enzymes, but also highlighted the need 
for bespoke RT primers that could negotiate RNA secondary structure and DNA polymerases, 
which could adequately displace the primed entities of the initiated DNA propagators of these 
reactions. 
Following on, it was shown that RNA structure could impede the performance of the 5’ UTR 
HCV RT-LAMP. In silico analysis of 5’ UTR RNA showed a high degree of secondary 
structure, predicted by the Vienna RNA folding software. Even so, there were certain domains 
of the RNA sequence that showed only a moderate level of folding, and thus these regions were 
predicted to be more suited for primer annealing positions that could initiate amplification via 
reverse transcriptase. All of the designed RT-LAMP primer sets performed efficiently when 
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the RNA secondary structure was negotiated (Set 34-40), while LAMP RT primers targeting 
highly structured regions of the HCV 5’UTR failed to amplify (13-18 and 13-20) altogether. 
In this thesis, two versions of the recombinant Bst 2.0 DNA polymerase (Bst 2.0 / Bst 2WS) 
were compared to a highly displacing combined DNA / RT polymerase (GSP-SSD). This work 
was carried out, to appropriate evaluate any differences in performance that could be attributed 
to the displacement activity associated with polymerases. Of the DNA polymerases tested, 
GSP-SSD proved to be the most optimal for the current 5’UTR RT-LAMP HCV. This 
polymerase not only increased the kinetics of amplification, but also generated far fewer NTCs 
compared to either Bst 2.0 tested. 
Primer dimerization, is a very well-known cause of non-specific activity, and when combined 
with highly efficient DNA polymerisation, increased rates of primer-derived amplification are 
more likely to occur (Friedberg et al., 2000, Poritz and Ririe, 2014). Despite the increased 
polymerisation efficiency of GSP-SSD, primer and target derived amplification specificities 
were maintained. This may be attributed to reduced activity of the enzyme at low temperatures, 
which would prevent mis-priming events from occurring during the reaction set up, without 
affecting performance of specific priming at optimal assay temperatures. In contrast, 
amplifications tested using Bst 2.0 at similar concentrations resulted in nonspecific 
amplifications, suggesting a higher degree of activity exhibited by the enzyme at lower 
temperatures. An alternative version of Bst 2.0 (Bst 2.0 WS) designed to avoid mis-priming 
during reaction set ups makes use of aptamers attached to the active site. It was demonstrated 
that modified enzymes, such as Bst 2.0 WS, can negatively affect performance of RT-LAMP, 
but not LAMP amplifications. This was observed for both the 5’UTR HCV RT-LAMP and the 
23S TB RT-LAMP but the LAMP amplifications were unaffected. 
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This optimisations of the RT-LAMP polymerisation and RT priming resulted in highly 
sensitive reactions capable of detecting as little as 5 cps. Despite this success further 
evaluations would still be needed to optimise assay chemistry and performance when 
challenged with inhibitory / extracted RNA from clinical samples. 
7.2 Inhibition of RT-LAMP assays 
One of the major drawbacks of any NAAT amplification, is their sensitivity to inhibitory 
substances, which result in either a reduction in amplification kinetics or a complete failure in 
detection (Bustin and Nolan, 2004, Schrader et al., 2012). Thus the inhibitory substances pose 
a real risk to amplification performance, particularly in the field of molecular diagnostics, 
where a failure to detect a true positive can lead to a mis-diagnosis and have a direct effects on 
a patients’ wellbeing and the downstream disease transmission rates (Huggett et al., 2008, 
Drosten et al., 2002). Although, inhibition of amplification has been widely studied and is 
thought to be a result of many factors, research has mainly focused on the inhibition of DNA 
polymerase function (Opel et al., 2010, Al-Soud and Rådström, 2001), and not reverse 
transcription. 
The main focus of the study presented in the chapter 4 was to determine the inhibitory effect 
of the chosen and commonly encountered polymerase inhibitors, including potassium and 
sodium salts, detergents and non-target nucleic acids, on the performance of RT assays 
specifically. In this study it was demonstrated that inhibition of polymerization not only 
depends upon the type of substance but also its concentration the effects of which can 
sometimes be mitigated by the assay chemistry. A clear correlation was between the 
concentration of the inhibitory salt tested and the impact on the amplification. However, it was 
noted that LAMP assays utilizing the Bst 2.0 DNA polymerase were less affected by salt 
inhibition when compared to GSP-SSD.  Interestingly, the addition of 10 mM of either 
potassium chloride or acetate resulted in significant increases in the amplification speed for 
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both tested assay chemistries but was not observed in the reactions challenged with equal 
amounts of sodium chloride.   
The acidic detergent LDS was shown to have no effect on the polymerization. Yet a large 
impact upon BART reporting was observed. Interestingly, the choice of buffer could modulate 
the effect of LDS on BART. It was concluded that low buffering capacities of certain buffers, 
which were insufficient to overcome the low pH of LDS (4≥pH), caused the decline in the light 
emission observed. Further work is however recommended to ascertain the impact of these 
detergents on RT-LAMP enzymology.   
The inhibitory effect of carrier non-target nucleic acids was also gauged in this study. Unlike 
all other inhibitory substances tested, carrier NA showed an increased inhibitory potency 
towards RNA assays specifically. Although, a significant inhibition of amplification of both, 
DNA and RNA templates was observed when challenged with salmon sperm DNA and tRNA, 
RNA assays suffered to a much higher extent. The reaction containing RNA templates not only 
suffered a significant reduction in the amplification speed but also a dramatic reduction in the 
overall assay sensitivity. In contrast, no effect on the assay sensitivity was detected under 
identical inhibitory conditions, when DNA template were amplified. This work has 
categorically established clear differences between the effects of commonly encountered 
polymerase inhibitors and their impact on RT and DNA polymerizations.  
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7.3 Development of amplification controls for RT-LAMP assays 
The main focus of the study presented in the chapter 5, was to develop a mechanism for 
controlling RT-LAMP amplification in a single-tube format, without causing interference of 
true positive activities or preferential amplification with respect to the IAC template. 
Due to high complexity of the RT-LAMP priming mechanism, and a requirement for an 
abundance of primers to drive efficient amplification of the RNA target, a competitive IAC 
mechanism was adopted. It was demonstrated that a significant reduction in amplification 
speed can be achieved by introducing mismatches, without compromising on the 
reproducibility. As expected, all of the tested mutations introduced into the BIP and FIP 
primers affected the performance of Mycobacterium complex 23s rRNA RT-LAMP 
amplification, regardless of the extent or location of the mutations. However, mutations 
introduced into specific poles of the LAMP primers (B1 and F1) had a greater impact on the 
kinetics compared to corresponding alterations in F2 and B2. Thus, it was concluded that the 
observed differences could be correlated with distinct roles each pole of the LAMP inchworm 
primers played within the initiation and propagation of target sequence amplification.  
The impact of these mutations was associated with the ability to form stable dumbbell 
intermediates – molecules crucial for propagation of isothermal LAMP reactions. Mismatches 
introduced within the B1 and F1 persist throughout the amplification reaction, since they are 
incorporated into the freshly synthesised target amplicon, and are not directly targeted by the 
primers. In contrast, mutation in the F2 and B2 sites could only affect the initiation rather than 
propagation, since once extended, the synthesised complementary strand will retain those exact 
same mutations thus resulting in a template containing full complementarity with the primers. 
The developed IAC model was tested under various inhibitory conditions. The initial 
assessment showed a significant delay in amplification time under unchallenged conditions, 
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and proved the potential of the test to report on the inhibitory nature of sample and sample 
preparation derived substances such as sodium chloride and carrier DNA, without affecting the 
core RT-LAMP amplification. The designed IAC model responded to most of the tested 
inhibitory substances such as carrier NA or salts, proving its viability as an amplification 
control. However, significant differences in the response of RT-LAMP and the IAC to sodium 
hydroxide inhibition were also observed. The developed IAC assay remained unaffected by 
sodium hydroxide, whereas the sensitivity of 23s rRNA detection was significantly 
compromised. The difference in sensitivity of RT-LAMP and IAC to certain inhibitory 
substances poses real risks for diagnostic assays. In our model, the IAC was determined to 
contain as much as 10 % DNA contamination originating from the in vitro transcription 
process. Since the effects of sodium hydroxide on the integrity of RNA targets has been widely 
reported, the differences in the response to this inhibitor could be attributed to the presence of 
this contaminant.  
Furthermore, it was observed that certain reactions containing limiting amounts of the target 
23s rRNA amplified significantly slower under inhibitory conditions. Thus, in a molecular 
diagnostic setting where unknown samples are tested, such result could indicate amplification 
of the IAC rather than an inhibited sample, if the assessment was done solely on the basis of 
the TTM under BART detection system. It was then concluded that an efficient method of 
differentiating between the IAC and both inhibited and non-challenged true target amplification 
was crucial for this technology. However, one of the main limitations of BART is its lack of 
multiplexing capabilities. Thus, an alternative method of differentiation was explored. 
It was hypothesised that by taking advantage of the high amounts of IAC used in each assay, a 
differentiation between the two targets could be performed when taking both the TTM and 
amplification frequencies into consideration. 
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A system was proposed, where standard 50 uL reactions containing the LAMP-BART reagents 
and the tested sample (including the IAC target) were split into 5 10 uL reactions and their 
amplification monitored in real time by BART platforms. However, an assessment of TTM and 
amplification frequencies would be performed based on a collective data from all 5 reactions 
as well as each reaction individually. Thus, in the proposed approach, if all 5 reactions 
amplified in a characteristic to 23s rRNA TTM then such sample would be considered true 
positive amplification likely to contain large amounts of the target RNA. Similarly, if only 1 
out of 5 10 uL reactions showed positive amplification profiles for 23s rRNA, and 4 amplified 
significantly slower, the overall result would still lead to positive diagnosis of the disease based 
on the single positive replicate. However, since the full detection was not achieved then the 
amount of present RNA was most likely at the limit of detection. In contrast, in a scenario 
where none of the reactions amplified the target in a characteristic to the 23s rRNA manner, 
but still managed to generated late positive profiles corresponding to the IAC amplification, 
such result would then be marked as a true negative. Thus using this approach, the samples 
containing limited copy number of the core target or those compromised by inhibition are less 
likely to fully amplify in all 5 reactions. Consequently, the TTM as well as amplification 
frequencies generated by such samples are less likely to be mistaken for the IAC detection 
profiles.  
In this chapter, it was demonstrated that reaction volume had no effect on the kinetics of the 
amplification, regardless of the type and amount of the template used. However, when limited 
amounts of the RT-LAMP template RNA was used, a reduction in amplification frequency was 
observed with the reduced reaction volume. Thus, it was concluded that the observed detrition 
in sensitivity of the RT-LAMP was caused by a limited amount of target available in the smaller 
reaction partition and was most likely further affected by stochastic variation. Furthermore, 
similar observations were made when amplification of the target RNA was performed in the 
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presence of impeded IAC template. When RT-LAMP amplifications were conducted in 10 uL 
reactions, two populations of peaks were generated, indicating that IAC had no effect on the 
overall sensitivity of the target RT-LAMP RNA. Thus, enabling full discrimination between 
the amplification of the core target and the IAC template. 
Fluorescent detection using a probe-based system was also explored as an alternative to BART. 
For over a decade, PCR based technologies have benefited from the specificity and 
multiplexing capabilities of fluorescent probes, but greatly limiting their use in the isothermal 
setting. In this study, the capability of dually labelled loop primers to detect nucleic acid 
amplification in a Taq independent manner, was reported. It was shown that full detection of 
the IAC can be achieved using this technology without accelerating the amplification.  
Fluorescent detection of LAMP using such probes would not only simplify the analysis but 
also increase the specificity of detection.  
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7.4 Isothermal mechanisms of miRNA detection 
Since disruption in miRNAs expression profiles have been associated with a wide range of 
different diseases, an efficient detection method could provide valuable insights into disease 
progression and early diagnosis. The main focus of this study was to develop a LAMP-based 
miRNA detection system that would offer a cost-effective, highly accessible detection 
platform. 
Due to the complexity of LAMP primer design, the use of this technology has been limited and 
used rarely for miRNA detection (Li at el. 2013). 
In chapter 6, we present an alternative method of miRNA detection, where the LAMP target 
was generated using a ligation-mediated step dependant on miRNA as a linker. Although, the 
specificity of the amplification was poor, this method was capable of successfully detecting 
125 fM of the target miRNA.  
Alternative methods of generating the dumbbell template using restriction mediated 
approaches were also presented in chapter 6. However, these methods failed due to the extent 
of non-specific amplification observed. The fidelity of both restriction mediated methods 
appeared to be compromised as a consequence of de novo DNA synthesis caused by activities 
associated with endonuclease and displacement polymerases. Although, this de novo synthesis 
artefact has already been reported, it is still unclear how the DNA synthesis is initiated. Most 
of the published accounts suggest the DNA polymerase is responsible for activity. This study 
has shown that the synthesised DNA originated from the tested endonucleases and was most 
likely amplified by the DNA polymerase. In addition, the observed effect was not limited to a 
chosen endonuclease but was likely a common feature when combined with displacing DNA 
polymerases.  
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However, several reports have already been published where nicking enzymes and strand 
displacement polymerases were successfully used for NA amplification using EXPAR or SDA. 
Nonetheless, most of these technologies utilise probe-based detection systems, thus are 
immune to the non-specific backgrounds. 
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Appendix 1 
Protocol 1: Standard HCV LAMP-BART assay  
Reaction mix setup: 
 
Master mix was prepared according to the reaction mix set up shown above. 15 uL of the master 
mix was then mixed with 5 uL of the appropriate HCV template in a 96-well plate (white) 
followed by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive 
film and loaded onto BISON set at 60 °C and ran for 90 min.  
 
 
 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded
M GW MS00001 464
Trehalose (25% solution) 250 75 mg/mL SS008 600
10 Isothermal Buffer 10 1 x MS00043 200
Dithiothreito l 1M 1000 10 mM SS003 20
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20
10 mM  APS 10000 250 µM MS00015 50
Ultraglow luciferase 46.6 0.05 RLU/mL MS00011 1.1
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5
100 mM  dNTP mix 25000 300 µM MS00032 24
HCV BIP 100 1.6 µM 32
HCV FIP 100 1.6 µM 32
HCV F3 100 0.4 µM 8
HCV B3 100 0.4 µM 8
HCV LoopF 100 0.8 µM 16
HCV LoopB 100 0.8 µM 16
Ribolock 40 0.05 U/µl MS00042 2.5
Gsp SSD pol 100 0.1 U/µl MS00041 2
Maxima RTase H - 200 0.2 u/µl MS00030 2.0
*HPLC Purified Primers 1500 Total  volume
Eurofins
251 
 
Appendix 2 
Protocol 2: Primer screening procedure using standard HCV LAMP-BART assay 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1388 uL of 
the initial reaction mix was then split into four aliquots of 347 uL each. Final master mix was 
prepared by adding 2 uL of F3 and B3, 4 uL of Loop B and F and 8 uL of FIP and BIP of the 
appropriate LAMP primer sets to the aliquots containing 347 uL of the initial master mix. 15 
uL of the final master mix was then mixed with 5 uL of the appropriate HCV template [10^4 
cp/5uL] in a 96-well plate (white) followed by an addition of two drops of mineral oil. Samples 
were sealed using a clear adhesive film and loaded onto BISON set at 60 °C and ran for 90 
min.  
Note: 100 uM primer stocks were used 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded
M GW MS00001 464
Trehalose (25% solution) 250 75 mg/mL SS008 600
10 Isothermal Buffer 10 1 x MS00043 200
Dithiothreito l 1M 1000 10 mM SS003 20
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20
10 mM  APS 10000 250 µM MS00015 50
Ultraglow luciferase 46.6 0.05 RLU/mL MS00011 1.1
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5
100 mM  dNTP mix 25000 300 µM MS00032 24
HCV BIP 100 1.6 µM
HCV FIP 100 1.6 µM
HCV F3 100 0.4 µM
HCV B3 100 0.4 µM
HCV LoopF 100 0.8 µM
HCV LoopB 100 0.8 µM
Ribolock 40 0.05 U/µl MS00042 2.5
Gsp SSD pol 100 0.1 U/µl MS00041 2
Maxima RTase H - 200 0.2 u/µl MS00030 2.0
*HPLC Purified Primers 1388 Total  volume
Eurofins
252 
 
Appendix 3 
Protocol 3: DNA polymerase screening procedure using standard HCV LAMP-BART 
assay 
Reaction mix set up: 
 
Initial master mixes (2x) were prepared according to the reaction mix set up shown above. 1498 
uL of each of the prepared initial reaction mixes were then split into two aliquots of 749 uL. 
Final master mixes were prepared by adding 1 uL of either GSP-SSD [100 U/uL], Bst 2.0 [200 
U/uL] or Bst 2.0WS [200 U/uL], or 1.5 uL of Bst large fragment [160 U/uL] to separate aliquots 
containing 749 uL of the initial master mix. 15 uL of the final master mix was then mixed with 
5 uL of the appropriate HCV template in a 96-well plate (white) followed by an addition of 
two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto 
BISON set at 60 °C and ran for 90 min.  
HCV RNA at concentrations 10^4, 10^3, 100, 50 and 10 cps/5uL were used in this study. 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded
M GW MS00001 464
Trehalose (25% solution) 250 75 mg/mL SS008 600
10 Isothermal Buffer 10 1 x MS00043 200
Dithiothreito l 1M 1000 10 mM SS003 20
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20
10 mM  APS 10000 250 µM MS00015 50
Ultraglow luciferase 46.6 0.05 RLU/mL MS00011 1.1
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5
100 mM  dNTP mix 25000 300 µM MS00032 24
HCV BIP 100 1.6 µM 32
HCV FIP 100 1.6 µM 32
HCV F3 100 0.4 µM 8
HCV B3 100 0.4 µM 8
HCV LoopF 100 0.8 µM 16
HCV LoopB 100 0.8 µM 16
Ribolock 40 0.05 U/µl MS00042 2.5
Gsp SSD pol 100 0.1 U/µl MS00041
Maxima RTase H - 200 0.2 u/µl MS00030 2.0
*HPLC Purified Primers 1498 Total  volume
Eurofins
253 
 
Appendix 4 
Protocol 4: Reverse transcriptases screening procedure using standard HCV LAMP-
BART assay 
Reaction mix set up: 
 
Initial master mixes (2x) were prepared according to the reaction mix set up shown above. 1498 
uL of each of the prepared initial reaction mixes were then split into two aliquots of 749 uL. 
Final master mixes were prepared by adding 1 uL of either Maxima RNaseH+ [200 U/uL], 
Maxima RNaseH+ [200 U/uL] or SuperScriptIV [200 U/uL] to separate aliquots containing 
749 uL of the initial master mix. 15 uL of the final master mix was then mixed with 5 uL of 
the appropriate HCV template in a 96-well plate (white) followed by an addition of two drops 
of mineral oil. Samples were sealed using a clear adhesive film and loaded onto BISON set at 
60 °C and ran for 90 min.  
HCV RNA at concentrations 10^4, 10^3, 100, 50, 10 and 1 cps/5uL were used in this study. 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded
M GW MS00001 464
Trehalose (25% solution) 250 75 mg/mL SS008 600
10 Isothermal Buffer 10 1 x MS00043 200
Dithiothreito l 1M 1000 10 mM SS003 20
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20
10 mM  APS 10000 250 µM MS00015 50
Ultraglow luciferase 46.6 0.05 RLU/mL MS00011 1.1
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5
100 mM  dNTP mix 25000 300 µM MS00032 24
HCV BIP 100 1.6 µM 32
HCV FIP 100 1.6 µM 32
HCV F3 100 0.4 µM 8
HCV B3 100 0.4 µM 8
HCV LoopF 100 0.8 µM 16
HCV LoopB 100 0.8 µM 16
Ribolock 40 0.05 U/µl MS00042 2.5
Gsp SSD pol 100 0.1 U/µl MS00041 2
Maxima RTase H - 200 0.2 u/µl MS00030
*HPLC Purified Primers 1498 Total  volume
Eurofins
254 
 
Appendix 5 
Protocol 5: Reaction buffers screening procedure using standard HCV LAMP-BART 
assay 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1300 uL of 
the prepared initial reaction mixes was then split into two aliquots of 650 uL each. Final master 
mix was prepared by adding 100 uL of either Isothermal [10x] or Thermopol [10x] buffers to 
separate aliquots containing 650 uL of the initial master mix. 15 uL of the final master mix was 
then mixed with 5 uL of the appropriate HCV template in a 96-well plate (white) followed by 
an addition of two drops of mineral oil. Samples were sealed using a clear adhesive film and 
loaded onto BISON set at 60 °C and ran for 90 min. 
HCV RNA at concentrations 10^4, 10^3, 100, 50, 10 and 1 cps/5uL were used in this study. 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded
M GW MS00001 464
Trehalose (25% solution) 250 75 mg/mL SS008 600
10 Isothermal Buffer 10 1 x MS00043
Dithiothreito l 1M 1000 10 mM SS003 20
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20
10 mM  APS 10000 250 µM MS00015 50
Ultraglow luciferase 46.6 0.05 RLU/mL MS00011 1.1
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5
100 mM  dNTP mix 25000 300 µM MS00032 24
HCV BIP 100 1.6 µM 32
HCV FIP 100 1.6 µM 32
HCV F3 100 0.4 µM 8
HCV B3 100 0.4 µM 8
HCV LoopF 100 0.8 µM 16
HCV LoopB 100 0.8 µM 16
Ribolock 40 0.05 U/µl MS00042 2.5
Gsp SSD pol 100 0.1 U/µl MS00041 2
Maxima RTase H - 200 0.2 u/µl MS00030 2.0
*HPLC Purified Primers 1300 Total  volume
Eurofins
255 
 
Appendix 6 
Protocol 6: Inhibitory substances screening procedure using standard HCV LAMP-
BART assay 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1498 uL of 
the initial reaction mixes was then split into two aliquots of 749 uL each. Final master mix was 
prepared by adding 1 uL of either GSP-SSD [100 U/uL] or Bst 2.0 [200 U/uL] to separate 
aliquots containing 749 uL of the initial master mix. 15 uL of the final master mix was then 
mixed with 5 uL of the appropriate inhibitory substance in a 96-well plate (white) followed by 
an addition of two drops of mineral oil. Samples were sealed using a clear adhesive film and 
loaded onto BISON set at 60 °C and ran for 90 min.  
Potassium and sodium chloride and Potassium acetate at concentrations 0 to 50 mM, were 
tested in this study.  
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded
M GW MS00001 462
Trehalose (25% solution) 250 75 mg/mL SS008 600
10 Isothermal Buffer 10 1 x MS00043 200
Dithiothreito l 1M 1000 10 mM SS003 20
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20
10 mM  APS 10000 250 µM MS00015 50
Ultraglow luciferase 46.6 0.05 RLU/mL MS00011 1.1
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5
100 mM  dNTP mix 25000 300 µM MS00032 24
HCV BIP 100 1.6 µM 32
HCV FIP 100 1.6 µM 32
HCV F3 100 0.4 µM 8
HCV B3 100 0.4 µM 8
HCV LoopF 100 0.8 µM 16
HCV LoopB 100 0.8 µM 16
Ribolock 40 0.05 U/µl MS00042 2.5
Gsp SSD pol 100 0.1 U/µl MS00041
HCV 5'UTR RNA 200000 100 cps/µl 2
Maxima RTase H - 200 0.2 u/µl MS00030 2.0
*HPLC Purified Primers 1498 Total  volume
Eurofins
256 
 
Appendix 7 
Protocol 7: Standard TB LAMP-BART assay (20 uL) 
Reaction mix set up: 
 
Master mix was prepared according to the reaction mix set up shown above. 15 uL of the master 
mix was then mixed with 5 uL of the appropriate M. bovi  template in a 96-well plate (white) 
followed by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive 
film and loaded onto BISON set at 60 °C and ran for 90 min.  
 
 
 
 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 325 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029 2.5
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1500 [µL]
M
W
G
257 
 
Appendix 8 
Protocol 8: DNA polymerase screening procedure using standard TB LAMP-BART 
assay 
Reaction mix set up: 
 
Initial master mixes (2x) were prepared according to the reaction mix set up shown above. 1498 
uL of each of the prepared initial reaction mixes were then split into two aliquots of 749 uL. 
Final master mixes were prepared by adding 1 uL of either GSP-SSD [100 U/uL], Bst 2.0 [200 
U/uL] or Bst 2.0WS [200 U/uL], or 1.3 uL Bst large fragment [160 U/uL] to separate aliquots 
containing 749 uL of the initial master mix. 15 uL of the final master mix was then mixed with 
5 uL of the appropriate TB M. bovis template in a 96-well plate (white) followed by an addition 
of two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto 
BISON set at 60 °C and ran for 90 min.  
M. bovis nucleic acids concentrations of 1000 and 100 cps/5uL were used in this study. 
Both genomic DNA and 23s rRNA were used.  
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 325 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1498 [µL]
M
W
G
258 
 
Appendix 9 
Protocol 9: Inhibitory substances screening procedure using standard TB LAMP-BART 
assay (no IAC) - LDS 
Reaction mix set up: 
 
Master mix was prepared according to the reaction mix set up shown above. 15 uL of the master 
mix was then mixed with 5 uL of the appropriate M. bovis template* in a 96-well plate (white) 
followed by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive 
film and loaded onto BISON set at 60 °C and ran for 90 min.  
*- dilutions of the templates were performed using the appropriate concentrations of the tested 
inhibitors as diluents. 
M. bovis 23s rRNA at concentration 1000 and 100 cps/5uL was used in this study.  
Serial dilutions (20 uL sample + 180 uL diluent) of the 23s rRNA top stock [10^6 cps/5uL]   
were carried out in order to obtain the appropriate template concentrations. 
For the inhibitory samples, 0.01 and 0.05% LDS was used as diluents. 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 325 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029 2.5
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1500 [µL]
M
W
G
259 
 
Appendix 10 
Protocol 10: Inhibitory substances screening procedure using standard TB LAMP-
BART assay (no IAC) – Bicine buffers comparison 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1000 uL of 
the initial reaction mix was then split into two aliquots of 500 uL each. Final master mix was 
prepared by adding 250 uL of either 500 mM [4x] or 50 mM [4x] Bicine buffers  to separate 
aliquots containing 500 uL of the initial master mix. 15 uL of the final master mix was then 
mixed with 5 uL of the appropriate M. bovis template* in a 96-well plate (white) followed by 
an addition of two drops of mineral oil. Samples were sealed using a clear adhesive film and 
loaded onto BISON set at 60 °C and ran for 90 min.  
*- dilutions of the templates were performed using the appropriate concentrations of the tested 
inhibitors as diluents. 
M. bovis 23s rRNA at concentration 10000 and 1000 cps/5uL was used in this study.  
Serial dilutions (20 uL sample + 180 uL diluent) of the 23s rRNA top stock [10^6 cps/5uL]   
were carried out in order to obtain the appropriate template concentrations. 
For the inhibitory samples, 0.05% LDS was used as diluent. 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 325 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029 2.5
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1000 [µL]
M
W
G
260 
 
Appendix 11 
Protocol 11: Inhibitory substances screening procedure using standard TB LAMP-
BART assay (no IAC) – carrier DNA 
Reaction mix set up: 
 
Master mix was prepared according to the reaction mix set up shown above. 15 uL of the master 
mix was then mixed with 5 uL of the appropriate M. bovis template* in a 96-well plate (white) 
followed by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive 
film and loaded onto BISON set at 60 °C and ran for 90 min.  
*- dilutions of the templates were performed using the appropriate concentrations of the tested 
inhibitors as diluents. 
M. bovis 23s rRNA at concentration 1000 and 100 cps/5uL was used in this study.  
Serial dilutions (20 uL sample + 180 uL diluent) of the 23s rRNA top stock [10^6 cps/5uL]   
were carried out in order to obtain the appropriate template concentrations. 
For the inhibitory samples, 1000 ng/5uL of salmon sperm DNA was used as diluent. 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 325 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029 2.5
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1500 [µL]
M
W
G
261 
 
Appendix 12 
Protocol 12: Primer mutations screening procedure using standard TB LAMP-BART 
assay 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1468 uL of 
the initial reaction mix was then split into four aliquots of 367 uL each. Final master mix was 
prepared by adding 8 uL of the appropriate version of the LAMP F primer to separate aliquots 
containing 367 uL of the initial master mix. 15 uL of the final master mix was then mixed with 
5 uL of the appropriate M. bovis template [10^4 cps/5uL] in a 96-well plate (white) followed 
by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive film 
and loaded onto BISON set at 60 °C and ran for 90 min. 
Note that the loop primers were not added. 
 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 325 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029 2.5
Lamp F   TB103 100 1.6 µM
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1468 [µL]
M
W
G
262 
 
Appendix 13 
Protocol 13: Assessment of DNA contamination in IAC RNA samples 
Initial master mix was prepared according to the reaction mix set up shown in appendix 7. 
However, Maxima RNaseH+ was not added to the initial master mix. 1498 uL of the initial 
master mix was then split into two aliquots of 749 uL each followed by an addition of 1 uL of 
either Maxima RNaseH+ [200 U/uL] or MGW. 15 uL of the final master mix was then mixed 
with 5 uL of the appropriate IAC template in a 96-well plate (white) followed by an addition 
of two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto 
BISON set at 60 °C and ran for 90 min.  
IAC RNA and DNA concentrations of 10^8, 10^7, 10^6 and 10^5 cps/5uL, were used in this 
study 
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Appendix 14 
Protocol 14: Standard TB LAMP-BART assay with IAC RNA at 10^6 cps/rxn 
Reaction mix set up: 
 
Master mix was prepared according to the reaction mix set up shown above. 15 uL of the master 
[10^6 cp/rxn IAC RNA] mix was then mixed with 5 uL of the appropriate M. bovis template 
in a 96-well plate (white) followed by an addition of two drops of mineral oil. Samples were 
sealed using a clear adhesive film and loaded onto BISON set at 60 °C and ran for 90 min.  
M. bovis 23s rRNA at concentrations 10^4, 10^3 and 100 cps/5uL were used in this study. 
 
 
 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
IAC RNA 10^7 5 x 10^4 cps/µl 10
M GW MS00001 315 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029 2.5
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1500 [µL]
M
W
G
264 
 
Appendix 15 
Protocol 15: Standard TB IAC LAMP-BART assay with ROX-HIV probe 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1482 uL of 
the initial reaction mix was then split into two aliquots of 741 uL each, followed by an addition 
of either 1 uL GSP-SSD or 1.3 uL Bst large fragment. Each of the two prepared aliquots was 
then split into two smaller aliquots of 370.5 uL each. Final master mix was prepared by adding 
4 uL of either HIV probe or MGW to the separate aliquots containing 370.5 uL of the initial 
master mix with either GSP-SSD or Bst large fragment. 15 uL of the final master mix was then 
mixed with 5 uL of the IAC RNA template [10^6 cps/5uL] in a 96-well plate (white) followed 
by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive film 
and loaded onto BISON set at 60 °C and ran for 90 min. 
Note: 50 mM Bicine buffer was used in this study 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 309 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
HIV probe 100 0.8 µM
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1482 [µL]
M
W
G
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Appendix 16 
Protocol 16: Inhibitory substances screening procedure using modified TB LAMP-
BART assay – Sodium chloride  
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1480 uL of 
the initial reaction mix was then split into two aliquots of 740 uL each. Final master mix was 
prepared by adding 5 uL of both MGW and IAC RNA or 5 uL of IAC and TB RNA to the 
separate aliquots containing 740 uL of the initial master mix. 15 uL of the final master mix was 
then mixed with 5 uL of the appropriate inhibitory substance in a 96-well plate (white) followed 
by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive film 
and loaded onto BISON set at 60 °C and ran for 90 min. 
Sodium chloride at concentrations 20, 30 and 40 mM was used in this study. 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M . bovis RNA 1000 5 cps/µl
IAC RNA 10^7 5 x 10^4 cps/µl
M GW MS00001 305 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029 2.5
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1480 [µL]
M
W
G
266 
 
Appendix 17 
Protocol 17: Inhibitory substances screening procedure using modified TB LAMP-
BART assay – carrier DNA  
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1480 uL of 
the initial reaction mix was then split into two aliquots of 740 uL each. Final master mix was 
prepared by adding 5 uL of MGW and 5 uL of either IAC or TB RNA to the separate aliquots 
containing 740 uL of the initial master mix. 15 uL of the final master mix was then mixed with 
5 uL of the appropriate inhibitory substance in a 96-well plate (white) followed by an addition 
of two drops of mineral oil. Samples were sealed using a clear adhesive film and loaded onto 
BISON set at 60 °C and ran for 90 min. 
Salmon sperm DNA at concentrations 50, 500 and 1000 ng/5uL was used in this study. 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M . bovis RNA 1000 5 cps/µl
IAC RNA 10^7 5 x 10^4 cps/µl
M GW MS00001 305 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 20 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 20 1610501
10 mM  APS 10000 250 µM MS00015 50 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 2.0 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 2.5 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029 2.5
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM 16
LoopF    TB101 100 0.8 µM 16
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1480 [µL]
M
W
G
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Appendix 18 
Protocol 18: Standard TB LAMP-BART assay (50 uL) 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1470 uL of 
the initial reaction mixes was then split into two aliquots of 735 uL each. Final master mix was 
prepared by adding 7.5 uL of MGW and 7.5 uL of either M. bovis TB template [10^4 cps/5uL] 
or IAC RNA [10^7 cps/5uL] to separate aliquots containing 735 uL of the initial master mix. 
50 uL of the final reaction mix (including templates) was then dispensed across 30 wells of a 
96-well plate (white) covered with 2 drops of mineral oil and sealed using adhesive clear film. 
Samples were run at 60 °C for 90 min on BISON.   
 
 
 
 
 
 
 
 
 
Dispense volume [µL]: 50
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 583 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 300 1616103
TB RNA 10^4 100 cp/5uL
IAC RNA 10^7 10^6 cp/5uL
Bicine Buffer 4x 1x STD 375 1507602
M gCl2, 100mM 100 2 mM MS00017 30 0011202
Dithiothreito l 1M 1000 10 mM SS003 15 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 15 1610501
10 mM  APS 10000 250 µM MS00015 37.5 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 1.2 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 1.8 0191605
100mM  dNTP mix (25mM  each)25000 400 µM MS00032 24 1436447
GSP 100 0.1 U/uL MS00029 1.5
Lamp F   TB103 100 1.6 µM 24
LAM P B TB087 100 1.6 µM 24
LoopB 083 100 0.8 µM 12
LoopF    TB101 100 0.8 µM 12
Disp B    TB100 100 0.4 µM 6
Disp F    TB115 100 0.4 µM 6
M axima RtaseH + 200 0.2 u/µl MS00030 1.5
Total Volume 1470 [µL]
M
W
G
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Appendix 19 
Protocol 19: Inhibitory substances screening procedure using standard TB LAMP-
BART assay (50 uL) – carrier DNA (500ng) 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1470 uL of 
the initial reaction mixes was then split into two aliquots of 735 uL each followed by an 
addition of 7.5 uL either MGW or TB M. bovis RNA. The two prepared initial master mixes 
(after additions) were then split into two smaller aliquots of 371.25 uL each. Final master mix 
was prepared by adding 3.75 uL of either MGW or carrier DNA [1000 ng/uL] to separate 
aliquots containing 371.25 uL of the initial master mix with either added TB RNA or MGW. 
50 uL and 10 uL of the final reaction mix (including templates) were then dispensed across  a 
96-well plate (white) covered with 2 drops of mineral oil and sealed using adhesive clear film. 
Samples were run at 60 °C for 90 min on BISON.   
 
 
 
 
 
 
Dispense volume [µL]: 50
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
M GW MS00001 568 RNBF0862
Carrier DNA 1000 10 ng/µl
Trehalose (25% solution) 250 50 mg/mL SS008 300 1616103
TB RNA 2 x 10^3 2 cps/uL
IAC RNA 2 x 10^6 2 x 10^4 cps/uL 15
Bicine Buffer 4x 1x STD 375 1507602
M gCl2, 100mM 100 2 mM MS00017 30 0011202
Dithiothreito l 1M 1000 10 mM SS003 15 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 15 1610501
10 mM  APS 10000 250 µM MS00015 37.5 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 1.2 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 1.8 0191605
100mM  dNTP mix (25mM  each)25000 400 µM MS00032 24 1436447
GSP 100 0.1 U/uL MS00029 1.5
Lamp F   TB103 100 1.6 µM 24
LAM P B TB087 100 1.6 µM 24
LoopB 083 100 0.8 µM 12
LoopF    TB101 100 0.8 µM 12
Disp B    TB100 100 0.4 µM 6
Disp F    TB115 100 0.4 µM 6
M axima RtaseH + 200 0.2 u/µl MS00030 1.5
Total Volume 1470 [µL]
M
W
G
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Appendix 20 
Protocol 20: Standard HBV LAMP-BART assay  
Reaction mix set up: 
 
Master mix was prepared according to the reaction mix set up shown above. 15 uL of the master 
mix was then mixed with 5 uL of the appropriate HBV template in a 96-well plate (white) 
followed by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive 
film and loaded onto BISON set at 60 °C and ran for 90 min.  
 
 
 
 
 
 
 
 
 
 
 
 
Dispence valume 15
Final conc
C o mpo nent Sto ck M ix+sample Units Spec uL required  A dded
M GW MS00001 466
25%  w/v trehalose 250 75 mg/mL SS008 600
Isothermal buffer 10 1 x 200
1M  DTT 1000 10  mM SS003 20
Luciferin, 10 mg/mL solution 10 0.1 mg/mL SS0004 20
10 mM  APS (Bio log) 10000 250 µM MS00015 50
Ultraglow luciferase 50.7 0.05 ug/mL MS00011 2.0
300U/ml ATP sulphurylase 300000 375 mu/mL MS00012 2.5
dATP 100mM 100000 300 µM MS00008 6
dTTP 100mM 100000 300 µM 6
dCTP 100mM 100000 300 µM 6
dGTP 100mM 100000 300 µM 6
Bst 2.0 WS 200000 200 units/mL MS00010 3.0
HBV-019 (DispB) 100 1.6  µM 8
HBV-024 (DispF) 100 1.6 µM 8
HBV-021 (Bloop) 100 0.8 µM 16
HBV-023 (Floop) 100 0.8 µM 16
HBV-020 (BIP) 100 0.4 µM 32
HBV-022 (FIP) 100 0.4 µM 32
 Total Volume 1500 (µL)
Supertemplate
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Appendix 21 
Protocol 21: Modified HBV LAMP-BART assay (no BART) 
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 742 uL of 
the initial reaction mixes was then split into two aliquots of 371 uL each. Final master mix was 
prepared by adding 4 uL of either MGW or ROX-labelled loopF probe [100 uM] to separate 
aliquots containing 371 uL of the initial master mix. 15 uL of the final reaction mix was then 
mixed with 5 uL of the appropriate HBV template in a 96-well plate (white) covered with 2 
drops of mineral oil and sealed using adhesive clear film. Samples were run at 60 °C for 90 
cycles on Strategene.  Note: each cycle was set to run for 1 min.  
 
 
 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
Final conc
C o mpo nent Sto ck M ix+sample Units Spec uL required  A dded
M GW MS00001 281
25%  w/v trehalose 250 75 mg/mL SS008 300
Isothermal buffer 10 1 x 100
1M  DTT 1000 10  mM SS003
Luciferin, 10 mg/mL solution 10 0.1 mg/mL SS0004
10 mM  APS (Bio log) 10000 250 µM MS00015
Ultraglow luciferase 50.7 0.05 ug/mL MS00011
300U/ml ATP sulphurylase 300000 375 mu/mL MS00012
dATP 100mM 100000 300 µM MS00008 3
dTTP 100mM 100000 300 µM 3
dCTP 100mM 100000 300 µM 3
dGTP 100mM 100000 300 µM 3
GSP 100000 200 units/mL MS00010 1.0
HBV-019 (DispB) 100 0.4  µM 4
HBV-024 (DispF) 100 0.4 µM 4
HBV-021 (Bloop) 100 0.8 µM 8
HBV-023 (Floop) 100 0.8 µM
HBV-020 (BIP) 100 1.6 µM 16
HBV-022 (FIP) 100 1.6 µM 16
 Total Volume 742 (µL)
Supertemplate
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Appendix 22 
Protocol 22: Modified HBV LAMP-BART assay  
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 742 uL of 
the initial reaction mixes was then split into two aliquots of 371 uL each. Final master mix was 
prepared by adding 4 uL of either MGW or ROX-labelled loopF probe [100 uM] to separate 
aliquots containing 371 uL of the initial master mix. 15 uL of the final reaction mix was then 
mixed with 5 uL of the appropriate HBV template in a 96-well plate (white) covered with 2 
drops of mineral oil and sealed using adhesive clear film. Samples were run at 60 °C for 90 
cycles on Strategene.  Note: each cycle was set to run for 1 min.  
 
 
 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
Final conc
C o mpo nent Sto ck M ix+sample Units Spec uL required  A dded
M GW MS00001 234
25%  w/v trehalose 250 75 mg/mL SS008 300
Isothermal buffer 10 1 x 100
1M  DTT 1000 10  mM SS003 10
Luciferin, 10 mg/mL solution 10 0.1 mg/mL SS0004 10
10 mM  APS (Bio log) 10000 250 µM MS00015 25
Ultraglow luciferase 50.7 0.05 ug/mL MS00011 1.0
300U/ml ATP sulphurylase 300000 375 mu/mL MS00012 1.3
dATP 100mM 100000 300 µM MS00008 3
dTTP 100mM 100000 300 µM 3
dCTP 100mM 100000 300 µM 3
dGTP 100mM 100000 300 µM 3
GSP 100000 200 units/mL MS00010 1.0
HBV-019 (DispB) 100 0.4  µM 4
HBV-024 (DispF) 100 0.4 µM 4
HBV-021 (Bloop) 100 0.8 µM 8
HBV-023 (Floop) 100 0.8 µM
ST 35-2 100 1.6 µM 16
ST 37-2 100 1.6 µM 16
 Total Volume 742 (µL)
Supertemplate
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Appendix 23 
Protocol 23: Standard fluorescent TB LAMP assay   
Reaction mix set up: 
 
Initial master mix was prepared according to the reaction mix set up shown above. 1498 uL of 
the initial reaction mixes was then split into two aliquots of 749 uL each. Final master mix was 
prepared by adding 1 uL of GSP-SSD [100 U/uL] or 1.3 uL Bst large fragment [160 U/uL] to 
separate aliquots containing 749 uL of the initial master mix. 15 uL of the final reaction mix 
was then mixed with 5 uL of the appropriate IAC template in a 96-well plate (white) covered 
with 2 drops of mineral oil and sealed using adhesive clear film. Samples were run at 60 °C for 
90 cycles on Strategene.  Note: each cycle was set to run for 1 min.  
 
 
 
 
 
 
 
 
 
Dispense volume [µL]: 15
F inal co nc
C o mpo nent Sto ck M ix+sample Units Spec  [µL]  A dded Lo t no .
SYBR 10x 0.1x 20
HIV probe 10^7 5 x 10^4 cps/µl 16
M GW MS00001 416 RNBF0862
Trehalose (25% solution) 250 50 mg/mL SS008 400 1616103
Bicine Buffer 4x 1x 500 1507602
M g2SO4, 100mM 100 2 mM MS00017 40 0011202
Dithiothreito l 1M 1000 10 mM SS003 1605002
Luciferin, 10 mg/mL solution 10 0.1  mg/mL SS0004 1610501
10 mM  APS 10000 250 µM MS00015 001
Ultraglow luciferase 50.7 0.025 µg/mL MS00011 201098
300U/ml ATP sulphurylase 300000 375 mU/mL MS00012 0191605
100mM  dNTP mix (25mM  each)25000 300 µM MS00032 24 1436447
Bst LF DNA polymerase 160000 200 u/mL MS00029
Lamp F   TB103 100 1.6 µM 32
LAM P B TB087 100 1.6 µM 32
Loop B   TB083 100 0.8 µM
LoopF    TB101 100 0.8 µM
Disp B    TB100 100 0.4 µM 8
Disp F    TB115 100 0.4 µM 8
M axima RtaseH + 200 0.2 u/µl MS00030 2
Total Volume 1498 [µL]
M
W
G
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Appendix 24 
Protocol 24: Standard miRNA LAMP-BART assay   
Reaction mix set up: 
 
Master mix was prepared according to the reaction mix set up shown above. 15 uL of the master 
mix was then mixed with 5 uL of the appropriate miRNA template in a 96-well plate (white) 
followed by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive 
film and loaded onto “Lucy” set at 60 °C and ran for 90 min.  
 
 
 
 
 
 
 
 
 
 
 
 
Reaction set-up
Volume/reaction [ul]: 20
Number reactions (inc. extra): 50
µl for bulk mix
142.0
100
200
5
10
33
60
10
25
10
15
40
100
750Total mix volume, ul
1.2 M KCl
5mM dNTPs (5mM of each)
10mg/ml LH2
10 mM APS (Biolog)
10x primer combinations
25U/ml ATP sulphurylase NEB*
8U/µl Bst DNA polymerase
Bulk mix
MGW
10x Thermopol buffer
25% Trehalose
0.55mg/ml rLuc Ultraglo
1M DTT
40mg/ml PVP
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Appendix 25 
Protocol 25: 10x primer combination   
Primer mix set up: 
 
Note: all primers used were stored at 100 uM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
volume added [uL]
2
2
8
8
4
4
72
100Total mix volume, ul
Loop F
MGW
Primer
F3
B3
FIP
BIP
Loop B
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Appendix 26 
Protocol 26: Reagent preparation for miRNA and LAMP assays  
1) Salmon sperm carrier DNA 
supplied by Invitrogen at 10mg/ml but NanoDrop for more accurate concentration, dilute 1/100 in serial dilution 
to ng/µl (typically 142ng/µl) use in assay at 100ng per partition, label and store at -20°C 
2) Molecular grade water 
supplied by Fisher (not Milli-Q or ELIX water), approximately 1.5ml per 2ml screw-top tube, label and store at 
-20°C 
3) 10x Thermopol buffer 
supplied by NEB at 10X concentration and used directly 
4) 25% Trehalose 
supplied by Sigma as a powder, prepare by adding 12.5g to 50ml MGW, produces approximately 80 aliquots of 
420µl per batch, label and store at -20°C 
5) 1M DTT 
supplied by Sigma as a powder, prepare by adding 1.54g to 10ml MGW, produces approximately 100 aliquots 
of 100µl per batch, label and store at -20°C 
6) 40mg/ml PVP 
supplies by Sigma as a powder, prepare by adding 0.4g to 10ml MGW, produces approximately 100 aliquots of 
100µl per batch, label and store at -20°C 
7) 1.2M KCl 
supplied by Fisher as a powder, prepare by adding 0.895g to 10ml MGW, produces approximately 80 aliquots 
of 100µl per batch, label and store at -20°C 
8) 5mM dNTPs 
supplied by Invitrogen at 100mM for each dNTP, prepare by adding 10µl of each to 160µl MGW in 8 tubes, 
produces 24 aliquots of 65µl per batch, label and store at -20°C 
9) 10mg/ml Luciferin 
D-luciferin K salt supplied by Europa Bioproducts, prepare by adding 10mg to 1ml MGW, produces 40 aliquots 
of 25µl per batch, label and store at -20°C 
10) 10mM APS 
supplied by Biolog at desired concentration, each vial produces 16 aliquots of 60µl, label and store at -20°C 
11) 0.55mg/ml Ultra-Glo Luciferase 
Ultra-glo luciferase supplied by Promega at 5.5mg/ml, prepare 100µl luciferase with 10µl 1M DTT, 100µl NEB 
Thermopol (10X) and 790µl MGW, produces 40 aliquots of 25µl per batch, label and store at -20°C 
12) 25U/ml ATP sulphurylase 
supplied by NEB at 300U/ml, dilute 4µl ATP-S with 44µl Diluent D or VENT Diluent when required 
13) 8U/ml Bst DNA polymerase 
supplied by NEB at 8000U/ml and used directly 
14) mineral oil 
supplied by Fisher, approximately 1.5ml per 2ml screw-top tube, label and store at room temperature 
15) primers 
supplied by Sigma or MWG Operon, dilute as indicated with MGW to 100µM, label and store at -20°C, enter 
details on Lab Collector 
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Appendix 27 
Protocol 27: SplintR ligation protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Volume [ul]
P1 [100uM] 1
P2 [100uM] 1
miRNA [100uM] 1
SplintR Buffer [10x] 2
SplintR [25 U/uL] 1
MGW 14
Total volume 20
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Appendix 28 
Protocol 28: Ampligase ligation protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Volume [ul]
P1 [100uM] 1
P2 [100uM] 1
miRNA [100uM] 1
Ampligase Buffer [10x] 2
Ampligase [5 U/uL] 1
MGW 14
Total volume 20
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Appendix 29 
Protocol 29: T4 ligation protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Volume [ul]
P1 [100uM] 1
P2 [100uM] 1
miRNA [100uM] 1
T4 Buffer [10x] 2
T4 ligase [400 U/uL] 1
MGW 14
Total volume 20
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Appendix 30 
Protocol 30: T7 ligation protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Volume [ul]
P1 [100uM] 1
P2 [100uM] 1
miRNA [100uM] 1
T7 Buffer [2x] 10
T7 ligase [3000 U/uL] 1
MGW 4
Total volume 20
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Appendix 31 
Protocol 31: Restriction digest protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Volume [ul]
Template 1
Buffer 5
Restriction Enzyme 1
MGW 43
Total volume 50
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Appendix 32 
Protocol 32: Restriction digest protocol under LAMP-BART reaction set up 
 
44 uL of the reaction mix was then mixed with 5 uL of the restriction template and 1 uL of 
the appropriate endonuclease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
µl for bulk mix
109.6
20
40
2
2
6.4
12
5
3
200Total mix volume, ul
1.2 M KCl
5mM dNTPs (5mM of each)
10mg/ml LH2
10 mM APS (Biolog)
10x primer combinations
25U/ml ATP sulphurylase NEB*
8U/µl Bst DNA polymerase
Bulk mix
MGW
10x Thermopol buffer
25% Trehalose
0.55mg/ml rLuc Ultraglo
1M DTT
40mg/ml PVP
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Appendix 33 
Protocol 33: Preparation of restriction templates 
 
Each template was purchased from Sigma and reconstituted at 100 uM concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Volume [ul]
2x QI MasterMix 50 PCR cycling conditions
Lin-DNA primer 10 94 °C 3 min
Template [100uM] 10 94 °C 30 sec
MGW 30 55 °C 30 sec
72 °C 30 sec
Total volume 100 72 °C 10 min
35 cycles
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Appendix 34 
Protocol 34: SDS-PAGE protocol 
 
SDS page Gels (For 2 gels, 0.75mm plates or 1 gel, 1.5mm plates) 
10% Gel 
• 4.1ml H2O 
• 2.5ml Tris 1.5M pH 8.8 
• 3.3ml Acrylamide (33%) 
• 100ul SDS (10%) 
• 50ul APS (10%) 
• 10ul TEMED 
Run at 45 V for 85 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
284 
 
Appendix 35 
Protocol 35: Endonuclease-based miRNA detection protocol 
Reaction set up: 
 
Master mix was prepared according to the reaction mix set up shown above. 15 uL of the master 
mix was then mixed with 5 uL of the appropriate miRNA template in a 96-well plate (white) 
followed by an addition of two drops of mineral oil. Samples were sealed using a clear adhesive 
film and loaded onto “Lucy” set at 60 °C and ran for 90 min.  
 
 
 
 
 
 
 
 
 
 
 
 
Volume/reaction [ul]: 20
Number reactions (inc. extra): 25
µl for bulk mix
50.0
50
100
5
5
BstUI 8
16.5
30
5
12.5
5
7.5
BstUI template 10
20
50
375Total mix volume, ul
1.2 M KCl
5mM dNTPs (5mM of each)
10mg/ml LH2
10 mM APS (Biolog)
10x primer combinations
25U/ml ATP sulphurylase NEB*
8U/µl Bst DNA polymerase
Bulk mix
MGW
10x Thermopol buffer
25% Trehalose
0.55mg/ml rLuc Ultraglo
1M DTT
40mg/ml PVP
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Appendix 36 
SDS-PAGE showing probe ligation via miRNA using SplintR ligase 
 
 
 
Lanes: 
L – 50 bp ladder (NEB) 
A – P1 
B – P2 
C – P1 + P2 
D – P1 + P2 + miRNA 
E – P1 + P2 
Note: lanes D and E show samples that underwent ligation reactions 
 
 
 
 
 
 
 
 
 
 
 
 
EBAL DC
50 bp
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Appendix 37 
Primer and probes sequences used in the ligation-based miRNA detection system 
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Appendix 38 
Primer and probes sequences used in the endonuclease-based miRNA detection system 
Probe (5’  3’) 
P1BstUI- TTTT-GTTCTATAGAGGAAGGGTCA-AGACTAT-TAGTCCTAGGCTGATCAGTG-TTTT-
ATATCCTGAGTGACTCCAA-CTAATGGGTCTATGT-CG-TAAGTCCAACTGGACTCCTT-TTTT-
AAGGAGTCCAGTTGGACTTA-CGCG-TCACACTTGAGGTCTCAGGGAA 
P1BsaWI- TTTT-GTTCTATAGAGGAAGGGTCA-AGACTAT-TAGTCCTAGGCTGATCAGTG-TTTT-
ATATCCTGAGTGACTCCAA-CTAATGGGTCTATGT-TAAGTCCAACTGGACTCCTT-TTTT-
AAGGAGTCCAGTTGGACTTA-CCGG-TCACACTTGAGGTCTCAGGGAA 
P1Nb.BsmI 
TTaaTTGTTCTATAGAGGAAGGGTCAAGACTATTAGTCCTAGGCTGATCAGTGTTTTATATCCTGAGcGAgacCT
tgTAATGGGTCTATGTCcattcTAAGTCCAACTGGACTCCTTTTTTAAGGAGTCCAGTTGGACTTAgaatGCattTCA
CACTTGAGGTCTCAGGGAA 
 
UUCCCUGAGACCUCAAGUGUGA- miRNA 
5’ – gttctcgctcagttgtgtt-tttt-tagaggggaagcgtaatcag – 3’ Primer L1v1 
5’-TTGGAGTCACTCAGGATAT-TTTT-TAGTCCTAGGCTGATCAGTG-3’ - Primer L1 
5’-GTTCTATAGAGGAAGGGTCA-3’- Displacement primer 
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Appendix 39 
HBV primers 
 
TB primers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer
HBV-019 GCTCAAGGCAACTCTATG
HBV-020 cccataggtattttgcgaaagGGATGGAAATTGCACCTG
HBV-021 caagatgatgggatgggaat
HBV-022 TCAGTGGTTCGTAGGGCccaataccacatcatccata
HBV-023 CCACTGTTTGGCTTTCAG
HBV-024 ctcaagatgctgcacag
Sequence 5' -> 3 '
Primer
 Lamp B  TB087
Lamp F   TB103
Loop B   TB083
LoopF    TB101
Disp B    TB100
Disp F    TB115
ACTCGCAGGCTCATTCTTTTTTCCGGAGGAGGGTGG
AAGGTTAACCCGTGTGGTTTTCGCGTGTGGGTCGCC
CAAAAGGCACGCCATCA
CGAAAGCGAGTCTGAATAG
AGAGTACCTGAAACCGTG
ATTCACACGCGCGTAT
5'→3' sequence
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Appendix 40 
Development of internal amplification controls for LAMP assays. 
 
Objectives: Slowing down the amplification of IC templates by mutating FIP primers.   
 
Materials and Methods 
Reaction mixture was prepared according to the “HBV set-up160916”. 1468 uL of the LAMP-BART mix was split 
into 4 aliquots of 367 uL each followed by the addition of 8 uL of the appropriate FIP primer [100mM]. 5 uL of 
the dsHBV template (LOT: 1529406) of 10000 cp/5uL was added to 15 uL of the final LAMP-BART reaction mix 
followed by an addition of mineral oil and ran for 90 min at 60°C on BISON 5.  
NOTE: HBV template was prepared by adding 500 uL of MGW into a dried HBV pellet of 10^8 cp resulting in a 
final concentration of 10^6 cp/5ul. 3 x 10-fold serial dilutions (10 uL Sample + 90 uL MGW) were prepared in 
order to achieve final concentrations of 1000 and 10000 cp/5 uL.   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Final conc
C o mpo nent Sto ck M ix+sample Units Spec uL required  A dded
M GW MS00001 498
25%  w/v trehalose 250 75 mg/mL SS008 600
Isothermal buffer 10 1 x 200
1M  DTT 1000 10  mM SS003 20
Luciferin, 10 mg/mL solution 10 0.1 mg/mL SS0004 20
10 mM  APS (Bio log) 10000 250 µM MS00015 50
Ultraglow luciferase 50.7 0.05 ug/mL MS00011 2.0
300U/ml ATP sulphurylase 300000 375 mu/mL MS00012 2.5
dATP 100mM 100000 300 µM MS00008 6
dTTP 100mM 100000 300 µM 6
dCTP 100mM 100000 300 µM 6
dGTP 100mM 100000 300 µM 6
Warm Start Bst 120000 200 units/mL MS00010 3.3
HBV-019 (DispB) 100 1.6  µM 8
HBV-024 (DispF) 100 1.6 µM 8
HBV-021 (Bloop) 100 0.8 µM 0
HBV-023 (Floop) 100 0.8 µM 0
HBV-020 (BIP) 100 0.4 µM 32
HBV-022 (FIP) 100 0.4 µM 0
 Total Volume 1468 (µL)
Supertemplate
HBV-019 GCTCAAGGCAACTCTATG
HBV-020 cccataggtattttgcgaaagGGATGGAAATTGCACCTG
HBV-021 caagatgatgggatgggaat
HBV-022 TCAGTGGTTCGTAGGGCccaataccacatcatccata
HBV-023 CCACTGTTTGGCTTTCAG
HBV-024 ctcaagatgctgcacag
Mut-HBV022FIPa – TCAGTGGTTCGTAGCCGccaataccacatcatccata
Mut-HBV022FIPb – TCAGTGGTTCGTTCCCGccaataccacatcatccata
Mut-HBV022FIPc – TCAGTGGTTCCATCCCGccaataccacatcatccata 
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Results 
 
 
 
 
 
 
 
 
 
 
 
 
In this experiment, the amplification slow down via template mutation idea was tested on the dsHBV template 
using mutated FIP primers. Note that in this instance, the primers were mutated rather than the primer binding 
sides on the IC template due to the cost of the template synthesis. 
 
In principle, the slow down technology is based on reduction of the Tms of the IC LAMP primers by mutating the 
F1 FIP biding side (or the primer F1 side itself) at the 3’ends. This reduction in Tm would then significantly impair 
the primer binding and folding to generate dumbbell structures thus impacting upon the amplification kinetics.  
 
In this experiment, three different mutated FIP primers were tested where 3 to 7 bp were mutated at the 3’ end 
of the F1 site. As expected, the TTMs were significantly affected regardless of the mutation introduced into the 
FIP primers. However, it was not surprising that the most significant delay in the amplification was observed in 
the reactions containing the FIP primer with 7 bp mutated. This mutation caused the most severe change to the 
Tm of the F1 site therefore impacting on the dumbbell generation most significantly.   
 
 
Conclusions 
The primer mutation experiment shows a huge promise as a potential IC method. Mutation of only one LAMP 
primer caused a major reduction in the amplification speed which could further be delayed by mutating the BIP 
primer.  
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Appendix 41 
Protocol 35: Mucin preparation 
Mucin from porcine stomach, type II, was purchased from Sigma-Aldrich, UK.  
15mg/mL of Mucin solution was prepared by adding 75 g of mucin to 3 mL of 1M NaOH 
solution and vortexed at maximum speed for 5 min. The prepared solution was then topped 
up to the final volume of 5 mL using 1M NaOH and vortexed for additional 5 min.  
The final mucin solution was stored at room temperature.  
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Appendix 42 
SDS-PAGE showing four DNA probes designed for the endonuclease-based miRNA 
detection technology.   
 
 
 
Lanes: 
L – 50 bp ladder (NEB) 
A – BstNI 
B – BsaWI 
C – BssKI 
D – BstUI 
 
AL D LCB
50 bp
